Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Breast Cancer Res Treat
    April 2024
  1. BRANDAO M, Martins-Branco D, De Angelis C, Vuylsteke P, et al
    Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07275.
    >> Share

  2. FORTNER RT, Brantley KD, Tworoger SS, Tamimi RM, et al
    Recreational physical activity and breast cancer risk by menopausal status and tumor hormone receptor status: results from the Nurses' Health Studies.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-023-07238.
    >> Share

  3. WANG Y, Sun W, Karlsson E, Kang Lovgren S, et al
    Clinical evaluation of deep learning-based risk profiling in breast cancer histopathology and comparison to an established multigene assay.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07303.
    >> Share

  4. RUKHSANA, Supty AT, Hussain M, Lee Y, et al
    STK3 higher expression association with clinical characteristics in intrinsic subtypes of breast cancer invasive ductal carcinoma patients.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07248.
    >> Share

  5. SULLIVAN M, Lei X, Giordano SH, Chavez-MacGregor M, et al
    Breast cancer (BC) and severe COVID-19 (C-19) outcomes: a matched analysis.
    Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07301.
    >> Share

  6. ALLSOPP RC, Guo Q, Page K, Bhagani S, et al
    Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study.
    Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07316.
    >> Share

  7. ALHUDIRI I, Nolan C, Ellis I, Elzagheid A, et al
    Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value.
    Breast Cancer Res Treat. 2024 Apr 5. doi: 10.1007/s10549-024-07293.
    >> Share

  8. YERUSHALMI R, Pomerantz A, Lewin R, Paluch-Shimon S, et al
    BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.
    Breast Cancer Res Treat. 2024 Apr 3. doi: 10.1007/s10549-024-07271.
    >> Share

  9. KONTOS M, Kanavidis P, Kuhn T, Masannat Y, et al
    Targeted axillary dissection: worldwide variations in clinical practice.
    Breast Cancer Res Treat. 2024;204:389-396.
    >> Share

  10. AI D, Turashvili G, Gjeorgjievski SG, Wang Q, et al
    Subspecialized breast pathologists have suboptimal interobserver agreement in Ki-67 evaluation using 20% as the cutoff.
    Breast Cancer Res Treat. 2024;204:415-422.
    >> Share

  11. COBLEIGH MA, Layng KV, Mauer E, Mahon B, et al
    Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.
    Breast Cancer Res Treat. 2024;204:407-414.
    >> Share

  12. BAHL M, Deng B
    Impact of pre-operative MRI on surgical management of screening digital breast tomosynthesis-detected invasive lobular carcinoma.
    Breast Cancer Res Treat. 2024;204:397-405.
    >> Share

  13. WALSH EA, Post K, Massad K, Horick N, et al
    Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial.
    Breast Cancer Res Treat. 2024;204:547-559.
    >> Share

  14. FLETCHER KA, Alkurashi MH, Lindsay AJ
    Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies.
    Breast Cancer Res Treat. 2024;204:631-642.
    >> Share

  15. WANG H, Yee D, Potter D, Jewett P, et al
    Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
    Breast Cancer Res Treat. 2024;204:589-597.
    >> Share

  16. VAN HEMERT A, van Loevezijn AA, Bosman A, Vlahu CA, et al
    Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome.
    Breast Cancer Res Treat. 2024;204:497-507.
    >> Share

  17. HARDY-ABELOOS C, Xiao J, Oh C, Barbee D, et al
    Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation.
    Breast Cancer Res Treat. 2024;204:485-495.
    >> Share

  18. BLOMQVIST C, Vehmanen L, Kellokumpu-Lehtinen PL, Huovinen R, et al
    Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study.
    Breast Cancer Res Treat. 2024 Apr 1. doi: 10.1007/s10549-024-07252.
    >> Share

  19. MARTINEZ-JANEZ N, Ezquerra MB, Manso Sanchez LM, Carrasco FH, et al
    First-line therapy with palbociclib in patients with advanced HR(+)/HER2(-) breast cancer: The real-life study PALBOSPAIN.
    Breast Cancer Res Treat. 2024 Apr 1. doi: 10.1007/s10549-024-07287.
    >> Share

    March 2024
  20. CAMPBELL EK, Campbell TM, Culakova E, Blanchard L, et al
    A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes.
    Breast Cancer Res Treat. 2024 Mar 30. doi: 10.1007/s10549-024-07284.
    >> Share

  21. BURO AW, Nguyen T, Abaskaron M, Haver MK, et al
    Lifestyle interventions with dietary strategies after breast cancer diagnosis: a systematic review.
    Breast Cancer Res Treat. 2024 Mar 29. doi: 10.1007/s10549-024-07278.
    >> Share

  22. GULIYEV M, Sen GA, Gulturk I, Majidova N, et al
    The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study.
    Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07291.
    >> Share

  23. JUNG JJ, Cheun JH, Kim HK, Lee HB, et al
    Comparison of long-term oncologic outcomes of central lumpectomy and conventional breast-conserving surgery for invasive breast cancer: propensity score matching analysis.
    Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07297.
    >> Share

  24. TENG YT, Wang YA, Dong YH, Liu JJ, et al
    Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics.
    Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07280.
    >> Share

  25. KAPLAN HG, Dowdell AK, Berry AB, Shimol RB, et al
    Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
    Breast Cancer Res Treat. 2024 Mar 24. doi: 10.1007/s10549-024-07270.
    >> Share

  26. GODINEZ PAREDES JM, Rodriguez I, Ren M, Orozco A, et al
    Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies.
    Breast Cancer Res Treat. 2024 Mar 23. doi: 10.1007/s10549-024-07300.
    >> Share

  27. DOUBBLESTEIN D, Koehler L, Anderson E, Scheiman N, et al
    Development of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains.
    Breast Cancer Res Treat. 2024 Mar 22. doi: 10.1007/s10549-024-07298.
    >> Share

  28. COLLIN LJ, Jones J, Nash R, Switchenko JM, et al
    Racial disparities in initiation of chemotherapy among breast cancer patients with discretionary treatment indication in the state of Georgia.
    Breast Cancer Res Treat. 2024 Mar 22. doi: 10.1007/s10549-024-07279.
    >> Share

  29. NASIRI N, Hu M, Hajizadeh M
    Trends in socioeconomic inequalities in breast cancer mortality in Canada: 1992-2019.
    Breast Cancer Res Treat. 2024 Mar 19. doi: 10.1007/s10549-024-07277.
    >> Share

  30. AUGUSTINSSON A, Loman N, Ehrencrona H
    Retrospective genetic testing (Traceback) in women with early-onset breast cancer after revised national guidelines: a clinical implementation study.
    Breast Cancer Res Treat. 2024 Mar 16. doi: 10.1007/s10549-024-07288.
    >> Share

  31. WU Q, Hatse S, Kenis C, Fernandez-Garcia J, et al
    Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases.
    Breast Cancer Res Treat. 2024 Mar 13. doi: 10.1007/s10549-024-07260.
    >> Share

  32. CHUNG HL, Middleton LP, Sun J, Whitman GJ, et al
    Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants.
    Breast Cancer Res Treat. 2024 Mar 12. doi: 10.1007/s10549-024-07261.
    >> Share

  33. FARLAND LV, Lind KE, Thomson CA, Saquib N, et al
    Infertility and risk of postmenopausal breast cancer in the women's health initiative.
    Breast Cancer Res Treat. 2024 Mar 9. doi: 10.1007/s10549-024-07257.
    >> Share

  34. GION M, Garcia-Mosquera JJ, Perez-Garcia JM, Peg V, et al
    Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
    Breast Cancer Res Treat. 2024 Mar 8. doi: 10.1007/s10549-024-07292.
    >> Share

  35. AVILA J, Leone J, Vallejo CT, Lin NU, et al
    Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade.
    Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07290.
    >> Share

  36. GARCIA-TORRALBA E, Perez Ramos M, Ivars Rubio A, Navarro Manzano E, et al
    Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes.
    Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07286.
    >> Share

  37. BAYRAKCEKEN E, Yarali S, Alkan O
    Identify risk factors affecting participation of Turkish women in mammography screening for breast cancer prevention.
    Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07296.
    >> Share

  38. FINSTERBUSCH K, van Diest PJ, Focke CM
    Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study.
    Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07281.
    >> Share

  39. CAMPBELL TM, Campbell EK, Culakova E, Blanchard LM, et al
    A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes.
    Breast Cancer Res Treat. 2024 Mar 6. doi: 10.1007/s10549-024-07266.
    >> Share

  40. SUN H, Kang EY, Chen H, Sweeney KJ, et al
    Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
    Breast Cancer Res Treat. 2024 Mar 5. doi: 10.1007/s10549-024-07256.
    >> Share

  41. PLICHTA JK, Thomas SM, Wang X, McDuff SGR, et al
    Survival among patients with untreated metastatic breast cancer: "What if I do nothing?".
    Breast Cancer Res Treat. 2024 Mar 5. doi: 10.1007/s10549-024-07265.
    >> Share

  42. KULOTHUNGAN V, Ramamoorthy T, Sathishkumar K, Mohan R, et al
    Burden of female breast cancer in India: estimates of YLDs, YLLs, and DALYs at national and subnational levels based on the national cancer registry programme.
    Breast Cancer Res Treat. 2024 Mar 4. doi: 10.1007/s10549-024-07264.
    >> Share

  43. WU Y, Li Z, Lee AV, Oesterreich S, et al
    Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
    Breast Cancer Res Treat. 2024 Mar 1. doi: 10.1007/s10549-024-07255.
    >> Share

    February 2024
  44. DOUBBLESTEIN D, Koehler L, Anderson E, Scheiman N, et al
    Development of a core outcome set for breast cancer-related lymphedema: a Delphi study.
    Breast Cancer Res Treat. 2024 Feb 29. doi: 10.1007/s10549-024-07262.
    >> Share

  45. HOSSEINI Y, Hadi Sichani P, Moslemi E, Nouri M, et al
    Pro-vegetarian dietary pattern and risk of breast cancer: a case-control study.
    Breast Cancer Res Treat. 2024 Feb 28. doi: 10.1007/s10549-024-07243.
    >> Share

  46. VOETS MM, Hassink NS, Veltman J, Slump CH, et al
    Opportunities for personalised follow-up in breast cancer: the gap between daily practice and recurrence risk.
    Breast Cancer Res Treat. 2024 Feb 26. doi: 10.1007/s10549-024-07246.
    >> Share

  47. FALEH S, Prakash I, Salehi A, Khan H, et al
    Preoperative factors that predict pathologic nodal involvement in early-stage HER2+ breast cancer: selecting cT1cN0 patients for treatment with neoadjuvant chemotherapy versus upfront surgery.
    Breast Cancer Res Treat. 2024 Feb 21. doi: 10.1007/s10549-024-07251.
    >> Share

  48. GEURTS SME, Ibragimova KIE, Ding N, Meegdes M, et al
    Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.
    Breast Cancer Res Treat. 2024 Feb 21. doi: 10.1007/s10549-023-07235.
    >> Share

  49. BUFMAN H, Faermann R, Halshtok-Neiman O, Shalmon A, et al
    Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience.
    Breast Cancer Res Treat. 2024 Feb 21. doi: 10.1007/s10549-023-07234.
    >> Share

  50. CHEN Y, Markowitz JC, Blanco C, Hershman DL, et al
    Geographical distance predicts psychiatric treatment retention for Hispanic women with comorbid major depression and breast cancer.
    Breast Cancer Res Treat. 2024 Feb 20. doi: 10.1007/s10549-024-07250.
    >> Share

  51. GAO L, Medford A, Spring L, Bar Y, et al
    Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA).
    Breast Cancer Res Treat. 2024 Feb 15. doi: 10.1007/s10549-024-07253.
    >> Share

  52. GUPTA S, Sinha Gupta S, De A, Banerjee R, et al
    Socio-cultural and financial issues against breast cancer screening behaviour among eligible Indian women: evidence for action.
    Breast Cancer Res Treat. 2024 Feb 12. doi: 10.1007/s10549-024-07244.
    >> Share

  53. MUTAI R, Kuchuk I, Goldshtein A, Yerushalmi R, et al
    The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2024 Feb 12. doi: 10.1007/s10549-024-07247.
    >> Share

  54. HWANG YH, Yoo TK, Lee SB, Kim J, et al
    Comparison of long-term oncological outcomes after central lumpectomy versus nipple-sparing breast-conserving surgery for centrally located breast cancer: a propensity score-matched study.
    Breast Cancer Res Treat. 2024 Feb 8. doi: 10.1007/s10549-024-07267.
    >> Share

  55. GOYAL RK, Zhang J, Davis KL, Sluga-O'Callaghan M, et al
    Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.
    Breast Cancer Res Treat. 2024 Feb 4. doi: 10.1007/s10549-023-07080.
    >> Share

  56. SIVAKANTHAN T, Tanner J, Mahata B, Agrawal A, et al
    Investigating the role of tumour-to-skin proximity in predicting nodal metastasis in breast cancer.
    Breast Cancer Res Treat. 2024 Feb 3. doi: 10.1007/s10549-023-07230.
    >> Share

  57. SCHWARTZ CJ, Khorsandi N, Blanco A, Mukhtar RA, et al
    Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
    Breast Cancer Res Treat. 2024;204:171-179.
    >> Share

  58. ADDAE JK, Sweeting RS, Meszoely IM, McCaffrey RL, et al
    Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience.
    Breast Cancer Res Treat. 2024;204:117-121.
    >> Share

  59. YANUS GA, Sokolenko AP, Imyanitov EN
    Northern origin of the BRCA2 c.5286 T > G founder allele.
    Breast Cancer Res Treat. 2024;204:191.
    >> Share

  60. KESKE A, Weisman P, Ospina-Romero M, Raut P, et al
    Breast cancers in monoallelic MUTYH germline mutation carriers have clinicopathological features overlapping with those in BRCA1 germline mutation carriers.
    Breast Cancer Res Treat. 2024;204:151-158.
    >> Share

  61. MOKBEL K, Alamoodi M
    "Enhancing survival outcomes through breast-conserving therapy in ipsilateral breast tumor recurrence: insights into metastasis and treatment strategies".
    Breast Cancer Res Treat. 2024;204:187.
    >> Share

  62. KARAKAWA R, Konishi T, Yoshimatsu H, Hashimoto Y, et al
    Association between body mass index and outcomes after autologous breast reconstruction: a nationwide inpatient database study in Japan.
    Breast Cancer Res Treat. 2024;204:69-78.
    >> Share

  63. YEH C, Zhou M, Bapodra N, Hershman D, et al
    Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials.
    Breast Cancer Res Treat. 2024;204:39-47.
    >> Share

  64. AL MASRY Z, Pic R, Dombry C, Devalland C, et al
    A new methodology to predict the oncotype scores based on clinico-pathological data with similar tumor profiles.
    Breast Cancer Res Treat. 2024;203:587-598.
    >> Share

  65. ZHAO YY, Ge HJ, Yang WT, Shao ZM, et al
    Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients.
    Breast Cancer Res Treat. 2024;203:543-551.
    >> Share

  66. LEE CS, Goldman L, Grimm LJ, Liu IX, et al
    Screening mammographic performance by race and age in the National Mammography Database: 29,479,665 screening mammograms from 13,181,241 women.
    Breast Cancer Res Treat. 2024;203:599-612.
    >> Share

    January 2024
  67. ZHU E, Zhang L, Wang J, Hu C, et al
    Deep learning-guided adjuvant chemotherapy selection for elderly patients with breast cancer.
    Breast Cancer Res Treat. 2024 Jan 31. doi: 10.1007/s10549-023-07237.
    >> Share

  68. VERSCHOOR N, Bos MK, de Kruijff IE, Van MN, et al
    Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.
    Breast Cancer Res Treat. 2024 Jan 31. doi: 10.1007/s10549-023-07231.
    >> Share

  69. WOOD SJ, Gao Y, Lee JH, Chen J, et al
    High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy.
    Breast Cancer Res Treat. 2024 Jan 30. doi: 10.1007/s10549-023-07233.
    >> Share

  70. NAAKTGEBOREN WR, Koevoets EW, Stuiver MM, van Harten WH, et al
    Effects of physical exercise during adjuvant chemotherapy for breast cancer on long-term tested and perceived cognition: results of a pragmatic follow-up study.
    Breast Cancer Res Treat. 2024 Jan 29. doi: 10.1007/s10549-023-07220.
    >> Share

  71. PRATHIBHA S, White M, Kolbow M, Hui JYC, et al
    Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
    Breast Cancer Res Treat. 2024 Jan 28. doi: 10.1007/s10549-023-07203.
    >> Share

  72. LEE IH, Lee SJ, Kang B, Lee J, et al
    Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer.
    Breast Cancer Res Treat. 2024 Jan 27. doi: 10.1007/s10549-023-07198.
    >> Share

  73. JOHANSSON H, Bellerba F, Macis D, Bertelsen BE, et al
    Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials.
    Breast Cancer Res Treat. 2024 Jan 26. doi: 10.1007/s10549-023-07241.
    >> Share

  74. OPPONG BA, Rumano RP, Paskett ED
    Expanding the use of patient navigation: health coaching-based navigation as a novel approach to addressing deficits in breast cancer survivorship support.
    Breast Cancer Res Treat. 2024 Jan 25. doi: 10.1007/s10549-023-07213.
    >> Share

  75. CETIN K, Kokten S, Sarikamis B, Yildirim S, et al
    The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer.
    Breast Cancer Res Treat. 2024 Jan 25. doi: 10.1007/s10549-023-07242.
    >> Share

  76. LICATA L, De Sanctis R, Vingiani A, Cosentini D, et al
    Real-world use of multigene signatures in early breast cancer: differences to clinical trials.
    Breast Cancer Res Treat. 2024 Jan 24. doi: 10.1007/s10549-023-07227.
    >> Share

  77. VAN DE LOO ME, Andour L, van Heesewijk AE, Oosterkamp HM, et al
    Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
    Breast Cancer Res Treat. 2024 Jan 24. doi: 10.1007/s10549-023-07222.
    >> Share

  78. NASRAZADANI A, Marti JLG, Lathrop K, Restrepo A, et al
    Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens.
    Breast Cancer Res Treat. 2024 Jan 23. doi: 10.1007/s10549-023-07236.
    >> Share

  79. COOMBES C, Angelou C, Al-Khalili Z, Hart W, et al
    Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
    Breast Cancer Res Treat. 2024 Jan 20. doi: 10.1007/s10549-023-07229.
    >> Share

  80. GUVEN DC, Sahin TK
    The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2024 Jan 19. doi: 10.1007/s10549-023-07226.
    >> Share

  81. HATZIPANAGIOTOU ME, Pigerl M, Gerken M, Rapple S, et al
    Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer.
    Breast Cancer Res Treat. 2024 Jan 19. doi: 10.1007/s10549-023-07207.
    >> Share

  82. NICOLETTI AP, Damin AP
    Factors influencing the first and the fifth years adherence to adjuvant endocrine therapy in breast cancer patients in a low income country.
    Breast Cancer Res Treat. 2024 Jan 15. doi: 10.1007/s10549-023-07221.
    >> Share

  83. BANG AS, Fay CJ, LeBoeuf NR, Etaee F, et al
    Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors.
    Breast Cancer Res Treat. 2024 Jan 15. doi: 10.1007/s10549-023-07217.
    >> Share

  84. READ SH, Quignot N, Kapso-Kapnang R, Comerford E, et al
    Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database.
    Breast Cancer Res Treat. 2024 Jan 11. doi: 10.1007/s10549-023-07201.
    >> Share

  85. JOYCE E, Tao X, Stearns V, Hayes DF, et al
    Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer.
    Breast Cancer Res Treat. 2024 Jan 10. doi: 10.1007/s10549-023-07218.
    >> Share

  86. BELTRAN-BLESS AA, Larocque G, Brackstone M, Arnaout A, et al
    The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey.
    Breast Cancer Res Treat. 2024 Jan 9. doi: 10.1007/s10549-023-07232.
    >> Share

  87. UMASHANKAR S, Li M, Blevins K, Kim MO, et al
    Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer.
    Breast Cancer Res Treat. 2024 Jan 9. doi: 10.1007/s10549-023-07206.
    >> Share

  88. VALENTE IVB, Garcia D, Abbott A, Spruill L, et al
    The anti-proliferative effects of a frankincense extract in a window of opportunity phase ia clinical trial for patients with breast cancer.
    Breast Cancer Res Treat. 2024 Jan 9. doi: 10.1007/s10549-023-07215.
    >> Share

  89. MA L, Gao Y, Huo Y, Tian T, et al
    Integrated analysis of diverse cancer types reveals a breast cancer-specific serum miRNA biomarker through relative expression orderings analysis.
    Breast Cancer Res Treat. 2024 Jan 8. doi: 10.1007/s10549-023-07208.
    >> Share

  90. CHANG CY, Jones BL, Hincapie-Castillo JM, Park H, et al
    Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors.
    Breast Cancer Res Treat. 2024 Jan 8. doi: 10.1007/s10549-023-07205.
    >> Share

  91. ZHONG J, Jiang H, Liu X, Liao H, et al
    Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer.
    Breast Cancer Res Treat. 2024 Jan 6. doi: 10.1007/s10549-023-07210.
    >> Share

  92. ZHANG F, Xu Y, Lin J, Pan H, et al
    Reciprocal regulation of forkhead box C1 and L1 cell adhesion molecule contributes to triple-negative breast cancer progression.
    Breast Cancer Res Treat. 2024 Jan 6. doi: 10.1007/s10549-023-07177.
    >> Share

  93. POP CF, Veys I, Bormans A, Larsimont D, et al
    Fluorescence imaging for real-time detection of breast cancer tumors using IV injection of indocyanine green with non-conventional imaging: a systematic review of preclinical and clinical studies of perioperative imaging technologies.
    Breast Cancer Res Treat. 2024 Jan 6. doi: 10.1007/s10549-023-07199.
    >> Share

  94. NAKAGAWA S, Miyashita M, Maeda I, Goda A, et al
    Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma.
    Breast Cancer Res Treat. 2024 Jan 5. doi: 10.1007/s10549-023-07209.
    >> Share

  95. ZHU Y, Zerdes I, Matikas A, Cruz IR, et al
    The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.
    Breast Cancer Res Treat. 2024 Jan 4. doi: 10.1007/s10549-023-07200.
    >> Share

  96. RONCATO R, Puglisi F, Gerratana L
    Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?
    Breast Cancer Res Treat. 2024;203:183-184.
    >> Share

  97. NICOSIA L, Rotili A, Pesapane F, Bozzini AC, et al
    Contrast-Enhanced Mammography (CEM) compared to Breast Magnetic Resonance (MRI) in the evaluation of breast lobular neoplasia.
    Breast Cancer Res Treat. 2024;203:135-143.
    >> Share

  98. GRABENSTETTER A, Brogi E, Thompson DM, Blinder VS, et al
    Impact of reactive changes on multigene testing: histopathologic analysis of low-grade breast cancers with high-risk 21-gene recurrence scores.
    Breast Cancer Res Treat. 2024;203:153-161.
    >> Share

  99. WANG J, Chen H, Koenig J, Wu Y, et al
    Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers.
    Breast Cancer Res Treat. 2024;203:73-83.
    >> Share

  100. JONES V, Schroeder MC, Roberson ML, De Andrade J, et al
    Differential response to neoadjuvant endocrine therapy for Black/African American and White women in NCDB.
    Breast Cancer Res Treat. 2024;203:125-134.
    >> Share

  101. WEINTRAUB MA, Liu D, DeMatteo R, Goncalves MD, et al
    Sodium-glucose cotransporter-2 inhibitors for hypergycemia in phosphoinositide 3-kinase pathway inhibition.
    Breast Cancer Res Treat. 2024;203:85-93.
    >> Share

  102. FAIRHURST K, Roberts K, Fairbrother P, Potter S, et al
    Current use of drains and management of seroma following mastectomy and axillary surgery: results of a United Kingdom national practice survey.
    Breast Cancer Res Treat. 2024;203:187-196.
    >> Share

  103. WESTBROOK L, Miltenburg D, Souter V, Maisenbacher MK, et al
    Hereditary cancer testing in a diverse sample across three breast imaging centers.
    Breast Cancer Res Treat. 2024;203:365-372.
    >> Share

  104. SOKOLENKO AP, Bakaeva EK, Venina AR, Kuligina ES, et al
    Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.
    Breast Cancer Res Treat. 2024;203:307-315.
    >> Share

    December 2023
  105. NAKHLIS F, Niman SM, Ueno NT, Troll E, et al
    Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
    Breast Cancer Res Treat. 2023 Dec 28. doi: 10.1007/s10549-023-07195.
    >> Share

  106. COGOLLOS-DE-LA-PENA R, Alvarez-Vargas A, Dominguez-Navarro F, Espelt A, et al
    Social inequalities in the use of physiotherapy in women diagnosed with breast cancer in Barcelona: DAMA cohort.
    Breast Cancer Res Treat. 2023 Dec 28. doi: 10.1007/s10549-023-07191.
    >> Share

  107. CHEN C, Ye L, Yi J, Liu T, et al
    Correction: FN1-mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer.
    Breast Cancer Res Treat. 2023 Dec 28. doi: 10.1007/s10549-023-07194.
    >> Share

  108. GONCALVES E, Fontes F, Rodrigues JR, Calisto R, et al
    Second primary cancers among females with a first primary breast cancer: a population-based study in Northern Portugal.
    Breast Cancer Res Treat. 2023 Dec 27. doi: 10.1007/s10549-023-07224.
    >> Share

  109. GREMKE N, Griewing S, Gohring J, Isselhard A, et al
    Is there an association between endometriosis and subsequent breast cancer? A retrospective cohort study from Germany.
    Breast Cancer Res Treat. 2023 Dec 23. doi: 10.1007/s10549-023-07211.
    >> Share

  110. DE WILD SR, Koppert LB, de Munck L, Vrancken Peeters MTFD, et al
    Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study.
    Breast Cancer Res Treat. 2023 Dec 22. doi: 10.1007/s10549-023-07178.
    >> Share

  111. SEUNG SJ, Saherawala H, Moldaver D, Shokar S, et al
    Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020.
    Breast Cancer Res Treat. 2023 Dec 21. doi: 10.1007/s10549-023-07185.
    >> Share

  112. BARNARD ME, Wang X, Petrick JL, Zirpoli GR, et al
    Psychosocial stressors and breast cancer gene expression in the Black Women's Health Study.
    Breast Cancer Res Treat. 2023 Dec 21. doi: 10.1007/s10549-023-07182.
    >> Share

  113. YAMAGUCHI A, Kawaguchi K, Kawanishi K, Maeshima Y, et al
    Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: propensity score matching and inverse probability of treatment weighting analysis.
    Breast Cancer Res Treat. 2023 Dec 21. doi: 10.1007/s10549-023-07163.
    >> Share

  114. RUGO HS, Van Poznak CH, Neven P, Danielewicz I, et al
    Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.
    Breast Cancer Res Treat. 2023 Dec 20. doi: 10.1007/s10549-023-07147.
    >> Share

  115. BALMANA J, Fasching PA, Couch FJ, Delaloge S, et al
    Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
    Breast Cancer Res Treat. 2023 Dec 19. doi: 10.1007/s10549-023-07165.
    >> Share

  116. BRUNELLE CL, Boyages J, Jung AW, Suami H, et al
    Breast lymphedema following breast-conserving treatment for breast cancer: current status and future directions.
    Breast Cancer Res Treat. 2023 Dec 15. doi: 10.1007/s10549-023-07161.
    >> Share

  117. JIA M, Pan L, Yang H, Gao J, et al
    Impact of neoadjuvant chemotherapy on breast cancer-related lymphedema after axillary lymph node dissection: a retrospective cohort study.
    Breast Cancer Res Treat. 2023 Dec 15. doi: 10.1007/s10549-023-07183.
    >> Share

  118. PAIK PS, Choi JE, Lee SW, Lee YJ, et al
    Correction to: Clinical characteristics and prognosis of postpartum breast cancer.
    Breast Cancer Res Treat. 2023 Dec 14. doi: 10.1007/s10549-023-07189.
    >> Share

  119. BARNARD ME, DuPre NC, Heine JJ, Fowler EE, et al
    Reproductive risk factors for breast cancer and association with novel breast density measurements among Hispanic, Black, and White women.
    Breast Cancer Res Treat. 2023 Dec 14. doi: 10.1007/s10549-023-07174.
    >> Share

  120. GHOLAMI M
    FTO is a major genetic link between breast cancer, obesity, and diabetes.
    Breast Cancer Res Treat. 2023 Dec 9. doi: 10.1007/s10549-023-07188.
    >> Share

  121. OLSSON LT, Hamilton AM, Van Alsten SC, Lund JL, et al
    Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer.
    Breast Cancer Res Treat. 2023 Dec 9. doi: 10.1007/s10549-023-07164.
    >> Share

  122. LI H, Plichta JK, Li K, Jin Y, et al
    Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
    Breast Cancer Res Treat. 2023 Dec 8. doi: 10.1007/s10549-023-07171.
    >> Share

  123. ACCORDINO MK, Lee S, Leu CS, Levin B, et al
    Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer.
    Breast Cancer Res Treat. 2023 Dec 7. doi: 10.1007/s10549-023-07172.
    >> Share

  124. KEESARI PR, Jain A, Ganampet NR, Subhasri GSD, et al
    Association between prediabetes and breast cancer: a comprehensive meta-analysis.
    Breast Cancer Res Treat. 2023 Dec 7. doi: 10.1007/s10549-023-07181.
    >> Share

  125. DIGKAS E, Smith DR, Wennstig AK, Matikas A, et al
    Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study.
    Breast Cancer Res Treat. 2023 Dec 7. doi: 10.1007/s10549-023-07184.
    >> Share

  126. YAHYA SMM, Nabih HK, Elsayed GH, Mohamed SIA, et al
    Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene.
    Breast Cancer Res Treat. 2023 Dec 7. doi: 10.1007/s10549-023-07170.
    >> Share

  127. ZWAGER MC, Holt-Kedde I, Timmer-Bosscha H, de Bock GH, et al
    Presence of crown-like structures in breast adipose tissue; differences between healthy controls, BRCA1/2 gene mutation carriers and breast cancer patients.
    Breast Cancer Res Treat. 2023 Dec 6. doi: 10.1007/s10549-023-07169.
    >> Share

  128. ALTUNDAG K
    The role of endocrine treatment on the risk of developing an ipsilateral invasive breast cancer in hormone receptor positive patients with ductal carcinoma in situ.
    Breast Cancer Res Treat. 2023 Dec 5. doi: 10.1007/s10549-023-07212.
    >> Share

  129. ONEGA T, Abraham L, Miglioretti DL, Lee CI, et al
    Digital mammography and digital breast tomosynthesis for detecting invasive lobular and ductal carcinoma.
    Breast Cancer Res Treat. 2023;202:505-514.
    >> Share

  130. SACAK B, Sakarya AH, Haytaoglu AA, Akdeniz Dogan Z, et al
    Do bilateral procedures further increase the complications for autologous breast reconstruction in obese patients?
    Breast Cancer Res Treat. 2023;202:435-442.
    >> Share

  131. KAWACHI K, Tang X, Kasajima R, Yamanaka T, et al
    Genetic analysis of low-grade adenosquamous carcinoma of the breast progressing to high-grade metaplastic carcinoma.
    Breast Cancer Res Treat. 2023;202:563-573.
    >> Share

  132. PRAVEEN KUMAR A, Vicente D, Liu J, Raj-Kumar PK, et al
    Association of clinicopathologic and molecular factors with the occurrence of positive margins in breast cancer.
    Breast Cancer Res Treat. 2023 Dec 1. doi: 10.1007/s10549-023-07157.
    >> Share

    November 2023
  133. MAYER EL, Tayob N, Ren S, Savoie JJ, et al
    A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
    Breast Cancer Res Treat. 2023 Nov 29. doi: 10.1007/s10549-023-07167.
    >> Share

  134. BLANSKY D, Ansari N, Gao L, Sokol ES, et al
    Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study.
    Breast Cancer Res Treat. 2023 Nov 24. doi: 10.1007/s10549-023-07179.
    >> Share

  135. ALAEIKHANEHSHIR S, Schmitz RSJM, van den Belt-Dusebout AW, van Duijnhoven FH, et al
    The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population.
    Breast Cancer Res Treat. 2023 Nov 14. doi: 10.1007/s10549-023-07168.
    >> Share

  136. LOONIS AT, Chesebro AL, Bay CP, Portnow LH, et al
    Positive predictive value of axillary lymph node cortical thickness and nodal, clinical, and tumor characteristics in newly diagnosed breast cancer patients.
    Breast Cancer Res Treat. 2023 Nov 10. doi: 10.1007/s10549-023-07155.
    >> Share

  137. MARTINS-BRANCO D, Kassapian M, Debien V, Caparica R, et al
    The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
    Breast Cancer Res Treat. 2023 Nov 8. doi: 10.1007/s10549-023-07159.
    >> Share

  138. RETELL JD, Cameron JK, Aitken JF, Youl P, et al
    Individual and area level factors associated with the breast cancer diagnostic-treatment interval in Queensland, Australia.
    Breast Cancer Res Treat. 2023 Nov 6. doi: 10.1007/s10549-023-07134.
    >> Share

  139. LEI L, Huang Y, Shi L, Ye W, et al
    Palbociclib sensitizes ER-positive breast cancer cells to fulvestrant by promoting the ubiquitin-mediated degradation of ER-alpha via SNHG17/Hippo-YAP axis.
    Breast Cancer Res Treat. 2023 Nov 4. doi: 10.1007/s10549-023-07138.
    >> Share

  140. MORI N
    Percutaneous and intravenous contrast material injection in contrast-enhanced ultrasound for sentinel lymph node evaluation in patients with breast cancer: importance of discussing difference in purposes.
    Breast Cancer Res Treat. 2023 Nov 4. doi: 10.1007/s10549-023-07166.
    >> Share

  141. GAUDIO M, Jacobs F, Benvenuti C, Saltalamacchia G, et al
    Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer.
    Breast Cancer Res Treat. 2023 Nov 4. doi: 10.1007/s10549-023-07151.
    >> Share

  142. RAJAN KK, Boersma C, Beek MA, Berendsen TA, et al
    Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2023 Nov 4. doi: 10.1007/s10549-023-07122.
    >> Share

  143. KANTOR ED, O'Connell K, Ergas IJ, Valice E, et al
    Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system.
    Breast Cancer Res Treat. 2023 Nov 4. doi: 10.1007/s10549-023-07126.
    >> Share

  144. KWON MR, Chang Y, Youn I, Kook SH, et al
    Diagnostic performance of screening mammography according to menstrual cycle among Asian women.
    Breast Cancer Res Treat. 2023;202:357-366.
    >> Share

  145. ALTUNDAG K
    Is mixed invasive ductal lobular carcinoma distinct from invasive lobular carcinoma?
    Breast Cancer Res Treat. 2023;202:409.
    >> Share

  146. BARKER CS, Chung CW, Mukherjee R, Siegel JB, et al
    The impact of nurse navigation on timeliness to treatment for benign high-risk breast pathology.
    Breast Cancer Res Treat. 2023;202:129-137.
    >> Share

  147. YANG L, Lin H, Shen Y, Roy M, et al
    Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study.
    Breast Cancer Res Treat. 2023;202:23-32.
    >> Share

  148. QU FL, Wu SY, Li JJ, Shao ZM, et al
    Ipsilateral breast tumor recurrence after breast-conserving surgery: insights into biology and treatment.
    Breast Cancer Res Treat. 2023;202:215-220.
    >> Share

  149. HASHIBA KA, Bahl M
    Ipsilateral tumor recurrence risk in women with ductal carcinoma in situ: application of the Van Nuys Prognostic Index and the Memorial Sloan Kettering Cancer Center nomogram.
    Breast Cancer Res Treat. 2023;202:185-190.
    >> Share

  150. BUBBERMAN JM, Claessen J, Feijen MMW, Meesters-Caberg MAJ, et al
    COVID-associated complications after reconstructive breast surgery: a retrospective cohort study.
    Breast Cancer Res Treat. 2023;202:257-265.
    >> Share

    October 2023
  151. AREVALO M, Pickering TA, Vernon SW, Fujimoto K, et al
    Racial/ethnic disparities in the association between patient care experiences and receipt of initial surgical breast cancer care: findings from SEER-CAHPS.
    Breast Cancer Res Treat. 2023 Oct 31. doi: 10.1007/s10549-023-07148.
    >> Share

  152. BLUM JL, DiCristo C, Gordon D, Karuturi MS, et al
    Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study.
    Breast Cancer Res Treat. 2023 Oct 30. doi: 10.1007/s10549-023-07145.
    >> Share

  153. PARK S, Choi C, Kim H, Shin YJ, et al
    Olaparib enhances sensitization of BRCA-proficient breast cancer cells to x-rays and protons.
    Breast Cancer Res Treat. 2023 Oct 30. doi: 10.1007/s10549-023-07150.
    >> Share

  154. HUANG HC, Guadamuz JS, Hoskins KF, Ko NY, et al
    Risk of contralateral breast cancer among Asian/Pacific Islander women in the United States.
    Breast Cancer Res Treat. 2023 Oct 28. doi: 10.1007/s10549-023-07140.
    >> Share

  155. SCHREUDER K, Bult TJ, Stroop B, Koppert LB, et al
    European quality indicators developed by the European Commission Initiative on Breast Cancer: a first nationwide assessment for the Dutch setting.
    Breast Cancer Res Treat. 2023 Oct 26. doi: 10.1007/s10549-023-07158.
    >> Share

  156. LI X, Li J, Hu Q, Zhang X, et al
    Association of physical weight statuses defined by body mass index (BMI) with molecular subtypes of premenopausal breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2023 Oct 26. doi: 10.1007/s10549-023-07139.
    >> Share

  157. MOLDOVEANU D, Hoskin TL, Day CN, Schulze AK, et al
    Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer.
    Breast Cancer Res Treat. 2023 Oct 25. doi: 10.1007/s10549-023-07152.
    >> Share

  158. ALTUNDAG K
    Interleukin-6 and C-Reactive protein in metastatic breast cancer patients treated with eribulin.
    Breast Cancer Res Treat. 2023 Oct 25. doi: 10.1007/s10549-023-07156.
    >> Share

  159. BRANDAO M, Martins-Branco D, De Angelis C, Vuylsteke P, et al
    Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
    Breast Cancer Res Treat. 2023 Oct 25. doi: 10.1007/s10549-023-07116.
    >> Share

  160. WOOLPERT KM, Ahern TP, Lash TL, O'Malley DL, et al
    Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2023 Oct 25. doi: 10.1007/s10549-023-07149.
    >> Share

  161. BENNETT DL, Winter AM, Billadello L, Lowdermilk MC, et al
    Breast cancer outcomes based on method of detection in community-based breast cancer registry.
    Breast Cancer Res Treat. 2023 Oct 25. doi: 10.1007/s10549-023-07092.
    >> Share

  162. LAMMERS SWM, Thurisch H, Vriens IJH, Meegdes M, et al
    The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
    Breast Cancer Res Treat. 2023 Oct 25. doi: 10.1007/s10549-023-07108.
    >> Share

  163. IWAMOTO T, Niikura N, Watanabe K, Takeshita T, et al
    Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
    Breast Cancer Res Treat. 2023 Oct 25. doi: 10.1007/s10549-023-07144.
    >> Share

  164. CHECK DK, Jackson BE, Reeder-Hayes KE, Dinan MA, et al
    Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer.
    Breast Cancer Res Treat. 2023 Oct 24. doi: 10.1007/s10549-023-07142.
    >> Share

  165. ROGERS C, Cobb AN, Lloren JIC, Chaudhary LN, et al
    National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial.
    Breast Cancer Res Treat. 2023 Oct 20. doi: 10.1007/s10549-023-07114.
    >> Share

  166. SHAH SA, Zhang Y, Correa AM, Hijaz BA, et al
    Rates of price disclosure associated with the surgical treatment of early-stage breast cancer one year after implementation of federal regulations.
    Breast Cancer Res Treat. 2023 Oct 18. doi: 10.1007/s10549-023-07160.
    >> Share

  167. HSU YC, Chen HL, Cheng CF, Chattopadhyay A, et al
    The largest genome-wide association study for breast cancer in Taiwanese Han population.
    Breast Cancer Res Treat. 2023 Oct 18. doi: 10.1007/s10549-023-07133.
    >> Share

  168. SHIM VC, Baker RJ, Jing W, Puentes R, et al
    Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system.
    Breast Cancer Res Treat. 2023 Oct 17. doi: 10.1007/s10549-023-07118.
    >> Share

  169. HU B, Hu J
    Complete elimination of estrogen receptor alpha by PROTAC estrogen receptor alpha degrader ERD-148 in breast cancer cells.
    Breast Cancer Res Treat. 2023 Oct 17. doi: 10.1007/s10549-023-07136.
    >> Share

  170. YUE M, Wu S, Liu C, Cai L, et al
    Clinicopathological features and prognostic analysis of HER2 low and fibrotic focus in HER2-negative breast cancer.
    Breast Cancer Res Treat. 2023 Oct 16. doi: 10.1007/s10549-023-07103.
    >> Share

  171. LEE TH, Ahn SH, Chung K, Park W, et al
    Quantitative assessment of breast volume changes after whole-breast irradiation for breast cancer using breast auto-segmentation.
    Breast Cancer Res Treat. 2023 Oct 13. doi: 10.1007/s10549-023-07146.
    >> Share

  172. GU S, Dusza S, Quigley E, Haliasos H, et al
    Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.
    Breast Cancer Res Treat. 2023 Oct 13. doi: 10.1007/s10549-023-07143.
    >> Share

  173. ROTHSCHILD HT, Clelland EN, Abel MK, Chien AJ, et al
    The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    Breast Cancer Res Treat. 2023 Oct 13. doi: 10.1007/s10549-023-07125.
    >> Share

  174. CARBAJAL-OCHOA W, Bravo-Solarte DC, Bernal AM, Anampa JD, et al
    Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.
    Breast Cancer Res Treat. 2023 Oct 13. doi: 10.1007/s10549-023-07132.
    >> Share

  175. GUMUSAY O, Huppert LA, Magbanua MJM, Wabl CA, et al
    A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
    Breast Cancer Res Treat. 2023 Oct 10. doi: 10.1007/s10549-023-07073.
    >> Share

  176. SCHIZA A, Fredriksson I, Sund M, Valachis A, et al
    Treatment utilization and effectiveness of neoadjuvant chemotherapy comparing men and women diagnosed with breast cancer: a Swedish retrospective cohort study.
    Breast Cancer Res Treat. 2023 Oct 9. doi: 10.1007/s10549-023-07129.
    >> Share

  177. LIM SZ, Yoo TK, Lee SB, Kim J, et al
    Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2023 Oct 5. doi: 10.1007/s10549-023-07104.
    >> Share

  178. VAN ROOZENDAAL LM, Vane MLG, Colier E, Strobbe LJA, et al
    Gene expression profiles in clinically T1-2N0 ER+HER2- breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed.
    Breast Cancer Res Treat. 2023 Oct 5. doi: 10.1007/s10549-023-07128.
    >> Share

  179. WU S, Ma X, Zhang X, Shi C, et al
    Relationship between oily fish intake and breast cancer based on estrogen receptor status: a Mendelian randomization study.
    Breast Cancer Res Treat. 2023 Oct 3. doi: 10.1007/s10549-023-07130.
    >> Share

  180. HE P, Li J, Chen M, Huang M, et al
    Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis.
    Breast Cancer Res Treat. 2023 Oct 3. doi: 10.1007/s10549-023-07105.
    >> Share

  181. SHARMA T, Zhang Y, Zigrossi A, Cravatt BF, et al
    Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers.
    Breast Cancer Res Treat. 2023;201:561-570.
    >> Share

  182. CHEN BF, Tsai YF, Lien PJ, Lin YS, et al
    Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases.
    Breast Cancer Res Treat. 2023;201:547-560.
    >> Share

  183. TSUNOKAKE S, Iwabuchi E, Miki Y, Kanai A, et al
    SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast.
    Breast Cancer Res Treat. 2023;201:499-513.
    >> Share

    September 2023
  184. LOPEZ-TARRUELLA S, Del Monte-Millan M, Roche-Molina M, Jerez Y, et al
    Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
    Breast Cancer Res Treat. 2023 Sep 29. doi: 10.1007/s10549-023-07094.
    >> Share

  185. PESAPANE F, Nicosia L, Tantrige P, Schiaffino S, et al
    Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study.
    Breast Cancer Res Treat. 2023 Sep 25. doi: 10.1007/s10549-023-07093.
    >> Share

  186. RAVANI LV, Calomeni P, Wang M, Deng D, et al
    Comparison of partial-breast irradiation and intraoperative radiation to whole-breast irradiation in early-stage breast cancer patients: a Kaplan-Meier-derived patient data meta-analysis.
    Breast Cancer Res Treat. 2023 Sep 22. doi: 10.1007/s10549-023-07112.
    >> Share

  187. BUN A, Nagahashi M, Kuroiwa M, Komatsu M, et al
    Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin.
    Breast Cancer Res Treat. 2023 Sep 21. doi: 10.1007/s10549-023-07086.
    >> Share

  188. HEREDIA A, Walbaum B, Vidal M, Itriago L, et al
    Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study.
    Breast Cancer Res Treat. 2023 Sep 21. doi: 10.1007/s10549-023-07117.
    >> Share

  189. SHIMIZU T, Oba T, Oshi M, Ito KI, et al
    Eribulin promotes proliferation of CD8(+) T cells and potentiates T cell-mediated anti-tumor activity against triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2023 Sep 21. doi: 10.1007/s10549-023-07111.
    >> Share

  190. ISHIZUKA Y, Horimoto Y, Eguchi H, Murakami F, et al
    BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2023 Sep 20. doi: 10.1007/s10549-023-07115.
    >> Share

  191. CHLEBOWSKI RT, Aragaki AK
    Long-term breast cancer incidence trends by mammography, obesity, and menopausal hormone therapy.
    Breast Cancer Res Treat. 2023 Sep 20. doi: 10.1007/s10549-023-07113.
    >> Share

  192. SHEKAR N, Vuong P, Kaur P
    Analysing potent biomarkers along phytochemicals for breast cancer therapy: an in silico approach.
    Breast Cancer Res Treat. 2023 Sep 20. doi: 10.1007/s10549-023-07107.
    >> Share

  193. VAN WIJK LM, Vermeulen S, Ter Haar NT, Kramer CJH, et al
    Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissue.
    Breast Cancer Res Treat. 2023 Sep 19. doi: 10.1007/s10549-023-07102.
    >> Share

  194. SHARMA R
    Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990-2019: an examination using estimates from the global burden of disease 2019 study.
    Breast Cancer Res Treat. 2023 Sep 17. doi: 10.1007/s10549-023-07075.
    >> Share

  195. KOSTEV K, Kalder M
    Low incidence of distant metastases in older women with non-metastatic breast cancer treated with primary endocrine therapy.
    Breast Cancer Res Treat. 2023 Sep 15. doi: 10.1007/s10549-023-07121.
    >> Share

  196. COSTEIRA B, da Silva FB, Fonseca F, Oom R, et al
    Long-term locoregional recurrence in patients treated for breast cancer.
    Breast Cancer Res Treat. 2023 Sep 14. doi: 10.1007/s10549-023-07089.
    >> Share

  197. ZHANG X, Huang L, Sun J, Liu J, et al
    Monopolar spindle 1 contributes to tamoxifen resistance in breast cancer through phosphorylation of estrogen receptor alpha.
    Breast Cancer Res Treat. 2023 Sep 11. doi: 10.1007/s10549-023-07098.
    >> Share

  198. PEDERSINI R, Lagana M, Bosio S, Zanini B, et al
    Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy.
    Breast Cancer Res Treat. 2023 Sep 11. doi: 10.1007/s10549-023-07095.
    >> Share

  199. DOSHI SD, DeStephano D, Accordino MK, Elkin E, et al
    Disparities with influenza vaccine use in long-term survivors of metastatic breast cancer.
    Breast Cancer Res Treat. 2023 Sep 9. doi: 10.1007/s10549-023-07109.
    >> Share

  200. SASADA S, Kondo N, Hashimoto H, Takahashi Y, et al
    Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.
    Breast Cancer Res Treat. 2023 Sep 9. doi: 10.1007/s10549-023-07097.
    >> Share

  201. HARTMANN S, Banys-Paluchowski M, Stickeler E, de Boniface J, et al
    Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study.
    Breast Cancer Res Treat. 2023 Sep 8. doi: 10.1007/s10549-023-07100.
    >> Share

  202. PISLAR N, Gasljevic G, Ratosa I, Kovac A, et al
    Absence of post-treatment changes in sentinel lymph nodes does not translate into increased regional recurrence rate in initially node-positive breast cancer patients.
    Breast Cancer Res Treat. 2023 Sep 7. doi: 10.1007/s10549-023-07084.
    >> Share

  203. TAKADA M, Imoto S, Ishida T, Ito Y, et al
    A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
    Breast Cancer Res Treat. 2023 Sep 7. doi: 10.1007/s10549-023-07099.
    >> Share

  204. DANIEL O, Ashrafi A, Muthoni MA, Njoki N, et al
    Delayed breast cancer presentation, diagnosis, and treatment in Kenya.
    Breast Cancer Res Treat. 2023 Sep 5. doi: 10.1007/s10549-023-07067.
    >> Share

  205. EOCHAGAIN CM, Battisti NML
    Reporting of older subgroups in registration breast cancer trials 2012-2021.
    Breast Cancer Res Treat. 2023 Sep 4. doi: 10.1007/s10549-023-07081.
    >> Share

  206. CZENCZEK-LEWANDOWSKA E, Szeliga E, Leszczak J
    The effect of aquatic and land exercise on the mental well-being of women following breast cancer surgery-comparative study.
    Breast Cancer Res Treat. 2023 Sep 4. doi: 10.1007/s10549-023-07088.
    >> Share

  207. SCHANDIZ H, Park D, Kaiser YL, Lyngra M, et al
    Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.
    Breast Cancer Res Treat. 2023;201:329-338.
    >> Share

  208. FRIEDMAN R, Spiegel DY, Kinney J, Willcox J, et al
    Quantifying radiation in the axillary bed at the site of lymphedema surgical prevention.
    Breast Cancer Res Treat. 2023;201:299-305.
    >> Share

  209. MARIAPUN S, Ho WK, Eriksson M, Tai MC, et al
    Evaluation of SNPs associated with mammographic density in European women with mammographic density in Asian women from South-East Asia.
    Breast Cancer Res Treat. 2023;201:237-245.
    >> Share

  210. JORDT N, Kjaergaard KA, Thomsen RW, Borgquist S, et al
    Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2023 Sep 1. doi: 10.1007/s10549-023-07043.
    >> Share

    August 2023
  211. CONLEY CC, Rodriguez JD, McIntyre M, Brownstein NC, et al
    Self-reported barriers to screening breast MRI among women at high risk for breast cancer.
    Breast Cancer Res Treat. 2023 Aug 28. doi: 10.1007/s10549-023-07085.
    >> Share

  212. TANG L, Wei D, Xu X, Mo D, et al
    FOXO1-regulated lncRNA CYP1B1-AS1 suppresses breast cancer cell proliferation by inhibiting neddylation.
    Breast Cancer Res Treat. 2023 Aug 28. doi: 10.1007/s10549-023-07090.
    >> Share

  213. CHEN Z, Jia H, Zhang H, Chen L, et al
    Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients.
    Breast Cancer Res Treat. 2023 Aug 28. doi: 10.1007/s10549-023-07079.
    >> Share

  214. SUI L, Yan Y, Jiang T, Ou D, et al
    Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case-control study.
    Breast Cancer Res Treat. 2023 Aug 28. doi: 10.1007/s10549-023-07057.
    >> Share

  215. ALEIXO GFP, Valente SA, Wei W, Moore HCF, et al
    Association of body composition and surgical outcomes in patients with early-stage breast cancer.
    Breast Cancer Res Treat. 2023 Aug 28. doi: 10.1007/s10549-023-07060.
    >> Share

  216. CHEN N, Cheng D, Sodipo MO, Barnard ME, et al
    Impact of age, race, and family history on COVID-19-related changes in breast cancer screening among the Boston mammography cohort study.
    Breast Cancer Res Treat. 2023 Aug 25. doi: 10.1007/s10549-023-07083.
    >> Share

  217. KAIYIN M, Lingling T, Leilei T, Wenjia L, et al
    Head-to-head comparison of contrast-enhanced mammography and contrast-enhanced MRI for assessing pathological complete response to neoadjuvant therapy in patients with breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2023 Aug 24. doi: 10.1007/s10549-023-07034.
    >> Share

  218. ISIKLAR AD, Aliyeva L, Yesilyurt A, Soyder A, et al
    Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
    Breast Cancer Res Treat. 2023 Aug 24. doi: 10.1007/s10549-023-07074.
    >> Share

  219. BAO T, Zhi WI, Baser RE, Li QS, et al
    Electro-acupuncture versus battle field auricular acupuncture in breast cancer survivors with chronic musculoskeletal pain: subgroup analysis of a randomized clinical trial.
    Breast Cancer Res Treat. 2023 Aug 24. doi: 10.1007/s10549-023-07072.
    >> Share

  220. LENZ L, Neff C, Solimeno C, Cogan ES, et al
    Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
    Breast Cancer Res Treat. 2023 Aug 17. doi: 10.1007/s10549-023-07046.
    >> Share

  221. MALMGREN JA, Guo B, Atwood MK, Hallam P, et al
    COVID-19 related change in breast cancer diagnosis, stage, treatment, and case volume: 2019-2021.
    Breast Cancer Res Treat. 2023 Aug 16. doi: 10.1007/s10549-023-06962.
    >> Share

  222. BEHROUZI R, Armstrong AC, Howell SJ
    CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.
    Breast Cancer Res Treat. 2023 Aug 16. doi: 10.1007/s10549-023-07035.
    >> Share

  223. DE PADUA SOUZA C, Carneiro ASB, de Oliveira Lessa AC, Lacerda DC, et al
    Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.
    Breast Cancer Res Treat. 2023 Aug 14. doi: 10.1007/s10549-023-07011.
    >> Share

  224. GOEL N, Hernandez AE, Ream M, Clarke ES, et al
    Effects of neighborhood disadvantage on cortisol and interviewer-rated anxiety symptoms in breast cancer patients initiating treatment.
    Breast Cancer Res Treat. 2023 Aug 10. doi: 10.1007/s10549-023-07050.
    >> Share

  225. VOLMER LL, Dannehl D, Engler T, Hahn M, et al
    Association between 21-gene-assay and detection of disseminated tumor cells in patients with early breast cancer: results from the IRMA trial.
    Breast Cancer Res Treat. 2023 Aug 9. doi: 10.1007/s10549-023-07031.
    >> Share

  226. PAIK PS, Choi JE, Lee SW, Lee YJ, et al
    Clinical characteristics and prognosis of postpartum breast cancer.
    Breast Cancer Res Treat. 2023 Aug 5. doi: 10.1007/s10549-023-07069.
    >> Share

  227. ROY AM, George A, Attwood K, Alaklabi S, et al
    Effect of neighborhood deprivation index on breast cancer survival in the United States.
    Breast Cancer Res Treat. 2023 Aug 5. doi: 10.1007/s10549-023-07053.
    >> Share

  228. BEVERLY HERY CM, Janse SA, Van Zee KJ, Naftalis EZ, et al
    Factors associated with insomnia symptoms over three years among premenopausal women with breast cancer.
    Breast Cancer Res Treat. 2023 Aug 5. doi: 10.1007/s10549-023-07058.
    >> Share

  229. HAO Y, Xiao J, Fu P, Yan L, et al
    Increases in BMI contribute to worsening inflammatory biomarkers related to breast cancer risk in women: a longitudinal study.
    Breast Cancer Res Treat. 2023 Aug 5. doi: 10.1007/s10549-023-07023.
    >> Share

  230. DAVEY MG, Abbas R, Kerin EP, Casey MC, et al
    Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer.
    Breast Cancer Res Treat. 2023 Aug 4. doi: 10.1007/s10549-023-07033.
    >> Share

  231. DUX J, Habibi M, Malik H, Jacobs L, et al
    Impact of axillary surgery on outcome of clinically node positive breast cancer treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2023 Aug 2. doi: 10.1007/s10549-023-07062.
    >> Share

  232. POREMBKA JH, Seiler SJ, Ozcan BB, Evans WP, et al
    Surviving the COVID-19 pandemic: navigating the recovery of breast imaging services in a safety-net hospital.
    Breast Cancer Res Treat. 2023;201:127-138.
    >> Share

  233. HENNEGHAN AM, Van Dyk K, Zhou X, Moore RC, et al
    Validating the PROMIS cognitive function short form in cancer survivors.
    Breast Cancer Res Treat. 2023;201:139-145.
    >> Share

  234. DUBASH TD, Bardia A, Chirn B, Reeves BA, et al
    Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
    Breast Cancer Res Treat. 2023;201:43-56.
    >> Share

  235. KRUSE M, Smyth EN, Bowman L, Gautam S, et al
    Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world.
    Breast Cancer Res Treat. 2023;201:105-115.
    >> Share

  236. SCHAFGEN B, Haller A, Sinn HP, Feisst M, et al
    Conventional specimen radiography in breast-conserving therapy: a useful tool for intraoperative margin assessment after neoadjuvant therapy?
    Breast Cancer Res Treat. 2023;201:57-66.
    >> Share

  237. CLARK BZ, Johnson RR, Berg WA, McAuliffe P, et al
    Response in axillary lymph nodes to neoadjuvant chemotherapy for breast cancers: correlation with breast response, pathologic features, and accuracy of radioactive seed localization.
    Breast Cancer Res Treat. 2023;200:363-373.
    >> Share

  238. MUHAMMAD N, Azeem A, Bakar MA, Prajzendanc K, et al
    Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan.
    Breast Cancer Res Treat. 2023 Aug 1. doi: 10.1007/s10549-023-07068.
    >> Share

  239. LI F, Chen H, Lu X, Wei Y, et al
    Combining the tumor-stroma ratio with tumor-infiltrating lymphocytes improves the prediction of pathological complete response in breast cancer patients.
    Breast Cancer Res Treat. 2023 Aug 1. doi: 10.1007/s10549-023-07026.
    >> Share

  240. DAHL AA, Smedsland SK, Vandraas KF, Bohn SK, et al
    High neuroticism is associated with common late adverse effects in a nationwide sample of long-term breast cancer survivors.
    Breast Cancer Res Treat. 2023 Aug 1. doi: 10.1007/s10549-023-07055.
    >> Share

  241. PAEIZ H, Salehi Z, Mashayekhi F, Saeidi Saedi H, et al
    The importance of SOCS1 - 1478 CA/del polymorphism and expression in breast cancer: a case-control study in the north of Iran.
    Breast Cancer Res Treat. 2023 Aug 1. doi: 10.1007/s10549-023-07070.
    >> Share

    July 2023
  242. JIANG C, Hu F, Li J, Gao G, et al
    Diagnostic value of alkaline phosphatase and bone-specific alkaline phosphatase for metastases in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2023 Jul 31. doi: 10.1007/s10549-023-07066.
    >> Share

  243. GREMKE N, Wagner U, Kalder M, Kostev K, et al
    Changes in the incidence of early-onset breast cancer in Germany between 2010 and 2022.
    Breast Cancer Res Treat. 2023 Jul 31. doi: 10.1007/s10549-023-07048.
    >> Share

  244. AMATO S, Ramsey J, Ahern TP, Rovnak J, et al
    Exploring the presence of bovine leukemia virus among breast cancer tumors in a rural state.
    Breast Cancer Res Treat. 2023 Jul 30. doi: 10.1007/s10549-023-07061.
    >> Share

  245. LIU X, Wang M, Wang Q, Zhang H, et al
    Diagnostic value of contrast-enhanced ultrasound for sentinel lymph node metastasis in breast cancer: an updated meta-analysis.
    Breast Cancer Res Treat. 2023 Jul 27. doi: 10.1007/s10549-023-07063.
    >> Share

  246. CLELLAND EN, Rothschild HT, Patterson A, Molina-Vega J, et al
    Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
    Breast Cancer Res Treat. 2023 Jul 27. doi: 10.1007/s10549-023-07059.
    >> Share

  247. VAN HAAREN ERM, Poodt IGM, Spiekerman van Weezelenburg MA, van Bastelaar J, et al
    Impact of analysis of the sentinel lymph node by one-step nucleic acid amplification (OSNA) compared to conventional histopathology on axillary and systemic treatment: data from the Dutch nationwide cohort of breast cancer patients.
    Breast Cancer Res Treat. 2023 Jul 27. doi: 10.1007/s10549-023-07065.
    >> Share

  248. FALTINOVA M, Vehmanen L, Lyytinen H, Haanpaa M, et al
    Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen meas
    Breast Cancer Res Treat. 2023 Jul 25. doi: 10.1007/s10549-023-07054.
    >> Share

  249. MUENDLEIN A, Heinzle C, Brandtner EM, Leiherer A, et al
    Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients.
    Breast Cancer Res Treat. 2023 Jul 25. doi: 10.1007/s10549-023-07045.
    >> Share

  250. DOLEGA-KOZIEROWSKI B, Kasprzak P, Lis M, Szynglarewicz B, et al
    Numerical and physical modeling of breast cancer based on image fusion and artificial intelligence.
    Breast Cancer Res Treat. 2023 Jul 25. doi: 10.1007/s10549-023-07056.
    >> Share

  251. UGURLU MU, Bugdayci O, Akmercan A, Kaya H, et al
    Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple?
    Breast Cancer Res Treat. 2023 Jul 25. doi: 10.1007/s10549-023-07041.
    >> Share

  252. SMEDSLAND SK, Vandraas KF, Falk RS, Horn J, et al
    Sexual health in long-term breast cancer survivors: a comparison with female population controls from the HUNT study.
    Breast Cancer Res Treat. 2023 Jul 25. doi: 10.1007/s10549-023-07021.
    >> Share

  253. KOBAYASHI K, Masuda N, Mizuno T, Miura K, et al
    Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
    Breast Cancer Res Treat. 2023 Jul 22. doi: 10.1007/s10549-023-07030.
    >> Share

  254. STAFFORD L, Sinclair M, Butow P, Hughes J, et al
    Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence in women with early breast cancer? An exploratory study.
    Breast Cancer Res Treat. 2023 Jul 22. doi: 10.1007/s10549-023-07039.
    >> Share

  255. WAAIJER MEC, Lemij AA, de Boer AZ, Bastiaannet E, et al
    The impact of geriatric characteristics and comorbidities on distant metastases and other cause mortality in older women with non-metastatic breast cancer treated with primary endocrine therapy.
    Breast Cancer Res Treat. 2023 Jul 21. doi: 10.1007/s10549-023-07029.
    >> Share

  256. ADACHI Y, Asaga S, Kumamaru H, Kinugawa N, et al
    Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry.
    Breast Cancer Res Treat. 2023 Jul 21. doi: 10.1007/s10549-023-07022.
    >> Share

  257. KNERR S, Guo B, Wernli KJ, Mittendorf KF, et al
    Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system.
    Breast Cancer Res Treat. 2023 Jul 20. doi: 10.1007/s10549-023-07007.
    >> Share

  258. SKJERVOLD AH, Valla M, Bofin AM
    Oestrogen receptor low positive breast cancer: associations with prognosis.
    Breast Cancer Res Treat. 2023 Jul 18. doi: 10.1007/s10549-023-07040.
    >> Share

  259. CHAUDHARY LN, Jorns JM, Sun Y, Cheng YC, et al
    Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy.
    Breast Cancer Res Treat. 2023 Jul 17. doi: 10.1007/s10549-023-07038.
    >> Share

  260. CHEN C, Ye L, Yi J, Liu T, et al
    FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer.
    Breast Cancer Res Treat. 2023 Jul 17. doi: 10.1007/s10549-023-07032.
    >> Share

  261. MOHAMED A, Olsson LT, Geradts J
    Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index.
    Breast Cancer Res Treat. 2023 Jul 15. doi: 10.1007/s10549-023-07025.
    >> Share

  262. BORKJA MLB, Giambelluca MS, Ytterhus B, Prestvik WS, et al
    S100A8 gene copy number and protein expression in breast cancer: associations with proliferation, histopathological grade and molecular subtypes.
    Breast Cancer Res Treat. 2023 Jul 14. doi: 10.1007/s10549-023-07019.
    >> Share

  263. CARBAJAL-OCHOA WH, Johnson D, Alvarez A, Bernal AM, et al
    Racial disparities in treatment and outcomes between non-Hispanic Black and non-Hispanic White women with nonmetastatic inflammatory breast cancer.
    Breast Cancer Res Treat. 2023 Jul 13. doi: 10.1007/s10549-023-07018.
    >> Share

  264. JINNA ND, Van Alsten S, Rida P, Seewaldt VL, et al
    Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study.
    Breast Cancer Res Treat. 2023 Jul 12. doi: 10.1007/s10549-023-07014.
    >> Share

  265. ANDERSON S, Bartow BB, Siegal GP, Huang X, et al
    The dynamics of HER2-low expression during breast cancer progression.
    Breast Cancer Res Treat. 2023 Jul 12. doi: 10.1007/s10549-023-07020.
    >> Share

  266. CHEN W, Hu L, Lu X, Wang X, et al
    The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.
    Breast Cancer Res Treat. 2023 Jul 11. doi: 10.1007/s10549-023-07028.
    >> Share

  267. KOTSOPOULOS J, Gronwald J, Huzarski T, Aeilts A, et al
    Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
    Breast Cancer Res Treat. 2023 Jul 11. doi: 10.1007/s10549-023-06991.
    >> Share

  268. WANG G, Tang M, Liu Z
    Letter to the editor regarding "Association between gout and subsequent breast cancer: a retrospective cohort study including 67,598 primary care patients in Germany".
    Breast Cancer Res Treat. 2023 Jul 10. doi: 10.1007/s10549-023-06975.
    >> Share

  269. JAASKELAINEN MM, Tiainen S, Siiskonen H, Ahtiainen M, et al
    The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer.
    Breast Cancer Res Treat. 2023 Jul 10. doi: 10.1007/s10549-023-07017.
    >> Share

  270. AVILA J, Herrick B, Attai DJ, Leone JP, et al
    Treatments for breast cancer in men: late effects and impact on quality of life.
    Breast Cancer Res Treat. 2023 Jul 7. doi: 10.1007/s10549-023-07027.
    >> Share

  271. TAN AR, O'Shaughnessy J, Cao S, Ahn S, et al
    Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer.
    Breast Cancer Res Treat. 2023 Jul 7. doi: 10.1007/s10549-023-07009.
    >> Share

  272. SHIBATA N, Yoshinami T, Tamaki K, Nukada T, et al
    Real-world data analysis of perioperative chemotherapy patterns, G-CSF use, and FN status in patients with early breast cancer.
    Breast Cancer Res Treat. 2023 Jul 6. doi: 10.1007/s10549-023-07015.
    >> Share

  273. PLOUMEN RAW, Claassens EL, Kooreman LFS, Keymeulen KBMI, et al
    Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis.
    Breast Cancer Res Treat. 2023 Jul 3. doi: 10.1007/s10549-023-07012.
    >> Share

  274. ALTWEGG KA, Pratap UP, Liu Z, Liu J, et al
    Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34.
    Breast Cancer Res Treat. 2023;200:151-162.
    >> Share

  275. DAVIES C, Whisker L, Skillman J, Macmillan D, et al
    Current practice and provision of oncoplastic breast-conserving surgery in the UK: results of the ANTHEM national practice questionnaire.
    Breast Cancer Res Treat. 2023;200:163-170.
    >> Share

  276. KUTLUER N, Solmaz OA, Yamacli V, Eristi B, et al
    Classification of breast tumors by using a novel approach based on deep learning methods and feature selection.
    Breast Cancer Res Treat. 2023;200:183-192.
    >> Share

  277. JOSHI U, Budhathoki P, Gaire S, Yadav SK, et al
    Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast.
    Breast Cancer Res Treat. 2023;200:217-224.
    >> Share

  278. CHU X, Wu M, Yang J, Fu Y, et al
    Organoid models derived from patients with malignant phyllodes tumor of the breast.
    Breast Cancer Res Treat. 2023;200:193-201.
    >> Share

  279. ROSIN J, Svegrup E, Valachis A, Zerdes I, et al
    Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2023 Jul 1. doi: 10.1007/s10549-023-07010.
    >> Share

    June 2023
  280. ARAI N, Hattori N, Yamashita S, Liu YY, et al
    HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity.
    Breast Cancer Res Treat. 2023 Jun 28. doi: 10.1007/s10549-023-07013.
    >> Share

  281. KAHN AM, Golestani R, Harigopal M, Pusztai L, et al
    Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer.
    Breast Cancer Res Treat. 2023 Jun 28. doi: 10.1007/s10549-023-06977.
    >> Share

  282. HWANG I, Kim JE, Jeong JH, Ahn JH, et al
    Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in n
    Breast Cancer Res Treat. 2023 Jun 26. doi: 10.1007/s10549-023-06971.
    >> Share

  283. HAMERSMA DT, Schreuder K, Geleijnse G, Heeg E, et al
    Comparing quality of breast cancer care in the Netherlands and Norway by federated propensity score analytics.
    Breast Cancer Res Treat. 2023 Jun 25. doi: 10.1007/s10549-023-06986.
    >> Share

  284. TAUSCH C, Daster K, Hayoz S, Matrai Z, et al
    Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
    Breast Cancer Res Treat. 2023 Jun 25. doi: 10.1007/s10549-023-06999.
    >> Share

  285. CHEN TW, Hsiao W, Dai MS, Lin CH, et al
    Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2023 Jun 21. doi: 10.1007/s10549-023-06967.
    >> Share

  286. MARTIN M, Carrasco E, Rodriguez-Lescure A, Andres R, et al
    Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Alamo IV registry.
    Breast Cancer Res Treat. 2023 Jun 20. doi: 10.1007/s10549-023-07002.
    >> Share

  287. LAW R, Krupa K, Rusby J
    Preventative therapy for breast cancer: a clinical experience.
    Breast Cancer Res Treat. 2023 Jun 19. doi: 10.1007/s10549-023-06985.
    >> Share

  288. ROLLIN FG, Agrawal SS, Garcia MLW
    It is the impact of racism, not race, that causes breast cancer inequities.
    Breast Cancer Res Treat. 2023 Jun 19. doi: 10.1007/s10549-023-07008.
    >> Share

  289. ALTUNDAG K
    Is there any association between declined creatinine clearence and higher endoxifen levels in older patients with non-metastatic breast cancer?
    Breast Cancer Res Treat. 2023 Jun 17. doi: 10.1007/s10549-023-07004.
    >> Share

  290. LI X, Dai A, Tran R, Wang J, et al
    Identifying miRNA biomarkers for breast cancer and ovarian cancer: a text mining perspective.
    Breast Cancer Res Treat. 2023 Jun 17. doi: 10.1007/s10549-023-06996.
    >> Share

  291. YAO S, Zhang Q, Yao X, Zhang X, et al
    Advances of neuroimaging in chemotherapy related cognitive impairment (CRCI) of patients with breast cancer.
    Breast Cancer Res Treat. 2023 Jun 17. doi: 10.1007/s10549-023-07005.
    >> Share

  292. ZHENG D, Thomas J 3rd
    Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer.
    Breast Cancer Res Treat. 2023 Jun 16. doi: 10.1007/s10549-023-06992.
    >> Share

  293. RODIN D, Sutradhar R, Jerzak KJ, Hahn E, et al
    Impact of non-adherence to endocrine therapy on recurrence risk in older women with stage I breast cancer after breast-conserving surgery.
    Breast Cancer Res Treat. 2023 Jun 16. doi: 10.1007/s10549-023-06989.
    >> Share

  294. RILLAMAS-SUN E, Kwan ML, Iribarren C, Cheng R, et al
    Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.
    Breast Cancer Res Treat. 2023 Jun 16. doi: 10.1007/s10549-023-06997.
    >> Share

  295. CHRISTENHUSZ A, den Dekker BM, van Dalen T, Jongen L, et al
    Radiofrequency localization of nonpalpable breast cancer in a multicentre prospective cohort study: feasibility, clinical acceptability, and safety.
    Breast Cancer Res Treat. 2023 Jun 15. doi: 10.1007/s10549-023-07006.
    >> Share

  296. MA G, Wang J, Fu J, Chen R, et al
    Heterogeneous circulating tumor cells correlate with responses to neoadjuvant chemotherapy and prognosis in patients with locally advanced breast cancer.
    Breast Cancer Res Treat. 2023 Jun 13. doi: 10.1007/s10549-023-06942.
    >> Share

  297. BRAVACCINI S, Mazza M, Maltoni R
    No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country.
    Breast Cancer Res Treat. 2023 Jun 13. doi: 10.1007/s10549-023-07000.
    >> Share

  298. QIAN L, Li L, Li Y, Li S, et al
    LncRNA HOTAIR as a ceRNA is related to breast cancer risk and prognosis.
    Breast Cancer Res Treat. 2023 Jun 9. doi: 10.1007/s10549-023-06982.
    >> Share

  299. MULLINS MA, Atluri N, Abrahamse P, Radhakrishnan A, et al
    Primary care provider attitudes about and tendency to use non-recommended surveillance tests after curative breast cancer treatment.
    Breast Cancer Res Treat. 2023 Jun 9. doi: 10.1007/s10549-023-06994.
    >> Share

  300. TUFAIL M
    DNA repair pathways in breast cancer: from mechanisms to clinical applications.
    Breast Cancer Res Treat. 2023 Jun 8. doi: 10.1007/s10549-023-06995.
    >> Share

  301. ZHANG J, Miki Y, Iwabuchi E, Xu J, et al
    Induction of SGK1 via glucocorticoid-influenced clinical outcome of triple-negative breast cancer patients.
    Breast Cancer Res Treat. 2023 Jun 7. doi: 10.1007/s10549-023-06990.
    >> Share

  302. ALTUNDAG K
    The association of telomere length with exercise and diet might be time-dependent in breast cancer survivors.
    Breast Cancer Res Treat. 2023 Jun 7. doi: 10.1007/s10549-023-07003.
    >> Share

  303. PIVATTO JUNIOR F, Santos ABS, Englert EF, Mazzutti G, et al
    Monocyte-to-lymphocyte ratio as predictor of cancer therapy-related cardiotoxicity in patients with breast cancer: a pilot cohort study.
    Breast Cancer Res Treat. 2023 Jun 5. doi: 10.1007/s10549-023-06979.
    >> Share

  304. GIAP F, Ma SJ, Oladeru OT, Hong YR, et al
    Palliative care utilization and racial and ethnic disparities among women with de novo metastatic breast cancer in the United States.
    Breast Cancer Res Treat. 2023 Jun 3. doi: 10.1007/s10549-023-06963.
    >> Share

  305. PHAKATHI B, Dix-Peek T, Van Den Berg E, Dickens C, et al
    PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study.
    Breast Cancer Res Treat. 2023 Jun 2. doi: 10.1007/s10549-023-06969.
    >> Share

  306. MA T, Semsarian CR, Barratt A, Parker L, et al
    Should low-risk DCIS lose the cancer label? An evidence review.
    Breast Cancer Res Treat. 2023;199:415-433.
    >> Share

  307. LIU J, Li F, Liu X, Lang R, et al
    Malignant phyllodes tumors of the breast: the malignancy grading and associations with prognosis.
    Breast Cancer Res Treat. 2023;199:435-444.
    >> Share

  308. ASHRAFIAN H
    Earliest depiction of unilateral gynecomastia in history 300-250 B.C.
    Breast Cancer Res Treat. 2023;199:585-586.
    >> Share

  309. FAUVEAU LR, Dao TN, Wallace LB, Mamawala MK, et al
    Positive surgical margins after breast-conserving surgery for ductal carcinoma in-situ: does histologic grade or estrogen receptor status matter?
    Breast Cancer Res Treat. 2023;199:215-220.
    >> Share

  310. ROTHSCHILD HT, Clelland E, Patterson A, Molina-Vega J, et al
    HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    Breast Cancer Res Treat. 2023;199:349-354.
    >> Share

  311. JOHNS C, Montalvo SK, Cauble M, Liu YL, et al
    Aspirin use is associated with improvement in distant metastases outcome in patients with residual disease after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2023;199:381-387.
    >> Share

  312. NARAYAN P, Kostrzewa CE, Zhang Z, O'Brien DAR, et al
    Metaplastic carcinoma of the breast: matched cohort analysis of recurrence and survival.
    Breast Cancer Res Treat. 2023;199:355-361.
    >> Share

  313. RASTOGI P, Tang G, Hassan S, Geyer CE Jr, et al
    Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
    Breast Cancer Res Treat. 2023;199:243-252.
    >> Share

  314. SARS C, Sackey H, Frisell J, Dickman PW, et al
    Current clinical practice in the management of phyllodes tumors of the breast: an international cross-sectional study among surgeons and oncologists.
    Breast Cancer Res Treat. 2023;199:293-304.
    >> Share

    May 2023
  315. HUANG P, Li Q
    Comments on the effects of exercise and diet on oxidative stress and telomere length in breast cancer survivors.
    Breast Cancer Res Treat. 2023 May 31. doi: 10.1007/s10549-023-06987.
    >> Share

  316. VEMURU S, Huang J, Colborn K, Yoon Y, et al
    Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2023 May 26. doi: 10.1007/s10549-023-06978.
    >> Share

  317. ZHOU Y, Zhou J, Hao X, Shi H, et al
    Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy.
    Breast Cancer Res Treat. 2023 May 25. doi: 10.1007/s10549-023-06972.
    >> Share

  318. CARU M, Abdullah S, Qiu L, Kanski B, et al
    Women with metastatic breast cancer don't just follow step-count trends, they exceed them: an exploratory study.
    Breast Cancer Res Treat. 2023 May 25. doi: 10.1007/s10549-023-06980.
    >> Share

  319. BOS MK, Lam SW, Motta G, Helmijr JCA, et al
    Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.
    Breast Cancer Res Treat. 2023 May 25. doi: 10.1007/s10549-023-06965.
    >> Share

  320. BRYL K, Chimonas S, Li X, Li SQ, et al
    The relationship between anxiety and vaginal-related sexual health in postmenopausal breast cancer survivors on aromatase inhibitors therapies: a cross sectional study.
    Breast Cancer Res Treat. 2023 May 24. doi: 10.1007/s10549-023-06981.
    >> Share

  321. MILOSEVIC V, Edelmann RJ, Winge I, Strell C, et al
    Vessel size as a marker of survival in estrogen receptor positive breast cancer.
    Breast Cancer Res Treat. 2023 May 24. doi: 10.1007/s10549-023-06974.
    >> Share

  322. MARTIN-SALVAGO MD, Sancho M, Lopez-Garcia MA, Cano Jimenez A, et al
    Value of total tumor load as a clinical and pathological factor in the prognosis of breast cancer patients receiving neoadjuvant treatment. Comparison of three populations with three different surgical approaches: NEOVATTL Pro 3 Study.
    Breast Cancer Res Treat. 2023 May 23. doi: 10.1007/s10549-023-06954.
    >> Share

  323. MICHEL A, Ro V, McGuinness JE, Mutasa S, et al
    Breast cancer risk prediction combining a convolutional neural network-based mammographic evaluation with clinical factors.
    Breast Cancer Res Treat. 2023 May 20. doi: 10.1007/s10549-023-06966.
    >> Share

  324. KUMAR N, Gann PH, McGregor SM, Sethi A, et al
    Quantification of subtype purity in Luminal A breast cancer predicts clinical characteristics and survival.
    Breast Cancer Res Treat. 2023 May 20. doi: 10.1007/s10549-023-06961.
    >> Share

  325. FAN Y, Zhong X, Wang Y, Wang Z, et al
    A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2023 May 18. doi: 10.1007/s10549-023-06964.
    >> Share

  326. LEE SY, Yoo TK, Kim J, Chung IY, et al
    Clinical significance of microinvasive breast cancer across the different subtypes and human epidermal growth factor receptor 2 expression levels.
    Breast Cancer Res Treat. 2023 May 15. doi: 10.1007/s10549-023-06955.
    >> Share

  327. BYCHKOVSKY BL, Lo MT, Yussuf A, Horton C, et al
    Correction to: Pathogenic variants among females with breast cancer and a non‑breast cancer reveal opportunities for cancer interception.
    Breast Cancer Res Treat. 2023 May 13. doi: 10.1007/s10549-023-06928.
    >> Share

  328. ODAI-AFOTEY A, Lederman RI, Ko NY, Gagnon H, et al
    Breast cancer treatment receipt and the role of financial stress, health literacy, and numeracy among diverse breast cancer survivors.
    Breast Cancer Res Treat. 2023 May 13:1-11. doi: 10.1007/s10549-023-06960.
    >> Share

  329. XIAO J, Hao Y, Wu X, Zhao X, et al
    Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study.
    Breast Cancer Res Treat. 2023 May 10. doi: 10.1007/s10549-023-06930.
    >> Share

  330. HU J, Lang R, Zhao W, Jia Y, et al
    The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.
    Breast Cancer Res Treat. 2023 May 9. doi: 10.1007/s10549-023-06945.
    >> Share

  331. CHANG CP, Ho TF, Snyder J, Dodson M, et al
    Breast cancer survivorship and sexual dysfunction: a population-based cohort study.
    Breast Cancer Res Treat. 2023 May 9. doi: 10.1007/s10549-023-06953.
    >> Share

  332. NIMBALKAR VP, Snijesh VP, Rajarajan S, Alexander A, et al
    Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis.
    Breast Cancer Res Treat. 2023 May 9. doi: 10.1007/s10549-023-06956.
    >> Share

  333. HERSHMAN DL, Chen BE, Sathe C, Parulekar WR, et al
    Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32).
    Breast Cancer Res Treat. 2023 May 9. doi: 10.1007/s10549-023-06922.
    >> Share

  334. SATHE C, Accordino MK, DeStephano D, Shah M, et al
    Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2023 May 8. doi: 10.1007/s10549-023-06957.
    >> Share

  335. KIM JS, Kim K, Jung W, Shin KH, et al
    Comparison of initial and sequential salvage brain-directed treatment in patients with 1-4 vs. 5-10 brain metastases from breast cancer (KROG 16-12).
    Breast Cancer Res Treat. 2023 May 3. doi: 10.1007/s10549-023-06936.
    >> Share

  336. PANDYA K, Scher A, Omene C, Ganesan S, et al
    Clinical efficacy of PARP inhibitors in breast cancer.
    Breast Cancer Res Treat. 2023 May 2. doi: 10.1007/s10549-023-06940.
    >> Share

  337. MAMTANI A, Sjoberg DD, Vincent A, Ehdaie B, et al
    Does a brief surgeon training in negotiation theory principles decrease rates of contralateral prophylactic mastectomy?
    Breast Cancer Res Treat. 2023;199:119-126.
    >> Share

    April 2023
  338. TERMAN E, Sheade J, Zhao F, Howard FM, et al
    The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.
    Breast Cancer Res Treat. 2023 Apr 29. doi: 10.1007/s10549-023-06943.
    >> Share

  339. DONAHUE PMC, MacKenzie A, Filipovic A, Koelmeyer L, et al
    Advances in the prevention and treatment of breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2023 Apr 27. doi: 10.1007/s10549-023-06947.
    >> Share

  340. ISAKOFF SJ, Said MR, Kwak AH, Glieberman E, et al
    Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study).
    Breast Cancer Res Treat. 2023 Apr 27. doi: 10.1007/s10549-023-06918.
    >> Share

  341. KIM SY, Choi Y, Kim YS, Ha SM, et al
    Use of imaging prediction model for omission of axillary surgery in early-stage breast cancer patients.
    Breast Cancer Res Treat. 2023 Apr 25. doi: 10.1007/s10549-023-06952.
    >> Share

  342. DIBBLE KE, Deng Z, Connor AE
    Differences in survivorship care experiences among older breast cancer survivors by clinical cancer characteristics, race/ethnicity, and socioeconomic factors: A SEER-CAHPS study.
    Breast Cancer Res Treat. 2023 Apr 24. doi: 10.1007/s10549-023-06948.
    >> Share

  343. GRECO G, Bickell NA, Lin S, Yagnik R, et al
    Subjective social status, race, and metabolic syndrome in women with breast cancer.
    Breast Cancer Res Treat. 2023 Apr 23. doi: 10.1007/s10549-023-06949.
    >> Share

  344. PARVEZ E, Chu M, Kirkwood D, Doumouras A, et al
    Patient reported symptom burden amongst immigrant and Canadian long-term resident women undergoing breast cancer surgery.
    Breast Cancer Res Treat. 2023 Apr 21. doi: 10.1007/s10549-023-06938.
    >> Share

  345. DALY MB, Rosenthal E, Cummings S, Bernhisel R, et al
    The association between age at breast cancer diagnosis and prevalence of pathogenic variants.
    Breast Cancer Res Treat. 2023 Apr 21. doi: 10.1007/s10549-023-06946.
    >> Share

  346. XU C, Wang Y, Hong Y, Yao R, et al
    Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment.
    Breast Cancer Res Treat. 2023 Apr 21. doi: 10.1007/s10549-023-06931.
    >> Share

  347. KUMAR R, Kuligina E, Sokolenko A, Siddiqui Q, et al
    Correction to: Genetic ablation of pregnancy zone protein promotes breast cancer progression by activating TGF-beta/SMAD signaling.
    Breast Cancer Res Treat. 2023 Apr 20. doi: 10.1007/s10549-023-06939.
    >> Share

  348. SAJJADI E, Venetis K, Fusco N
    Letter to the editor regarding the article "pregnancy-associated breast cancer: a multicenter study comparing clinicopathological factors, diagnosis, and treatment outcomes with non-pregnant patients".
    Breast Cancer Res Treat. 2023 Apr 19. doi: 10.1007/s10549-023-06951.
    >> Share

  349. GREMKE N, Griewing S, Kostev K, Wagner U, et al
    Association between gout and subsequent breast cancer: a retrospective cohort study including 67,598 primary care patients in Germany.
    Breast Cancer Res Treat. 2023 Apr 18. doi: 10.1007/s10549-023-06944.
    >> Share

  350. SOUWER ETD, Sanchez-Spitman A, Moes DJAR, Gelderblom H, et al
    Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer.
    Breast Cancer Res Treat. 2023 Apr 17. doi: 10.1007/s10549-023-06925.
    >> Share

  351. YAM C, Mittendorf EA, Garber HR, Sun R, et al
    A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
    Breast Cancer Res Treat. 2023 Apr 15. doi: 10.1007/s10549-023-06929.
    >> Share

  352. KAKATI RT, Kim H, Whitman A, Spanheimer PM, et al
    High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer.
    Breast Cancer Res Treat. 2023 Apr 15. doi: 10.1007/s10549-023-06937.
    >> Share

  353. COURNEYA KS, An KY, Arthuso FZ, Bell GJ, et al
    Associations between health-related fitness and quality of life in newly diagnosed breast cancer patients.
    Breast Cancer Res Treat. 2023 Apr 14. doi: 10.1007/s10549-023-06935.
    >> Share

  354. FWELO P, Nwosu KOS, Adekunle TE, Afolayan O, et al
    Racial/ethnic and socioeconomic differences in breast cancer surgery performed and delayed treatment: mediating impact on mortality.
    Breast Cancer Res Treat. 2023 Apr 13. doi: 10.1007/s10549-023-06941.
    >> Share

  355. GARCIA-TEJEDOR A, Falo C, Fernandez-Gonzalez S, Laplana M, et al
    Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.
    Breast Cancer Res Treat. 2023 Apr 12. doi: 10.1007/s10549-023-06926.
    >> Share

  356. QU FL, Li JJ, Shao ZM
    Comments on: a prediction model for distant metastasis after isolated locoregional recurrence of breast cancer.
    Breast Cancer Res Treat. 2023 Apr 10. doi: 10.1007/s10549-023-06932.
    >> Share

  357. PARKER BA, Shatsky RA, Schwab RB, Wallace AM, et al
    Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
    Breast Cancer Res Treat. 2023 Apr 8. doi: 10.1007/s10549-023-06914.
    >> Share

  358. NICHOLS HB, House MG, Yarosh R, Mitra S, et al
    Hypertensive conditions of pregnancy, preterm birth, and premenopausal breast cancer risk: a premenopausal breast cancer collaborative group analysis.
    Breast Cancer Res Treat. 2023 Apr 5. doi: 10.1007/s10549-023-06903.
    >> Share

  359. GODINA C, Tryggvadottir H, Bosch A, Borgquist S, et al
    Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer.
    Breast Cancer Res Treat. 2023 Apr 5. doi: 10.1007/s10549-023-06919.
    >> Share

  360. SAYED S, Koka H, Abubakar M, Gardner K, et al
    Tumour Infiltrating Lymphocytes (TILs) and immune composition in breast cancer patients from Kenya: Spatial distributions and associations with risk factors and tumour characteristics.
    Breast Cancer Res Treat. 2023 Apr 3. doi: 10.1007/s10549-023-06921.
    >> Share

  361. DAVE RV, Elsberger B, Taxiarchi VP, Gandhi A, et al
    Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study.
    Breast Cancer Res Treat. 2023 Apr 3:1-15. doi: 10.1007/s10549-023-06893.
    >> Share

  362. HOGAN MP, Horvat JV, Ross DS, Sevilimedu V, et al
    Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment.
    Breast Cancer Res Treat. 2023;198:349-359.
    >> Share

  363. ALIKHASSI A, Li X, Au F, Kulkarni S, et al
    False-positive incidental lesions detected on contrast-enhanced breast MRI: clinical and imaging features.
    Breast Cancer Res Treat. 2023;198:321-334.
    >> Share

  364. SORSCHER S
    Mitigating fear of cancer recurrence.
    Breast Cancer Res Treat. 2023;198:401.
    >> Share

  365. VAN LOEVEZIJN AA, Geluk CS, van den Berg MJ, van Werkhoven ED, et al
    Immediate or delayed oncoplastic surgery after breast conserving surgery at the Netherlands Cancer Institute: a cohort study of 251 cases.
    Breast Cancer Res Treat. 2023;198:295-307.
    >> Share

  366. KWONG A, Ho CYS, Shin VY, Ng ATL, et al
    Molecular characteristics of Asian male BRCA-related cancers.
    Breast Cancer Res Treat. 2023;198:391-400.
    >> Share

  367. BALOGUN Z, Steiman JG, Schwartz JL, Lee JS, et al
    Single-institution outcomes after excision of benign phyllodes tumors: low recurrence risk even with positive margins.
    Breast Cancer Res Treat. 2023;198:569-572.
    >> Share

  368. GOLD N, Christensen RAG, Arneja J, Aminoleslami A, et al
    Screening behaviours, demographics, and stage at diagnosis in the publicly funded Ontario Breast Screening Program.
    Breast Cancer Res Treat. 2023;198:523-533.
    >> Share

  369. LACAZE JL, Chira C, Glemarec G, Monselet N, et al
    Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution.
    Breast Cancer Res Treat. 2023;198:463-474.
    >> Share

  370. CARMEN A, Anne O, Monika S, Daniel E, et al
    Does the toxicity of endocrine therapy persist into long-term survivorship?: Patient-reported outcome results from a follow-up study beyond a 10-year-survival.
    Breast Cancer Res Treat. 2023;198:475-485.
    >> Share

    March 2023
  371. WATANABE K, Niikura N, Kikawa Y, Oba M, et al
    Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
    Breast Cancer Res Treat. 2023 Mar 31. doi: 10.1007/s10549-023-06911.
    >> Share

  372. CHENG JM, Canzoniero J, Lee S, Soni S, et al
    Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis.
    Breast Cancer Res Treat. 2023 Mar 31:1-9. doi: 10.1007/s10549-023-06910.
    >> Share

  373. LAWRENSON R, Lao C, Stanley J, Campbell I, et al
    Impact of diabetes on surgery and radiotherapy for breast cancer.
    Breast Cancer Res Treat. 2023 Mar 30. doi: 10.1007/s10549-023-06915.
    >> Share

  374. NTHONTHO KC, Tawe L, Paganotti GM
    Pharmacogenetics: uncovering the complex relationship between HIV and non-adherence among South African breast cancer patients treated with tamoxifen.
    Breast Cancer Res Treat. 2023 Mar 30. doi: 10.1007/s10549-023-06913.
    >> Share

  375. NARII N, Zha L, Komatsu M, Kitamura T, et al
    Cholesterol and breast cancer risk: a cohort study using health insurance claims and health checkup databases.
    Breast Cancer Res Treat. 2023 Mar 30. doi: 10.1007/s10549-023-06917.
    >> Share

  376. ACEVEDO F, Walbaum B, Camus M, Manzor M, et al
    Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients.
    Breast Cancer Res Treat. 2023 Mar 29. doi: 10.1007/s10549-023-06909.
    >> Share

  377. RASSY E, Filleron T, Viansone A, Lacroix-Triki M, et al
    Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
    Breast Cancer Res Treat. 2023 Mar 29. doi: 10.1007/s10549-023-06912.
    >> Share

  378. ELDER K, Matheson J, Nickson C, Box G, et al
    Contrast enhanced mammography in breast cancer surveillance.
    Breast Cancer Res Treat. 2023 Mar 25. doi: 10.1007/s10549-023-06916.
    >> Share

  379. IWATA H, Yamamoto Y, Sakai T, Hasegawa Y, et al
    Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
    Breast Cancer Res Treat. 2023 Mar 22. doi: 10.1007/s10549-023-06874.
    >> Share

  380. BROWN JC, Sturgeon K, Sarwer DB, Troxel AB, et al
    The effects of exercise and diet on oxidative stress and telomere length in breast cancer survivors.
    Breast Cancer Res Treat. 2023 Mar 18. doi: 10.1007/s10549-023-06868.
    >> Share

  381. CHEW MINMIN S, Bacotti A, Chen Y, Anders C, et al
    Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases.
    Breast Cancer Res Treat. 2023 Mar 17. doi: 10.1007/s10549-023-06908.
    >> Share

  382. LIU X, Wang Y, Cao K, Yao L, et al
    Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants.
    Breast Cancer Res Treat. 2023 Mar 17. doi: 10.1007/s10549-023-06904.
    >> Share

  383. SCOTT OW, TinTin S, Harborg S, Kuper-Hommel MJJ, et al
    Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study.
    Breast Cancer Res Treat. 2023 Mar 17. doi: 10.1007/s10549-022-06815.
    >> Share

  384. FARLAND LV, Wang S, Rich-Edwards JW, Gaskins AJ, et al
    History of infertility and risk of breast cancer: a prospective cohort study.
    Breast Cancer Res Treat. 2023 Mar 16. doi: 10.1007/s10549-023-06907.
    >> Share

  385. EBNER F, Salmen J, Dayan D, Kiesel M, et al
    Implications for surveillance for breast cancer patients based on the internally and externally validated BRENDA-metastatic recurrence score.
    Breast Cancer Res Treat. 2023 Mar 14. doi: 10.1007/s10549-023-06898.
    >> Share

  386. FIASCARELLI A, Merlino G, Capano S, Talucci S, et al
    Antitumor activity of the PI3K delta-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
    Breast Cancer Res Treat. 2023 Mar 13. doi: 10.1007/s10549-023-06895.
    >> Share

  387. TAYLOR C, Meisel J, Foreman AJ, Russell C, et al
    Using Oncotype DX breast recurrence score(R) assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2023 Mar 10. doi: 10.1007/s10549-023-06890.
    >> Share

  388. HURSON AN, Hamilton AM, Olsson LT, Kirk EL, et al
    Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay.
    Breast Cancer Res Treat. 2023 Mar 9. doi: 10.1007/s10549-023-06888.
    >> Share

  389. DIBBLE KE, Baumgartner RN, Boone SD, Baumgartner KB, et al
    Treatment-related side effects among Hispanic and non-Hispanic white long-term breast cancer survivors by tamoxifen use and duration.
    Breast Cancer Res Treat. 2023 Mar 9. doi: 10.1007/s10549-023-06900.
    >> Share

  390. VAN HEMERT AKE, van Olmen JP, Boersma LJ, Maduro JH, et al
    De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study.
    Breast Cancer Res Treat. 2023 Mar 9. doi: 10.1007/s10549-023-06899.
    >> Share

  391. ILOZUMBA MN, Yaghjyan L, Datta S, Zhao J, et al
    mTOR pathway candidate genes and physical activity interaction on breast cancer risk in black women from the women's circle of health study.
    Breast Cancer Res Treat. 2023 Mar 8. doi: 10.1007/s10549-023-06902.
    >> Share

  392. MWANGI KW, Kamita MK, Waweru JW, Sayed S, et al
    Adaptive immune receptor features related to breast cancer tissue in Kenyan patients: high immunoglobulin gene expression and high levels of gamma-delta T-cells.
    Breast Cancer Res Treat. 2023 Mar 8. doi: 10.1007/s10549-023-06897.
    >> Share

  393. MAZZONETTO P, Milanezi F, D'Andrea M, Martins S, et al
    BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil.
    Breast Cancer Res Treat. 2023 Mar 7. doi: 10.1007/s10549-023-06892.
    >> Share

  394. JIANG H, Li H, Song G, Di L, et al
    Pegylated liposomal doxorubicin (Duomeisu((R))) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study.
    Breast Cancer Res Treat. 2023 Mar 6:1-13. doi: 10.1007/s10549-023-06894.
    >> Share

  395. TSAI JH, Li CL, Yeh DC, Hung CS, et al
    Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: a multicenter retrospective case-control study.
    Breast Cancer Res Treat. 2023 Mar 4. doi: 10.1007/s10549-023-06867.
    >> Share

  396. MURATA T, Yoshida M, Shiino S, Ogawa A, et al
    A prediction model for distant metastasis after isolated locoregional recurrence of breast cancer.
    Breast Cancer Res Treat. 2023 Mar 4. doi: 10.1007/s10549-023-06901.
    >> Share

  397. DIX-PEEK T, Phakathi BP, van den Berg EJ, Dickens C, et al
    Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer.
    Breast Cancer Res Treat. 2023 Mar 3. doi: 10.1007/s10549-023-06886.
    >> Share

  398. OSWALD AJ, Symeonides SN, Wheatley D, Chan S, et al
    Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
    Breast Cancer Res Treat. 2023 Mar 2. doi: 10.1007/s10549-023-06873.
    >> Share

  399. THOREN L, Margolin S, Eliasson E, Bergh J, et al
    Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records.
    Breast Cancer Res Treat. 2023 Mar 1. doi: 10.1007/s10549-023-06887.
    >> Share

  400. BYCHKOVSKY BL, Lo MT, Yussuf A, Horton C, et al
    Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
    Breast Cancer Res Treat. 2023 Mar 1. doi: 10.1007/s10549-023-06870.
    >> Share

    February 2023
  401. ALTUNDAG K
    Metastatic pure invasive lobular breast cancer or metastatic mixed invasive ductal and lobular breast cancer: are they different entities?
    Breast Cancer Res Treat. 2023 Feb 28. doi: 10.1007/s10549-023-06906.
    >> Share

  402. MALHOTRA MK, Pahuja S, Kiesel BF, Appleman LJ, et al
    A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
    Breast Cancer Res Treat. 2023 Feb 28. doi: 10.1007/s10549-023-06889.
    >> Share

  403. GUILLEN VS, Ziegler Y, Gopinath C, Kumar S, et al
    Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs.
    Breast Cancer Res Treat. 2023 Feb 27. doi: 10.1007/s10549-023-06878.
    >> Share

  404. LIU Q, Liu N, van der Noord V, van der Stel W, et al
    Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia.
    Breast Cancer Res Treat. 2023 Feb 24. doi: 10.1007/s10549-023-06863.
    >> Share

  405. BEAULIEU-JONES BR, Shewmaker G, Fefferman A, Kenzik K, et al
    Mitigating disparities in breast cancer treatment at an academic safety-net hospital.
    Breast Cancer Res Treat. 2023 Feb 24. doi: 10.1007/s10549-023-06875.
    >> Share

  406. ROSSI C, Fraticelli S, Fanizza M, Ferrari A, et al
    Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature.
    Breast Cancer Res Treat. 2023 Feb 21. doi: 10.1007/s10549-023-06872.
    >> Share

  407. ZHAO J, Wu Y, Xiao T, Cheng C, et al
    A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1-CDK4 interaction.
    Breast Cancer Res Treat. 2023 Feb 19. doi: 10.1007/s10549-023-06866.
    >> Share

  408. THILL M, Zahn MO, Welt A, Stickeler E, et al
    Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL.
    Breast Cancer Res Treat. 2023 Feb 18. doi: 10.1007/s10549-023-06882.
    >> Share

  409. GASTOUNIOTI A, Cohen EA, Pantalone L, Ehsan S, et al
    Changes in mammographic density and risk of breast cancer among a diverse cohort of women undergoing mammography screening.
    Breast Cancer Res Treat. 2023 Feb 17. doi: 10.1007/s10549-023-06879.
    >> Share

  410. ZHANG H, Zheng J, Fu Y, Ling J, et al
    Overexpression of POU3F2 promotes radioresistance in triple-negative breast cancer via Akt pathway activation.
    Breast Cancer Res Treat. 2023 Feb 17. doi: 10.1007/s10549-023-06876.
    >> Share

  411. MOTA BS, Reis YN, de Barros N, Cardoso NP, et al
    Effects of preoperative magnetic resonance image on survival rates and surgical planning in breast cancer conservative surgery: randomized controlled trial (BREAST-MRI trial).
    Breast Cancer Res Treat. 2023 Feb 14. doi: 10.1007/s10549-023-06884.
    >> Share

  412. EOM KY, Berg KA, Joseph NE, Runner K, et al
    Neighborhood and racial influences on triple negative breast cancer: evidence from Northeast Ohio.
    Breast Cancer Res Treat. 2023 Feb 13. doi: 10.1007/s10549-023-06883.
    >> Share

  413. KIM SE, Kim WJ, Choi D, Lee DY, et al
    Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer.
    Breast Cancer Res Treat. 2023 Feb 13. doi: 10.1007/s10549-023-06877.
    >> Share

  414. SUND M, Garmo H, Andersson A, Margolin S, et al
    Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk.
    Breast Cancer Res Treat. 2023 Feb 11. doi: 10.1007/s10549-023-06871.
    >> Share

  415. ALLMAN R, Mu Y, Dite GS, Spaeth E, et al
    Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk.
    Breast Cancer Res Treat. 2023 Feb 7. doi: 10.1007/s10549-022-06834.
    >> Share

  416. VAKLAVAS C, Stringer-Reasor EM, Elkhanany AM, Ryan KJ, et al
    A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.
    Breast Cancer Res Treat. 2023 Feb 3. doi: 10.1007/s10549-023-06864.
    >> Share

  417. ALTUNDAG K
    High maximum standardized uptake value might be associated more with T2b (>/= 4 cm) than T2a (< 4 cm) in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer.
    Breast Cancer Res Treat. 2023 Feb 3. doi: 10.1007/s10549-023-06869.
    >> Share

  418. ROSENBERG S, Devir M, Kaduri L, Grinshpun A, et al
    Distinct breast cancer phenotypes in BRCA 1/2 carriers based on ER status.
    Breast Cancer Res Treat. 2023 Feb 2. doi: 10.1007/s10549-022-06851.
    >> Share

  419. ZHI WI, Baser RE, Talukder D, Mei YZ, et al
    Mechanistic and thermal characterization of acupuncture for chemotherapy-induced peripheral neuropathy as measured by quantitative sensory testing.
    Breast Cancer Res Treat. 2023;197:535-545.
    >> Share

  420. KIM H, Wang H, Demanelis K, Clump DA, et al
    Factors associated with ductal carcinoma in situ (DCIS) treatment patterns and patient-reported outcomes across a large integrated health network.
    Breast Cancer Res Treat. 2023;197:683-692.
    >> Share

  421. YOON CI, Lee HS, Jeon S, Kim D, et al
    Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea.
    Breast Cancer Res Treat. 2023;197:603-612.
    >> Share

  422. SHAMMAS RL, Sisk GC, Coroneos CJ, Offodile AC 2nd, et al
    Textbook outcomes in DIEP flap breast reconstruction: a Delphi study to establish consensus.
    Breast Cancer Res Treat. 2023;197:559-568.
    >> Share

    January 2023
  423. WHITE MJ, Kolbow M, Prathibha S, Praska C, et al
    Chemotherapy refusal and subsequent survival in healthy older women with high genomic risk estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2023 Jan 24. doi: 10.1007/s10549-023-06862.
    >> Share

  424. ENGELKING M, Marmor S, Burjak M, Hinojos M, et al
    Use of endocrine therapy for estrogen receptor-positive breast cancer among American Indians and Alaska natives.
    Breast Cancer Res Treat. 2023 Jan 23. doi: 10.1007/s10549-022-06826.
    >> Share

  425. MAGBANUA MJM, van 't Veer L, Clark AS, Chien AJ, et al
    Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
    Breast Cancer Res Treat. 2023 Jan 23. doi: 10.1007/s10549-022-06803.
    >> Share

  426. CROWN A, McCartan D, Curry MA, Patil S, et al
    Pregnancy-associated breast cancer: does timing of presentation affect outcome?
    Breast Cancer Res Treat. 2023 Jan 20. doi: 10.1007/s10549-022-06833.
    >> Share

  427. DE LIGT KM, de Rooij BH, Hedayati E, Karsten MM, et al
    International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients.
    Breast Cancer Res Treat. 2023 Jan 20. doi: 10.1007/s10549-022-06827.
    >> Share

  428. DE MAAR JS, Luyendijk M, Suelmann BBM, van der Kruijssen DEW, et al
    Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference-a Dutch population-based study from 2008 to 2018.
    Breast Cancer Res Treat. 2023 Jan 17. doi: 10.1007/s10549-022-06837.
    >> Share

  429. IBRAGIMOVA KIE, Geurts SME, Meegdes M, Erdkamp F, et al
    Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry.
    Breast Cancer Res Treat. 2023 Jan 12. doi: 10.1007/s10549-022-06832.
    >> Share

  430. HAN S, Lee SB, Gong G, Lee J, et al
    Prognostic significance of pretreatment (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer who underwent adjuvant chemotherapy.
    Breast Cancer Res Treat. 2023 Jan 12. doi: 10.1007/s10549-022-06852.
    >> Share

  431. LOFT M, Lok SW, De Boer R, Malik L, et al
    Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer.
    Breast Cancer Res Treat. 2023 Jan 9. doi: 10.1007/s10549-022-06856.
    >> Share

  432. ZWAGER MC, Bense R, Waaijer S, Qiu SQ, et al
    Assessing the role of tumour-associated macrophage subsets in breast cancer subtypes using digital image analysis.
    Breast Cancer Res Treat. 2023 Jan 9. doi: 10.1007/s10549-022-06859.
    >> Share

  433. HASSAN AM, Ketheeswaran S, Adesoye T, Shah SA, et al
    Association between patient-surgeon race and gender concordance and patient-reported outcomes following breast cancer surgery.
    Breast Cancer Res Treat. 2023 Jan 9. doi: 10.1007/s10549-022-06858.
    >> Share

  434. TAN QT, Alcantara VS, Sultana R, Loh KW, et al
    Pregnancy-associated breast cancer: a multicenter study comparing clinicopathological factors, diagnosis and treatment outcomes with non-pregnant patients.
    Breast Cancer Res Treat. 2023 Jan 8. doi: 10.1007/s10549-022-06855.
    >> Share

  435. GOYAL RK, Holmes HM, Chen H, Abughosh S, et al
    Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States.
    Breast Cancer Res Treat. 2023 Jan 7. doi: 10.1007/s10549-022-06845.
    >> Share

  436. MEERNIK C, Jorgensen K, Wu CF, Murphy CC, et al
    Disparities in the use of assisted reproductive technologies after breast cancer: a population-based study.
    Breast Cancer Res Treat. 2023 Jan 6. doi: 10.1007/s10549-022-06857.
    >> Share

  437. ALTUNDAG K
    Possible mechanism behind the association between disrupted sleep quality and breast cancer outcome.
    Breast Cancer Res Treat. 2023 Jan 5. doi: 10.1007/s10549-022-06842.
    >> Share

  438. HARDY-ABELOOS C, Xiao J, Oh C, Barbee D, et al
    Early effectiveness and toxicity outcomes of reirradiation after breast conserving surgery for recurrent or new primary breast cancer.
    Breast Cancer Res Treat. 2023 Jan 5. doi: 10.1007/s10549-022-06853.
    >> Share

  439. SHANMUGALINGAM A, Hitos K, Pathmanathan N, Edirimmane S, et al
    Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
    Breast Cancer Res Treat. 2023 Jan 5. doi: 10.1007/s10549-023-06860.
    >> Share

  440. HARRIS SR
    A rare but persistent cause of decreased function secondary to adjuvant radiation therapy in women with breast cancer.
    Breast Cancer Res Treat. 2023 Jan 5. doi: 10.1007/s10549-022-06854.
    >> Share

  441. KUHN EP, Pirruccello J, Boothe JT, Li Z, et al
    Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients-a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy.
    Breast Cancer Res Treat. 2023 Jan 2. doi: 10.1007/s10549-022-06849.
    >> Share

  442. VAN LOEVEZIJN AA, Winter-Warnars HAO, Hernandez GS, de Bloeme CM, et al
    Clinical impact of MRI-detected additional lesions in breast cancer patients with neoadjuvant systemic therapy at the Netherlands cancer institute.
    Breast Cancer Res Treat. 2023 Jan 2. doi: 10.1007/s10549-022-06840.
    >> Share

  443. SHIINO S, Quinn C, Ball G, Syed BM, et al
    Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis.
    Breast Cancer Res Treat. 2023;197:245-254.
    >> Share

  444. KADA MOHAMMED S, Dabakuyo Yonli TS, Desmoulins I, Manguem Kamga A, et al
    Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry.
    Breast Cancer Res Treat. 2023;197:377-385.
    >> Share

  445. HUEBNER H, Ruebner M, Kurbacher C, Hadji P, et al
    Return of individual genomic research results within the PRAEGNANT multicenter registry study.
    Breast Cancer Res Treat. 2023;197:355-368.
    >> Share

  446. MAMTANI A, Grabenstetter A, Sevilimedu V, Morrow M, et al
    Do non-classic invasive lobular carcinomas derive a benefit from neoadjuvant chemotherapy?
    Breast Cancer Res Treat. 2023;197:417-423.
    >> Share

  447. OGONY J, Hoskin TL, Stallings-Mann M, Winham S, et al
    Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers.
    Breast Cancer Res Treat. 2023;197:277-285.
    >> Share

  448. KECHIN A, Boyarskikh U, Barinov A, Tanas A, et al
    A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia.
    Breast Cancer Res Treat. 2023;197:387-395.
    >> Share

  449. FRIEDMAN R, Bustos VP, Pardo J, Tillotson E, et al
    Superficial and functional imaging of the tricipital lymphatic pathway: a modern reintroduction.
    Breast Cancer Res Treat. 2023;197:235-242.
    >> Share

  450. QU FL, Li JJ, Shao ZM
    Comments on: The clinical relevance of various methods of classifying ipsilateral breast tumor recurrence as either true local recurrence or new primary.
    Breast Cancer Res Treat. 2023;197:243-244.
    >> Share

    December 2022
  451. MASCHMANN RM, De Jesus RG, Werutsky G, Rebelatto TF, et al
    Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115).
    Breast Cancer Res Treat. 2022 Dec 31. doi: 10.1007/s10549-022-06809.
    >> Share

  452. WU WC, Huang CC, Tsai YF, Lin YS, et al
    The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis.
    Breast Cancer Res Treat. 2022 Dec 31. doi: 10.1007/s10549-022-06753.
    >> Share

  453. HASSING CMS, Mejdahl MK, Laenkholm AV, Kroman N, et al
    Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study.
    Breast Cancer Res Treat. 2022 Dec 28. doi: 10.1007/s10549-022-06839.
    >> Share

  454. LUIS C, Dias J, Firmino-Machado J, Fernandes R, et al
    A retrospective study in tumour characteristics and clinical outcomes of overweight and obese women with breast cancer.
    Breast Cancer Res Treat. 2022 Dec 28. doi: 10.1007/s10549-022-06836.
    >> Share

  455. SHAH C, Whitworth P, Valente S, Schwarz GS, et al
    Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: clinical practice guidelines.
    Breast Cancer Res Treat. 2022 Dec 24. doi: 10.1007/s10549-022-06850.
    >> Share

  456. BISCHOFF H, Bigot C, Moinard-Butot F, Pflumio C, et al
    A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Dec 23. doi: 10.1007/s10549-022-06844.
    >> Share

  457. ALVAREZ A, Bernal AM, Anampa J
    Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Dec 23. doi: 10.1007/s10549-022-06847.
    >> Share

  458. DINAN MA, Pitafi S, Greenup RA, Long JB, et al
    Genetic testing in privately insured women with surgically treated breast cancer.
    Breast Cancer Res Treat. 2022 Dec 21. doi: 10.1007/s10549-022-06829.
    >> Share

  459. FRANKS J, Caston NE, Elkhanany A, Gerke T, et al
    Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2022 Dec 21. doi: 10.1007/s10549-022-06823.
    >> Share

  460. AYENI OA, Chiwambutsa S, Chen WC, Kapungu N, et al
    The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa.
    Breast Cancer Res Treat. 2022 Dec 20. doi: 10.1007/s10549-022-06835.
    >> Share

  461. OHBE H, Hachiya T, Yamaji T, Nakano S, et al
    Development and validation of genome-wide polygenic risk scores for predicting breast cancer incidence in Japanese females: a population-based case-cohort study.
    Breast Cancer Res Treat. 2022 Dec 20. doi: 10.1007/s10549-022-06843.
    >> Share

  462. HUANG J, Tong Y, Hong J, Huang O, et al
    Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial.
    Breast Cancer Res Treat. 2022 Dec 16. doi: 10.1007/s10549-022-06821.
    >> Share

  463. MOORE JX, Andrzejak SE, Jones S, Han Y, et al
    Exploring the intersectionality of race/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000-2016.
    Breast Cancer Res Treat. 2022 Dec 15. doi: 10.1007/s10549-022-06830.
    >> Share

  464. KANG BH, Jang BS, Kim IA
    Radiosensitivity is associated with antitumor immunity in estrogen receptor-negative breast cancer.
    Breast Cancer Res Treat. 2022 Dec 14. doi: 10.1007/s10549-022-06818.
    >> Share

  465. LIU Y, Wang Y, Feng S, Xu Z, et al
    Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
    Breast Cancer Res Treat. 2022 Dec 13. doi: 10.1007/s10549-022-06817.
    >> Share

  466. CAETANO DOS SANTOS FL, Michalek IM, Wojciechowska U, Didkowska J, et al
    Changes in the survival of patients with breast cancer: Poland, 2000-2019.
    Breast Cancer Res Treat. 2022 Dec 12:1-9. doi: 10.1007/s10549-022-06828.
    >> Share

  467. STOYLES N, Cheville A, Zucker D, Richards B, et al
    Risk factors for reduced function in women with a history of breast cancer.
    Breast Cancer Res Treat. 2022 Dec 10. doi: 10.1007/s10549-022-06838.
    >> Share

  468. SHIMOMURA A, Yoshida M, Kubo T, Yamashita S, et al
    Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer.
    Breast Cancer Res Treat. 2022 Dec 9. doi: 10.1007/s10549-022-06822.
    >> Share

  469. GOTTSCHAU M, Kjaer SK, Viuff JH, Jensen A, et al
    Ovarian removal and subsequent breast cancer prognosis: a nationwide cohort study.
    Breast Cancer Res Treat. 2022 Dec 8. doi: 10.1007/s10549-022-06825.
    >> Share

  470. MODI AP, Nguyen JPT, Wang J, Ahn JS, et al
    Geometric tumor embolic budding characterizes inflammatory breast cancer.
    Breast Cancer Res Treat. 2022 Dec 6. doi: 10.1007/s10549-022-06819.
    >> Share

  471. GAO SL, Wang DY, Wang X, Zhang B, et al
    Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up.
    Breast Cancer Res Treat. 2022 Dec 5. doi: 10.1007/s10549-022-06762.
    >> Share

  472. XU B, Li W, Zhang Q, Li Q, et al
    Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
    Breast Cancer Res Treat. 2022 Dec 4. doi: 10.1007/s10549-022-06775.
    >> Share

  473. XU B, Sun T, Shi Y, Cui J, et al
    Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
    Breast Cancer Res Treat. 2022 Dec 2. doi: 10.1007/s10549-022-06785.
    >> Share

  474. AIHARA T, Kumamaru H, Ishitobi M, Miyashita M, et al
    Prognosis and effectiveness of chemotherapy for medullary breast carcinoma.
    Breast Cancer Res Treat. 2022;196:635-645.
    >> Share

  475. WILLIAMS AD, Pawloski KR, Wen HY, Sevilimedu V, et al
    Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age.
    Breast Cancer Res Treat. 2022;196:565-570.
    >> Share

  476. SHAFI S, Hu Y, Parwani AV, Ding Q, et al
    Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center.
    Breast Cancer Res Treat. 2022;196:463-469.
    >> Share

  477. CHA E, Ambinder EB, Oluyemi ET, Mullen LA, et al
    High-risk lesions in the breast diagnosed by MRI-guided core biopsy: upgrade rates and features associated with malignancy.
    Breast Cancer Res Treat. 2022;196:517-525.
    >> Share

  478. GUZZO HM, Valente SA, Schwarz GS, ElSherif A, et al
    Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction.
    Breast Cancer Res Treat. 2022;196:657-664.
    >> Share

  479. CASAUBON J, Niakan S, Vicks E, Perez Coulter A, et al
    The effect of delay of excisional biopsy on upstage rate for atypical ductal hyperplasia, flat epithelial atypia, intraductal papilloma, and radial scar.
    Breast Cancer Res Treat. 2022;196:527-534.
    >> Share

    November 2022
  480. ROSENBERG SM, Zheng Y, Gelber S, Ruddy KJ, et al
    Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.
    Breast Cancer Res Treat. 2022 Nov 27. doi: 10.1007/s10549-022-06810.
    >> Share

  481. HABBOUS S, Barisic A, Homenauth E, Kandasamy S, et al
    Estimating the incidence of breast cancer recurrence using administrative data.
    Breast Cancer Res Treat. 2022 Nov 23. doi: 10.1007/s10549-022-06812.
    >> Share

  482. D'CUNHA K, Park Y, Protani MM, Reeves MM, et al
    Circadian rhythm disrupting behaviours and cancer outcomes in breast cancer survivors: a systematic review.
    Breast Cancer Res Treat. 2022 Nov 23. doi: 10.1007/s10549-022-06792.
    >> Share

  483. AHN JH, Park JM, Choi SB, Go J, et al
    Early experience of robotic axillary lymph node dissection in patients with node-positive breast cancer.
    Breast Cancer Res Treat. 2022 Nov 23. doi: 10.1007/s10549-022-06760.
    >> Share

  484. ALJOHANI AI, Toss MS, Green AR, Rakha EA, et al
    The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development.
    Breast Cancer Res Treat. 2022 Nov 22. doi: 10.1007/s10549-022-06801.
    >> Share

  485. ACEVEDO F, Walbaum B, Medina L, Merino T, et al
    Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study.
    Breast Cancer Res Treat. 2022 Nov 21. doi: 10.1007/s10549-022-06814.
    >> Share

  486. KAWAI M, Takada M, Nakayama T, Masuda N, et al
    Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis
    Breast Cancer Res Treat. 2022 Nov 21. doi: 10.1007/s10549-022-06816.
    >> Share

  487. BURNETTE SE, Poehlein E, Lee HJ, Force J, et al
    Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer.
    Breast Cancer Res Treat. 2022 Nov 21. doi: 10.1007/s10549-022-06798.
    >> Share

  488. WANG H, Sheng X, Yan T, Xu Y, et al
    Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer.
    Breast Cancer Res Treat. 2022 Nov 21. doi: 10.1007/s10549-022-06791.
    >> Share

  489. NOTEWARE L, Broadwater G, Dalal N, Alder L, et al
    Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.
    Breast Cancer Res Treat. 2022 Nov 20. doi: 10.1007/s10549-022-06799.
    >> Share

  490. NUSSBAUMER RL, Maggi N, Castrezana L, Zehnpfennig L, et al
    The impact of neoadjuvant systemic treatment on postoperative complications in breast cancer surgery.
    Breast Cancer Res Treat. 2022 Nov 20. doi: 10.1007/s10549-022-06811.
    >> Share

  491. BARDIA A, Mayer I, Winer E, Linden HM, et al
    The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Nov 19. doi: 10.1007/s10549-022-06797.
    >> Share

  492. BERGMAN R, Berko YA, Sanchez V, Sanders ME, et al
    Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer.
    Breast Cancer Res Treat. 2022 Nov 17. pii: 10.1007/s10549-022-06794.
    >> Share

  493. GLYNN D, Bliss J, Brunt AM, Coles CE, et al
    Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis.
    Breast Cancer Res Treat. 2022 Nov 17. pii: 10.1007/s10549-022-06802.
    >> Share

  494. YAZAKI S, Shimoi T, Yoshida M, Sumiyoshi-Okuma H, et al
    Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 Nov 16. pii: 10.1007/s10549-022-06787.
    >> Share

  495. LACOURT TE, Koncz Z, Tullos EA, Tripathy D, et al
    A detailed description of the distress trajectory from pre- to post-treatment in breast cancer patients receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 Nov 16. pii: 10.1007/s10549-022-06805.
    >> Share

  496. LI J, Sun B, Li Y, Li S, et al
    Correlation analysis between shear-wave elastography and pathological profiles in breast cancer.
    Breast Cancer Res Treat. 2022 Nov 14. pii: 10.1007/s10549-022-06804.
    >> Share

  497. JOYCE E, Carr G, Wang S, Brummett CM, et al
    Association between nociplastic pain and premature endocrine therapy discontinuation in breast cancer patients.
    Breast Cancer Res Treat. 2022 Nov 13. pii: 10.1007/s10549-022-06806.
    >> Share

  498. YANG Z, Xu H, Yang Y, Duan C, et al
    Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis.
    Breast Cancer Res Treat. 2022 Nov 12. pii: 10.1007/s10549-022-06790.
    >> Share

  499. NEUNER JM, Fergestrom N, Pezzin LE, Laud PW, et al
    Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer.
    Breast Cancer Res Treat. 2022 Nov 10. pii: 10.1007/s10549-022-06704.
    >> Share

  500. WALPOLE ET, Youl PH, Moore J, Morris M, et al
    Development of a key performance indicator for breast cancer in Queensland, Australia.
    Breast Cancer Res Treat. 2022 Nov 9. pii: 10.1007/s10549-022-06796.
    >> Share

  501. BHATTACHARYA M, Parsons H, Call K, Blaes A, et al
    Impact of a pre-existing diagnosis of mental illness on stage of breast cancer diagnosis among older women.
    Breast Cancer Res Treat. 2022 Nov 9. pii: 10.1007/s10549-022-06793.
    >> Share

  502. CHEN R, Qi Y, Huang Y, Liu W, et al
    Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population.
    Breast Cancer Res Treat. 2022 Nov 8. pii: 10.1007/s10549-022-06781.
    >> Share

  503. LE MK, Odate T, Kawai M, Oishi N, et al
    Investigating the role of core needle biopsy in evaluating tumor-stroma ratio (TSR) of invasive breast cancer: a retrospective study.
    Breast Cancer Res Treat. 2022 Nov 6. pii: 10.1007/s10549-022-06768.
    >> Share

  504. PLICHTA JK, Rushing CN, Lewis HC, Rooney MM, et al
    Implications of missing data on reported breast cancer mortality.
    Breast Cancer Res Treat. 2022 Nov 5. pii: 10.1007/s10549-022-06764.
    >> Share

  505. LU C, Yang Y, Lingmei L, Qiujuan H, et al
    Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
    Breast Cancer Res Treat. 2022 Nov 5. pii: 10.1007/s10549-022-06788.
    >> Share

  506. EIJKELBOOM AH, de Munck L, Menke-van der Houven van Oordt CW, Broeders MJM, et al
    Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study.
    Breast Cancer Res Treat. 2022 Nov 5. pii: 10.1007/s10549-022-06732.
    >> Share

  507. POWELL M, Fuller S, Gunderson E, Benz C, et al
    A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia.
    Breast Cancer Res Treat. 2022 Nov 4. pii: 10.1007/s10549-022-06789.
    >> Share

  508. CORSO G, Girardi A, Calvello M, Gandini S, et al
    Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer.
    Breast Cancer Res Treat. 2022 Nov 4. pii: 10.1007/s10549-022-06776.
    >> Share

  509. HUPPERT LA, Walker Z, Li M, Kim MO, et al
    Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study.
    Breast Cancer Res Treat. 2022 Nov 2. pii: 10.1007/s10549-022-06771.
    >> Share

  510. LEVY J, Farag F, Cole J
    Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience.
    Breast Cancer Res Treat. 2022;196:207-213.
    >> Share

  511. GAO W, Lu S, Zeng Y, Chen X, et al
    Axilla lymph node dissection can be safely omitted in patients with 1-2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis.
    Breast Cancer Res Treat. 2022;196:129-141.
    >> Share

  512. HASSING CMS, Mejdahl MK, Laenkholm AV, Kroman N, et al
    Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors
    Breast Cancer Res Treat. 2022;196:197-206.
    >> Share

  513. QU FL, Lin CJ, Liu ZB, Cao AY, et al
    Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
    Breast Cancer Res Treat. 2022;196:97-109.
    >> Share

  514. LOSURDO A, Lisa AVE, Tomatis M, Ponti A, et al
    Highly specialized Breast Centers did not experience delay of care during COVID-19 pandemic in Italy: the Senonetwork experience.
    Breast Cancer Res Treat. 2022;196:87-95.
    >> Share

  515. NICOSIA L, Lissidini G, Sargenti M, Bozzini AC, et al
    Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center.
    Breast Cancer Res Treat. 2022;196:371-377.
    >> Share

  516. LAITMAN Y, Nielsen SM, Bernstein-Molho R, Heald B, et al
    Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis.
    Breast Cancer Res Treat. 2022;196:355-361.
    >> Share

  517. POTTER S, Fairhurst K, Cowan K, Vincent S, et al
    Identifying research priorities in breast cancer surgery: a UK priority setting partnership with the James Lind Alliance.
    Breast Cancer Res Treat. 2022 Nov 1. pii: 10.1007/s10549-022-06756.
    >> Share

  518. SUBHAM S, Jeppson JD, Worcester C, Schatmeyer B, et al
    EGFR as a potent CAR T target in triple negative breast cancer brain metastases.
    Breast Cancer Res Treat. 2022 Nov 1. pii: 10.1007/s10549-022-06783.
    >> Share

  519. GUPTA T, Vinayak S, Telli M
    Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 Nov 1. pii: 10.1007/s10549-022-06780.
    >> Share

    October 2022
  520. EIJKELBOOM AH, de Munck L, de Vries M, Francken AB, et al
    Routine and interval detection of locoregional breast cancer recurrences and risk of subsequent distant metastasis.
    Breast Cancer Res Treat. 2022 Oct 31. pii: 10.1007/s10549-022-06757.
    >> Share

  521. XIE XF, Zhang QY, Huang JY, Chen LP, et al
    Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial.
    Breast Cancer Res Treat. 2022 Oct 30. pii: 10.1007/s10549-022-06770.
    >> Share

  522. GHAZALEH AA, Handschin TM, Buckowiecki J, Chammartin FS, et al
    Combining reconstructive and ablative surgical treatment of chronic breast cancer-related lymphedema (BCRL): safe and effective.
    Breast Cancer Res Treat. 2022 Oct 26. pii: 10.1007/s10549-022-06778.
    >> Share

  523. LIM GH, Alcantara VS, Ng RP, Ng R, et al
    Patterns of breast cancer second recurrences in patients after mastectomy.
    Breast Cancer Res Treat. 2022 Oct 26. pii: 10.1007/s10549-022-06772.
    >> Share

  524. BURCH AE, Irish WD, Wong JH
    A population health assessment of screening mammography on breast cancer mortality in North Carolina.
    Breast Cancer Res Treat. 2022 Oct 26. pii: 10.1007/s10549-022-06773.
    >> Share

  525. LOBANOVA O, Medvedieva N, Fishchuk L, Dubitska O, et al
    Methylation of promoter region of BRCA1 gene versus pathogenic variants of gene: risk factor or clinical marker of breast cancer.
    Breast Cancer Res Treat. 2022 Oct 25. pii: 10.1007/s10549-022-06774.
    >> Share

  526. DESALEGN Z, Yohannes M, Porsch M, Stuckrath K, et al
    Intrinsic subtypes in Ethiopian breast cancer patient.
    Breast Cancer Res Treat. 2022 Oct 25. pii: 10.1007/s10549-022-06769.
    >> Share

  527. POHLMANN PR, Graham D, Wu T, Ottaviano Y, et al
    HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
    Breast Cancer Res Treat. 2022 Oct 25. pii: 10.1007/s10549-022-06743.
    >> Share

  528. REINHARDT K, Stuckrath K, Hartung C, Kaufhold S, et al
    PIK3CA-mutations in breast cancer.
    Breast Cancer Res Treat. 2022 Oct 24. pii: 10.1007/s10549-022-06637.
    >> Share

  529. LIANG Z, Bian X, Shim H
    Retraction Note to: Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression.
    Breast Cancer Res Treat. 2022 Oct 23. pii: 10.1007/s10549-022-06779.
    >> Share

  530. TOOHEY K, Hunter M, McKinnon K, Casey T, et al
    systematic review of multimodal prehabilitation in breast cancer.
    Breast Cancer Res Treat. 2022 Oct 21. pii: 10.1007/s10549-022-06759.
    >> Share

  531. VIHERVUORI H, Korpinen K, Autere TA, Repo H, et al
    Varying outcomes of triple-negative breast cancer in different age groups-prognostic value of clinical features and proliferation.
    Breast Cancer Res Treat. 2022 Oct 19. pii: 10.1007/s10549-022-06767.
    >> Share

  532. FREEDMAN RA, Ko NY, Lederman RI, Gagnon H, et al
    Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors.
    Breast Cancer Res Treat. 2022 Oct 11. pii: 10.1007/s10549-022-06752.
    >> Share

  533. MORENO GA, Molina MI, Eastwood D, Auer PL, et al
    Contemporary evaluation of estrogen receptor and progesterone receptor expression in breast cancer-associated stroma.
    Breast Cancer Res Treat. 2022 Oct 8. pii: 10.1007/s10549-022-06754.
    >> Share

  534. BROWN L, Naffouje SA, Sam C, Laronga C, et al
    Neoadjuvant systemic therapy in geriatric breast cancer patients: a National Cancer Database (NCDB) analysis.
    Breast Cancer Res Treat. 2022 Oct 8. pii: 10.1007/s10549-022-06751.
    >> Share

  535. ZHENG Q, Luo H, Xia W, Lu Q, et al
    Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study.
    Breast Cancer Res Treat. 2022 Oct 7. pii: 10.1007/s10549-022-06746.
    >> Share

  536. LAW JW, Campbell A, Weller C, Johanson C, et al
    Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis.
    Breast Cancer Res Treat. 2022 Oct 6. pii: 10.1007/s10549-022-06738.
    >> Share

  537. LOESER AL, Gao L, Bardia A, Burkard ME, et al
    Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).
    Breast Cancer Res Treat. 2022 Oct 6. pii: 10.1007/s10549-022-06755.
    >> Share

  538. VERMA N, Blackford AL, Thorner E, Lehman J, et al
    Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer.
    Breast Cancer Res Treat. 2022 Oct 5. pii: 10.1007/s10549-022-06750.
    >> Share

  539. STANKOWSKI TJ, Schumacher JR, Hanlon BM, Tucholka JL, et al
    Barriers to breast reconstruction for socioeconomically disadvantaged women.
    Breast Cancer Res Treat. 2022;195:413-419.
    >> Share

  540. JOBSEN JJ, Struikmans H, Siemerink E, van der Palen J, et al
    The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary.
    Breast Cancer Res Treat. 2022;195:249-262.
    >> Share

  541. RASK G, Nazemroaya A, Jansson M, Wadsten C, et al
    Correlation of tumour subtype with long-term outcome in small breast carcinomas: a Swedish population-based retrospective cohort study.
    Breast Cancer Res Treat. 2022;195:367-377.
    >> Share

  542. VAN OMMEN-NIJHOF A, Jacobse JN, Steggink LC, Lefrandt JD, et al
    Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors.
    Breast Cancer Res Treat. 2022 Oct 1. pii: 10.1007/s10549-022-06714.
    >> Share

    September 2022
  543. PAN B, Xu Y, Zhou Y, Yao R, et al
    Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003-2017).
    Breast Cancer Res Treat. 2022 Sep 27. pii: 10.1007/s10549-022-06747.
    >> Share

  544. JIMBO H, Horimoto Y, Ishizuka Y, Nogami N, et al
    Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Sep 26. pii: 10.1007/s10549-022-06748.
    >> Share

  545. INOUE Y, Fujishima M, Ono M, Masuda J, et al
    Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer.
    Breast Cancer Res Treat. 2022 Sep 24. pii: 10.1007/s10549-022-06726.
    >> Share

  546. OPPONG BA, Rolle AA, Ndumele A, Li Y, et al
    Are there differences in outcomes by race among women with metastatic triple-negative breast cancer?
    Breast Cancer Res Treat. 2022 Sep 24. pii: 10.1007/s10549-022-06736.
    >> Share

  547. MAN V, Luk WP, Fung LH, Kwong A, et al
    The role of pre-operative axillary ultrasound in assessment of axillary tumor burden in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2022 Sep 22. pii: 10.1007/s10549-022-06699.
    >> Share

  548. MCCARTHY AM, Manning AK, Hsu S, Welch M, et al
    Breast cancer polygenic risk scores are associated with short-term risk of poor prognosis breast cancer.
    Breast Cancer Res Treat. 2022 Sep 22. pii: 10.1007/s10549-022-06739.
    >> Share

  549. HEEKE AL, Elliott A, Feldman R, O'Connor HF, et al
    Molecular characterization of ESR1 variants in breast cancer.
    Breast Cancer Res Treat. 2022 Sep 20. pii: 10.1007/s10549-022-06740.
    >> Share

  550. CHITKARA A, Mesa-Eguiagaray I, Wild SH, Hall PS, et al
    Reproductive history differs by molecular subtypes of breast cancer among women aged
    Breast Cancer Res Treat. 2022 Sep 18. pii: 10.1007/s10549-022-06721.
    >> Share

  551. ALEIXO GFP, Valente SA, Wei W, Moore HCF, et al
    Association of sarcopenia with endocrine therapy toxicity in patients with early breast cancer.
    Breast Cancer Res Treat. 2022 Sep 17. pii: 10.1007/s10549-022-06741.
    >> Share

  552. PEZO RC, Chan KKW, Mata DGMM, Menjak I, et al
    Impact of body mass index on survival in women receiving chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2022 Sep 17. pii: 10.1007/s10549-022-06744.
    >> Share

  553. ALVAREZ FA, Kaddour H, Lyu Y, Preece C, et al
    Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment.
    Breast Cancer Res Treat. 2022 Sep 17. pii: 10.1007/s10549-022-06733.
    >> Share

  554. WILSON JM, Colebaugh CA, Flowers KM, Edwards RR, et al
    Early postoperative psychological distress as a mediator of subsequent persistent postsurgical pain outcomes among younger breast cancer patients.
    Breast Cancer Res Treat. 2022 Sep 14. pii: 10.1007/s10549-022-06720.
    >> Share

  555. CHEN M, Li S, Huang M, Guo J, et al
    Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 Sep 13. pii: 10.1007/s10549-022-06707.
    >> Share

  556. THILL M, Wimberger P, Grafe A, Klare P, et al
    Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).
    Breast Cancer Res Treat. 2022 Sep 12. pii: 10.1007/s10549-022-06710.
    >> Share

  557. ALTUNDAG K
    Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06742.
    >> Share

  558. SMITH CEP, Marcom PK, Mitri Z, Ko NY, et al
    Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06718.
    >> Share

  559. WATANABE H, Nakagomi H, Hirotsu Y, Amemiya K, et al
    TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06731.
    >> Share

  560. GREMKE N, Griewing S, Kalder M, Kostev K, et al
    Positive association between body height and breast cancer prevalence: a retrospective study with 135,741 women in Germany.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06730.
    >> Share

  561. GUNDA A, Eshwaraiah MS, Gangappa K, Kaur T, et al
    A comparative analysis of recurrence risk predictions in ER+/HER2- early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06729.
    >> Share

  562. NGUYEN THN, Nguyen TTN, Nguyen TTM, Nguyen LHM, et al
    Panels of circulating microRNAs as potential diagnostic biomarkers for breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2022 Sep 9. pii: 10.1007/s10549-022-06728.
    >> Share

  563. SWARNKAR P, Mokbel L, Mokbel K
    De-escalation of breast cancer treatment for Her2-positive breast cancer.
    Breast Cancer Res Treat. 2022 Sep 9. pii: 10.1007/s10549-022-06737.
    >> Share

  564. SAJDIK C, Schuster E, Holzer B, Krainer M, et al
    Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients.
    Breast Cancer Res Treat. 2022 Sep 8. pii: 10.1007/s10549-022-06717.
    >> Share

  565. PARK SY, Suh KJ, Lee DW, Ryu HS, et al
    Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy.
    Breast Cancer Res Treat. 2022 Sep 7. pii: 10.1007/s10549-022-06566.
    >> Share

  566. XIE W, Cao M, Zhong Z, Huang Z, et al
    Survival outcomes for breast conserving surgery versus mastectomy among elderly women with breast cancer.
    Breast Cancer Res Treat. 2022 Sep 7. pii: 10.1007/s10549-022-06725.
    >> Share

  567. HOWARD FM, He G, Peterson JR, Pfeiffer JR, et al
    Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform.
    Breast Cancer Res Treat. 2022 Sep 5. pii: 10.1007/s10549-022-06722.
    >> Share

  568. SONG YM, Qian XL, Xia XQ, Li YQ, et al
    STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
    Breast Cancer Res Treat. 2022 Sep 3. pii: 10.1007/s10549-022-06679.
    >> Share

  569. SANLI AN, Altundag K
    Strict definition of a small tumor in breast cancer should be revisited.
    Breast Cancer Res Treat. 2022 Sep 2. pii: 10.1007/s10549-022-06734.
    >> Share

  570. WEISS A, King C, Vincuilla J, Parker T, et al
    Rates of pathologic nodal disease among cN0 and cN1 patients undergoing routine axillary ultrasound and neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022;195:181-189.
    >> Share

  571. LINFIELD DT, Rothberg MB, Pfoh ER, Noss R, et al
    Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system.
    Breast Cancer Res Treat. 2022;195:153-160.
    >> Share

    August 2022
  572. CHOONG GM, Liddell S, Ferre RAL, O'Sullivan CC, et al
    Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
    Breast Cancer Res Treat. 2022 Aug 31. pii: 10.1007/s10549-022-06713.
    >> Share

  573. KWON SS, Nam BD, Lee MY, Lee MH, et al
    Increased EAT volume after anthracycline chemotherapy is associated with a low risk of cardiotoxicity in breast cancer.
    Breast Cancer Res Treat. 2022 Aug 31. pii: 10.1007/s10549-022-06696.
    >> Share

  574. MUNGMUNPUNTIPANJTIP R, Sriwijitalai W, Wiwanitkit V
    Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: correspondence.
    Breast Cancer Res Treat. 2022 Aug 31. pii: 10.1007/s10549-022-06719.
    >> Share

  575. SU Y, Wu C, Chang Y, Li L, et al
    USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells.
    Breast Cancer Res Treat. 2022 Aug 30. pii: 10.1007/s10549-022-06711.
    >> Share

  576. KLINTMAN M, Rosendahl AH, Randeris B, Eriksson M, et al
    Postmenopausal overweight and breast cancer risk; results from the KARMA cohort.
    Breast Cancer Res Treat. 2022 Aug 30. pii: 10.1007/s10549-022-06664.
    >> Share

  577. GUPTA T, Purington N, Liu M, Han S, et al
    Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
    Breast Cancer Res Treat. 2022 Aug 28. pii: 10.1007/s10549-022-06716.
    >> Share

  578. FERRAIUOLO RM, Fifield BA, Hamm C, Porter LA, et al
    Stabilization of c-Myc by the atypical cell cycle regulator, Spy1, decreases efficacy of breast cancer treatments.
    Breast Cancer Res Treat. 2022 Aug 27. pii: 10.1007/s10549-022-06715.
    >> Share

  579. ROZENBLIT M, Blenman K, Harigopal M, Reisenbichler E, et al
    PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer.
    Breast Cancer Res Treat. 2022 Aug 26. pii: 10.1007/s10549-022-06712.
    >> Share

  580. WHITAKER KD, Wang X, Ascha M, Showalter TN, et al
    Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Aug 26. pii: 10.1007/s10549-022-06701.
    >> Share

  581. FILE DM, Pascual T, Deal AM, Wheless A, et al
    Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Aug 25. pii: 10.1007/s10549-022-06700.
    >> Share

  582. NEMATI SHAFAEE M, Goutsouliak K, Lin H, Bevers TB, et al
    Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers.
    Breast Cancer Res Treat. 2022 Aug 25. pii: 10.1007/s10549-022-06688.
    >> Share

  583. WALSH EM, Gucalp A, Patil S, Edelweiss M, et al
    Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
    Breast Cancer Res Treat. 2022 Aug 20. pii: 10.1007/s10549-022-06669.
    >> Share

  584. MURALI B, Durbin L, Vijaykumar S, Yang L, et al
    Treatment of HR+/HER2- breast cancer in urban mainland China: results from the CancerMPact Survey 2019.
    Breast Cancer Res Treat. 2022 Aug 20. pii: 10.1007/s10549-022-06709.
    >> Share

  585. KUILMAN MM, Ellappalayam A, Barcaru A, Haan JC, et al
    BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.
    Breast Cancer Res Treat. 2022 Aug 19. pii: 10.1007/s10549-022-06698.
    >> Share

  586. CUNNINGHAM N, Shepherd S, Mohammed K, Lee KA, et al
    Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.
    Breast Cancer Res Treat. 2022 Aug 17. pii: 10.1007/s10549-022-06703.
    >> Share

  587. ZANG F, Ding X, Chen J, Hu L, et al
    Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype.
    Breast Cancer Res Treat. 2022 Aug 16. pii: 10.1007/s10549-022-06702.
    >> Share

  588. LIN L, Soesan M, van Balen DEM, Beijnen JH, et al
    The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer.
    Breast Cancer Res Treat. 2022 Aug 16. pii: 10.1007/s10549-022-06681.
    >> Share

  589. LU Y, Gehr AW, Anikpo I, Meadows RJ, et al
    Cardiotoxicity among socioeconomically marginalized breast cancer patients.
    Breast Cancer Res Treat. 2022 Aug 15. pii: 10.1007/s10549-022-06695.
    >> Share

  590. CHIKERMANE SG, Sharma M, Abughosh SM, Aparasu RR, et al
    Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes.
    Breast Cancer Res Treat. 2022 Aug 15. pii: 10.1007/s10549-022-06706.
    >> Share

  591. BRIGHT EE, Genung SR, Stanton AL, Arch JJ, et al
    A mixed-methods study of the technical feasibility and patient acceptability of a real-time adherence monitor in breast cancer survivors taking adjuvant endocrine therapy.
    Breast Cancer Res Treat. 2022 Aug 12. pii: 10.1007/s10549-022-06705.
    >> Share

  592. ENGVALL K, Green H, Fredrikson M, Lagerlund M, et al
    Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study.
    Breast Cancer Res Treat. 2022 Aug 9. pii: 10.1007/s10549-022-06670.
    >> Share

  593. TERADA M, Kondo N, Wanifuchi-Endo Y, Fujita T, et al
    Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study.
    Breast Cancer Res Treat. 2022 Aug 8. pii: 10.1007/s10549-022-06693.
    >> Share

  594. SAMUSIEVA A, Serga S, Klymenko S, Rybchenko L, et al
    Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.
    Breast Cancer Res Treat. 2022 Aug 5. pii: 10.1007/s10549-022-06692.
    >> Share

  595. YANG J, Guo W, Huang R, Zhou C, et al
    Letter to the editor regarding "Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer".
    Breast Cancer Res Treat. 2022 Aug 5. pii: 10.1007/s10549-022-06663.
    >> Share

  596. IHENACHO U, Hamilton AS, Mack WJ, Wu AH, et al
    Lifetime personal cigarette smoking and risk of young-onset breast cancer by subtype among non-Hispanic Black and White women in the Young Women's Health History Study.
    Breast Cancer Res Treat. 2022 Aug 4. pii: 10.1007/s10549-022-06675.
    >> Share

  597. MCALEESE CE, Butcher NJ, Minchin RF
    Arylamine N-acetyltransferase 1 deficiency inhibits drug-induced cell death in breast cancer cells: switch from cytochrome C-dependent apoptosis to necroptosis.
    Breast Cancer Res Treat. 2022 Aug 2. pii: 10.1007/s10549-022-06668.
    >> Share

  598. MUTKA M, Virtakoivu R, Joensuu K, Hollmen M, et al
    Clever-1 positive macrophages in breast cancer.
    Breast Cancer Res Treat. 2022 Aug 2. pii: 10.1007/s10549-022-06683.
    >> Share

  599. WANG X, Fan Z, Wang X, He Y, et al
    Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study.
    Breast Cancer Res Treat. 2022 Aug 2. pii: 10.1007/s10549-022-06686.
    >> Share

  600. KONISHI T, Fujiogi M, Shigemi D, Nishioka K, et al
    Surgical and obstetric outcomes of breast cancer surgery during pregnancy: a nationwide database study in Japan.
    Breast Cancer Res Treat. 2022 Aug 2. pii: 10.1007/s10549-022-06659.
    >> Share

  601. CHEN CS, Smith EML, Stringer KA, Henry NL, et al
    Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.
    Breast Cancer Res Treat. 2022;194:551-560.
    >> Share

  602. SELLA T, Kantor O, Weiss A, Partridge AH, et al
    The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy.
    Breast Cancer Res Treat. 2022;194:663-672.
    >> Share

  603. LIM E, Boyle F, Okera M, Loi S, et al
    An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
    Breast Cancer Res Treat. 2022 Aug 1. pii: 10.1007/s10549-022-06690.
    >> Share

  604. PAN K, Aragaki AK, Michael Y, Thomson CA, et al
    Long-term dietary intervention influence on physical activity in the Women's Health Initiative Dietary Modification randomized trial.
    Breast Cancer Res Treat. 2022;195:43-54.
    >> Share

    July 2022
  605. MCVICKER L, Cardwell CR, McIntosh SA, McMenamin UC, et al
    Cancer-specific mortality in breast cancer patients with hypothyroidism: a UK population-based study.
    Breast Cancer Res Treat. 2022 Jul 31. pii: 10.1007/s10549-022-06674.
    >> Share

  606. WANG Y, Tesch ME, Lim C, Xu YH, et al
    Risk of recurrence and pregnancy outcomes in young women with breast cancer who do and do not undergo fertility preservation.
    Breast Cancer Res Treat. 2022 Jul 30. pii: 10.1007/s10549-022-06650.
    >> Share

  607. TANG M, O'Grady S, Crown J, Duffy MJ, et al
    MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975.
    Breast Cancer Res Treat. 2022 Jul 30. pii: 10.1007/s10549-022-06673.
    >> Share

  608. FREEDMAN RA, Revette AC, Gagnon H, Perilla-Glen A, et al
    Acceptability of a companion patient guide to support expert consensus guidelines on surveillance mammography in older breast cancer survivors.
    Breast Cancer Res Treat. 2022 Jul 30. pii: 10.1007/s10549-022-06676.
    >> Share

  609. ANKERSMID JW, Lansink Rotgerink FK, Strobbe LJA, van Uden-Kraan CF, et al
    Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors.
    Breast Cancer Res Treat. 2022 Jul 30. pii: 10.1007/s10549-022-06684.
    >> Share

  610. KONG L, Xiong Y, Wang D, Huang L, et al
    Intermedin (adrenomedullin 2) promotes breast cancer metastasis via Src/c-Myc-mediated ribosome production and protein translation.
    Breast Cancer Res Treat. 2022 Jul 28. pii: 10.1007/s10549-022-06687.
    >> Share

  611. BAADE PD, Fowler H, Kou K, Dunn J, et al
    A prognostic survival model for women diagnosed with invasive breast cancer in Queensland, Australia.
    Breast Cancer Res Treat. 2022 Jul 28. pii: 10.1007/s10549-022-06682.
    >> Share

  612. SACCHINI V, Norton L
    Escalating de-escalation in breast cancer treatment.
    Breast Cancer Res Treat. 2022 Jul 28. pii: 10.1007/s10549-022-06685.
    >> Share

  613. KAPLAN HG, Malmgren JA, Guo B, Atwood MK, et al
    Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999-2018.
    Breast Cancer Res Treat. 2022 Jul 22. pii: 10.1007/s10549-022-06678.
    >> Share

  614. NGAI V, Tai JCJ, Taj S, Khanfar H, et al
    Non-invasive predictors of axillary lymph node burden in breast cancer: a single-institution retrospective analysis.
    Breast Cancer Res Treat. 2022 Jul 21. pii: 10.1007/s10549-022-06672.
    >> Share

  615. BRAAL CL, Westenberg JD, Buijs SM, Abrams S, et al
    Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial.
    Breast Cancer Res Treat. 2022 Jul 16. pii: 10.1007/s10549-022-06643.
    >> Share

  616. HOWARD FM, Pearson AT, Nanda R
    Clinical trials of immunotherapy in triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 Jul 14. pii: 10.1007/s10549-022-06665.
    >> Share

  617. HAMILTON E, Cortes J, Ozyilkan O, Chen SC, et al
    nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Jul 12. pii: 10.1007/s10549-022-06662.
    >> Share

  618. NIKOLOV I, Kostev K, Kalder M
    Incidence of other cancer diagnoses in women with breast cancer: a retrospective cohort study with 42,248 women.
    Breast Cancer Res Treat. 2022 Jul 12. pii: 10.1007/s10549-022-06666.
    >> Share

  619. ALDRICH MB, Rasmussen JC, DeSnyder SM, Woodward WA, et al
    Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging.
    Breast Cancer Res Treat. 2022 Jul 10. pii: 10.1007/s10549-022-06667.
    >> Share

  620. DAVEY MG, Kerin MJ
    Using menopause status and 21-gene expression assay to inform chemotherapy benefit in node-positive breast cancer.
    Breast Cancer Res Treat. 2022 Jul 10. pii: 10.1007/s10549-022-06671.
    >> Share

  621. WU R, Gandhi S, Tokumaru Y, Asaoka M, et al
    Intratumoral PDGFB gene predominantly expressed in endothelial cells is associated with angiogenesis and lymphangiogenesis, but not with metastasis in breast cancer.
    Breast Cancer Res Treat. 2022 Jul 6. pii: 10.1007/s10549-022-06661.
    >> Share

  622. SKARPING I, Nilsson K, Dihge L, Fridhammar A, et al
    The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer.
    Breast Cancer Res Treat. 2022 Jul 5. pii: 10.1007/s10549-022-06636.
    >> Share

  623. CHEN L, Chen Y, Xie Z, Luo J, et al
    Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Breast Cancer Res Treat. 2022 Jul 5. pii: 10.1007/s10549-022-06649.
    >> Share

  624. VIDULA N, Yau C, Rugo H
    Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.
    Breast Cancer Res Treat. 2022 Jul 4. pii: 10.1007/s10549-022-06660.
    >> Share

  625. OKONOGI N, Karasawa K, Nitta Y, Mori Y, et al
    Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer.
    Breast Cancer Res Treat. 2022 Jul 4. pii: 10.1007/s10549-022-06644.
    >> Share

  626. GECZIK AM, Ferris JS, Terry MB, Andrulis IL, et al
    Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evaluation of the weight, physical activity, and alcohol
    Breast Cancer Res Treat. 2022 Jul 2. pii: 10.1007/s10549-022-06656.
    >> Share

  627. DONEY K, Leisenring W, Linden H
    Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer.
    Breast Cancer Res Treat. 2022 Jul 2. pii: 10.1007/s10549-022-06658.
    >> Share

  628. ELALAOUI SC, Laarabi FZ, Afif L, Lyahyai J, et al
    Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region.
    Breast Cancer Res Treat. 2022;194:187-198.
    >> Share

  629. SHERMAN ME, de Bel T, Heckman MG, White LJ, et al
    Serum hormone levels and normal breast histology among premenopausal women.
    Breast Cancer Res Treat. 2022;194:149-158.
    >> Share

  630. FRIEDMAN-ELDAR O, Burke J, de Castro Silva I, Baumrucker CC, et al
    Stalled at the intersection: insurance status and disparities in post-mastectomy breast reconstruction.
    Breast Cancer Res Treat. 2022;194:327-335.
    >> Share

  631. ZHANG Y, Luo X, Chen M, Yang L, et al
    Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses.
    Breast Cancer Res Treat. 2022;194:279-295.
    >> Share

  632. MOUSA-DOUST D, Dingee CK, Chen L, Bazzarelli A, et al
    Excision of breast fibroepithelial lesions: when is it still necessary?-A 10-year review of a regional centre.
    Breast Cancer Res Treat. 2022;194:307-314.
    >> Share

  633. GONZALEZ A, Del Greco F, Vargas-Roig L, Brun B, et al
    PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina.
    Breast Cancer Res Treat. 2022;194:403-412.
    >> Share

  634. VICTORIA M, Marie B, Dominique R, Caroline A, et al
    Breast reconstruction and quality of life five years after cancer diagnosis: VICAN French National cohort.
    Breast Cancer Res Treat. 2022;194:449-461.
    >> Share

    June 2022
  635. FAUER AJ, Ganz PA, Brauer ER
    A mixed method study of medical oncologists' perceived barriers and motivators to addressing long-term effects in breast cancer survivors.
    Breast Cancer Res Treat. 2022 Jun 29. pii: 10.1007/s10549-022-06657.
    >> Share

  636. CHEUN JH, Lee YJ, Lee JH, Shin Y, et al
    Surgical margin status and survival outcomes of breast cancer patients treated with breast-conserving surgery and whole-breast irradiation after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 Jun 28. pii: 10.1007/s10549-021-06500.
    >> Share

  637. BURKBAUER L, Goldbach M, Huang C, Lewandowski J, et al
    Awareness of link between obesity and breast cancer risk is associated with willingness to participate in weight loss intervention.
    Breast Cancer Res Treat. 2022 Jun 25. pii: 10.1007/s10549-022-06546.
    >> Share

  638. FWELO P, Yusuf ZI, Adjei A, Huynh G, et al
    Racial and ethnic disparities in the refusal of surgical treatment in women 40 years and older with breast cancer in the USA between 2010 and 2017.
    Breast Cancer Res Treat. 2022 Jun 24. pii: 10.1007/s10549-022-06653.
    >> Share

  639. POGGIO F, Ceppi M, Fregatti P, Lambertini M, et al
    Comment on "Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and metaanalysis".
    Breast Cancer Res Treat. 2022 Jun 24. pii: 10.1007/s10549-022-06590.
    >> Share

  640. CASTELO M, Lu J, Paszat L, Veitch Z, et al
    Long-term survival in elderly women receiving chemotherapy for non-metastatic breast cancer: a population-based analysis.
    Breast Cancer Res Treat. 2022 Jun 22. pii: 10.1007/s10549-022-06646.
    >> Share

  641. HAARSMA R, van Loevezijn AA, Donswijk ML, Scholten AN, et al
    Added value of repeat sentinel lymph node biopsy in FDG-PET/CT node-negative patients with ipsilateral breast cancer recurrence.
    Breast Cancer Res Treat. 2022 Jun 21. pii: 10.1007/s10549-022-06654.
    >> Share

  642. ZHANG Z, Zhang H, Yu J, Xu L, et al
    miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2022 Jun 21. pii: 10.1007/s10549-022-06642.
    >> Share

  643. WERNLI KJ, Smith RE, Henderson LM, Zhao W, et al
    Decision quality and regret with treatment decisions in women with breast cancer: Pre-operative breast MRI and breast density.
    Breast Cancer Res Treat. 2022 Jun 20. pii: 10.1007/s10549-022-06648.
    >> Share

  644. KHOURY T, Aljabab S, Yao S, Ambrosone C, et al
    Tumor-associated mononuclear cells in the tumor bed of triple-negative breast cancer associate with clinical outcomes in the post-neoadjuvant chemotherapy setting.
    Breast Cancer Res Treat. 2022 Jun 18. pii: 10.1007/s10549-022-06641.
    >> Share

  645. SELLA T, Exman P, Ren S, Freret TS, et al
    Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis.
    Breast Cancer Res Treat. 2022 Jun 17. pii: 10.1007/s10549-022-06621.
    >> Share

  646. YADAV S, Sangaralingham L, Payne SR, Giridhar KV, et al
    Surveillance mammography after treatment for male breast cancer.
    Breast Cancer Res Treat. 2022 Jun 17. pii: 10.1007/s10549-022-06645.
    >> Share

  647. CORKE L, Luzhna L, Willemsma K, Illmann C, et al
    Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer.
    Breast Cancer Res Treat. 2022 Jun 15. pii: 10.1007/s10549-022-06640.
    >> Share

  648. JU J, Du F, Gao SL, Si YR, et al
    Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
    Breast Cancer Res Treat. 2022 Jun 14. pii: 10.1007/s10549-022-06629.
    >> Share

  649. WELLERDIECK NEA, Wessels P, Los M, Sonke GS, et al
    Local and systemic therapy in breast cancer patients with central nervous system metastases.
    Breast Cancer Res Treat. 2022 Jun 9. pii: 10.1007/s10549-022-06605.
    >> Share

  650. KONISHI T, Fujiogi M, Michihata N, Matsui H, et al
    Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study.
    Breast Cancer Res Treat. 2022 Jun 4. pii: 10.1007/s10549-022-06638.
    >> Share

  651. SUTHERLAND A, Huppe A, Wagner JL, Amin AL, et al
    The clinical impact of MRI on surgical planning for patients with in-breast tumor recurrence.
    Breast Cancer Res Treat. 2022;193:515-522.
    >> Share

  652. POMERANTZ A, Tsoref D, Grubstein A, Wadhawker S, et al
    Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis.
    Breast Cancer Res Treat. 2022;193:507-514.
    >> Share

  653. BYCHKOVSKY B, Laws A, Katlin F, Hans M, et al
    Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen.
    Breast Cancer Res Treat. 2022;193:417-427.
    >> Share

  654. SKENDERI F, Alahmad MAM, Tahirovic E, Alahmad YM, et al
    HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome.
    Breast Cancer Res Treat. 2022;193:523-533.
    >> Share

  655. SIVADAS A, Kok VC, Ng KL
    Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers.
    Breast Cancer Res Treat. 2022;193:361-379.
    >> Share

  656. NAKAGOMI H, Inoue M, Hirotsu Y, Amemiya K, et al
    PIK3CA-AKT pathway predominantly acts in developing ipsilateral breast tumor recurrence long after breast-conserving surgery.
    Breast Cancer Res Treat. 2022;193:349-359.
    >> Share

  657. WEBSTER TK, Roth SC, Yu D, Baltodano PA, et al
    Safe perioperative tamoxifen use in autologous breast free flap reconstruction: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2022;193:241-251.
    >> Share

  658. MESA-EGUIAGARAY I, Wild SH, Bird SM, Williams LJ, et al
    Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype.
    Breast Cancer Res Treat. 2022 Jun 1. pii: 10.1007/s10549-022-06632.
    >> Share

    May 2022
  659. OSHI M, Gandhi S, Yan L, Tokumaru Y, et al
    Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
    Breast Cancer Res Treat. 2022 May 31. pii: 10.1007/s10549-022-06633.
    >> Share

  660. PICADO O, Kwon D, Rojas K, Crystal J, et al
    Impact of genomic assays on treatment and outcomes in locally advanced breast cancer.
    Breast Cancer Res Treat. 2022 May 30. pii: 10.1007/s10549-022-06625.
    >> Share

  661. SCHREIER A, Munoz-Arcos L, Alvarez A, Sparano JA, et al
    Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
    Breast Cancer Res Treat. 2022 May 28. pii: 10.1007/s10549-022-06574.
    >> Share

  662. SATO F, Sagara A, Tajima K, Miura S, et al
    COL8A1 facilitates the growth of triple-negative breast cancer via FAK/Src activation.
    Breast Cancer Res Treat. 2022 May 28. pii: 10.1007/s10549-022-06635.
    >> Share

  663. CASWELL-JIN JL, Shafaee MN, Xiao L, Liu M, et al
    Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population.
    Breast Cancer Res Treat. 2022 May 27. pii: 10.1007/s10549-022-06634.
    >> Share

  664. TOWFIGHI P, Deldar R, Haffner ZK, Aminpour N, et al
    A comparative analysis of males and females with breast cancer undergoing mastectomy using the American College of Surgeon's National Surgical Quality Improvement Project (NSQIP).
    Breast Cancer Res Treat. 2022 May 27. pii: 10.1007/s10549-022-06628.
    >> Share

  665. BEN DORI S, Aizic A, Zubkov A, Tsuriel S, et al
    The risk of PD-L1 expression misclassification in triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 May 27. pii: 10.1007/s10549-022-06630.
    >> Share

  666. CULLINANE C, Brien AO, Shrestha A, Hanlon EO, et al
    The association between breast density and breast cancer pathological response to neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 May 23. pii: 10.1007/s10549-022-06616.
    >> Share

  667. GOPINATH P, Veluswami S, Gopisetty G, Sundersingh S, et al
    Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer.
    Breast Cancer Res Treat. 2022 May 21. pii: 10.1007/s10549-022-06617.
    >> Share

  668. MAKARI-JUDSON G, Viskochil R, Katz D, Barham R, et al
    Insulin resistance and weight gain in women treated for early stage breast cancer.
    Breast Cancer Res Treat. 2022 May 21. pii: 10.1007/s10549-022-06624.
    >> Share

  669. DETTWYLER SA, Thull DL, McAuliffe PF, Steiman JG, et al
    Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
    Breast Cancer Res Treat. 2022 May 21. pii: 10.1007/s10549-022-06619.
    >> Share

  670. EROGLU I, Sevilimedu V, Park A, King TA, et al
    Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS.
    Breast Cancer Res Treat. 2022 May 20. pii: 10.1007/s10549-021-06499.
    >> Share

  671. ROOT JC, Zhou X, Ahn J, Small BJ, et al
    Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study.
    Breast Cancer Res Treat. 2022 May 19. pii: 10.1007/s10549-022-06623.
    >> Share

  672. PEREZ EA, Dang C, Lee C, Singh J, et al
    Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
    Breast Cancer Res Treat. 2022 May 19. pii: 10.1007/s10549-021-06469.
    >> Share

  673. OPDAM M, van der Noort V, Kleijn M, Glas A, et al
    Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.
    Breast Cancer Res Treat. 2022 May 19. pii: 10.1007/s10549-022-06618.
    >> Share

  674. MCGUINNESS JE, Ro V, Mutasa S, Pan S, et al
    Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer.
    Breast Cancer Res Treat. 2022 May 16. pii: 10.1007/s10549-022-06614.
    >> Share

  675. PAPAUTSKY EL, Carlson M, Johnson SM, Montague H, et al
    Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients.
    Breast Cancer Res Treat. 2022 May 14. pii: 10.1007/s10549-022-06615.
    >> Share

  676. SAJAL IH, Chowdhury M, Wang T, Euhus D, et al
    CBCRisk-Black: a personalized contralateral breast cancer risk prediction model for black women.
    Breast Cancer Res Treat. 2022 May 13. pii: 10.1007/s10549-022-06612.
    >> Share

  677. PARIKH DA, Kody L, Brain S, Heditsian D, et al
    Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
    Breast Cancer Res Treat. 2022 May 11. pii: 10.1007/s10549-022-06611.
    >> Share

  678. O'SHAUGHNESSY J, Brufsky A, Rugo HS, Tolaney SM, et al
    Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 May 11. pii: 10.1007/s10549-022-06602.
    >> Share

  679. GEYER CE JR, Bandos H, Rastogi P, Jacobs SA, et al
    Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
    Breast Cancer Res Treat. 2022 May 4. pii: 10.1007/s10549-022-06613.
    >> Share

  680. VAN BARELE M, Rieborn A, Heemskerk-Gerritsen BAM, Obdeijn IM, et al
    Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study.
    Breast Cancer Res Treat. 2022 May 4. pii: 10.1007/s10549-022-06608.
    >> Share

  681. SWARNKAR PK, Mokbel K
    Axillary radiation alone is a suboptimal treatment for ypN + in patients with triple negative breast cancer and axillary lymph node dissection should be considered in this setting.
    Breast Cancer Res Treat. 2022 May 3. pii: 10.1007/s10549-022-06610.
    >> Share

  682. JIA H, Zhao P, Chen Z, Wang G, et al
    Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast.
    Breast Cancer Res Treat. 2022;193:111-120.
    >> Share

  683. CHAVDA J, Mishra A, Silodia A, Yadav SK, et al
    Validation sentinel lymph node biopsy study in cN0 axilla using low-cost dual dye technique: potential solution for resource poor settings.
    Breast Cancer Res Treat. 2022;193:105-110.
    >> Share

  684. HALL PE, Schmid P
    Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies.
    Breast Cancer Res Treat. 2022;193:21-35.
    >> Share

  685. SIOKA C
    Radiotherapy, chemotherapy, and heart disease.
    Breast Cancer Res Treat. 2022;193:239-240.
    >> Share

    April 2022
  686. PATEL BK, Pepin K, Brandt KR, Mazza GL, et al
    Association of breast cancer risk, density, and stiffness: global tissue stiffness on breast MR elastography (MRE).
    Breast Cancer Res Treat. 2022 Apr 30. pii: 10.1007/s10549-022-06607.
    >> Share

  687. FONNESBECH HJORTH C, Damkier P, Bjerregaard Stage T, Feddersen S, et al
    Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.
    Breast Cancer Res Treat. 2022 Apr 30. pii: 10.1007/s10549-022-06596.
    >> Share

  688. MALLORY MA, Whiting K, Park A, Gonen M, et al
    Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ.
    Breast Cancer Res Treat. 2022 Apr 29. pii: 10.1007/s10549-022-06532.
    >> Share

  689. GIATROMANOLAKI A, Gkegka AG, Pouliliou S, Biziota E, et al
    Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis.
    Breast Cancer Res Treat. 2022 Apr 28. pii: 10.1007/s10549-022-06609.
    >> Share

  690. ANDERSON KS, Erick TK, Chen M, Daley H, et al
    The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers.
    Breast Cancer Res Treat. 2022 Apr 28. pii: 10.1007/s10549-022-06562.
    >> Share

  691. BIGHAM Z, Robles Y, Freund KM, Palmer JR, et al
    Hypertensive diseases of pregnancy and risk of breast cancer in the Black Women's Health Study.
    Breast Cancer Res Treat. 2022 Apr 28. pii: 10.1007/s10549-022-06606.
    >> Share

  692. MCDONALD BC, Van Dyk K, Deardorff RL, Bailey JN, et al
    Multimodal MRI examination of structural and functional brain changes in older women with breast cancer in the first year of antiestrogen hormonal therapy.
    Breast Cancer Res Treat. 2022 Apr 27. pii: 10.1007/s10549-022-06597.
    >> Share

  693. LACOUTURE ME, Goldfarb SB, Markova A, Chawla SP, et al
    Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.
    Breast Cancer Res Treat. 2022 Apr 26. pii: 10.1007/s10549-022-06584.
    >> Share

  694. LI J, Li C, Feng Z, Liu L, et al
    Effect of estradiol as a continuous variable on breast cancer survival by menopausal status: a cohort study in China.
    Breast Cancer Res Treat. 2022 Apr 25. pii: 10.1007/s10549-022-06593.
    >> Share

  695. HOWELL DM, Metcalfe K, Kong S, Stephen J, et al
    Risk factors for psychological morbidity and the protective role of coping self-efficacy in young women with breast cancer early in diagnosis: a national multicentre cohort study.
    Breast Cancer Res Treat. 2022 Apr 24. pii: 10.1007/s10549-022-06576.
    >> Share

  696. BOMAN C, Edman Kessler L, Bergh J, Matikas A, et al
    Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study.
    Breast Cancer Res Treat. 2022 Apr 24. pii: 10.1007/s10549-022-06591.
    >> Share

  697. HUANG HC, Smart MH, Zolekar A, Deng H, et al
    Impact of socioeconomic status and rurality on cancer-specific survival among women with de novo metastatic breast cancer by race/ethnicity.
    Breast Cancer Res Treat. 2022 Apr 23. pii: 10.1007/s10549-022-06603.
    >> Share

  698. PURI A, Mylavarapu C, Xu J, Patel TA, et al
    Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases.
    Breast Cancer Res Treat. 2022 Apr 23. pii: 10.1007/s10549-022-06595.
    >> Share

  699. DE BONIFACE J, Frisell J, Kuhn T, Wiklander-Brakenhielm I, et al
    False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
    Breast Cancer Res Treat. 2022 Apr 22. pii: 10.1007/s10549-022-06588.
    >> Share

  700. DREDZE LM, Friger M, Ariad S, Koretz M, et al
    Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years.
    Breast Cancer Res Treat. 2022 Apr 22. pii: 10.1007/s10549-022-06598.
    >> Share

  701. ZHANG H, Barner JC, Moczygemba LR, Rascati KL, et al
    Neoadjuvant chemotherapy use trends among older women with breast cancer: 2010-2017.
    Breast Cancer Res Treat. 2022 Apr 21. pii: 10.1007/s10549-022-06604.
    >> Share

  702. VANDRAAS K, Falk RS, Bohn SKH, Kiserud C, et al
    Work ability 8 years after breast cancer: exploring the role of social support in a nation-wide survey.
    Breast Cancer Res Treat. 2022 Apr 21. pii: 10.1007/s10549-022-06599.
    >> Share

  703. O'DONNELL E, Shapiro Y, Comander A, Isakoff S, et al
    Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast).
    Breast Cancer Res Treat. 2022 Apr 20. pii: 10.1007/s10549-022-06594.
    >> Share

  704. LEMIJ AA, de Glas NA, Derks MGM, Bastiaannet E, et al
    Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer.
    Breast Cancer Res Treat. 2022 Apr 19. pii: 10.1007/s10549-022-06583.
    >> Share

  705. ZHANG YX, Liang ZZ, Li YQ, Lin Y, et al
    Association between weight change and breast cancer prognosis.
    Breast Cancer Res Treat. 2022 Apr 18. pii: 10.1007/s10549-022-06592.
    >> Share

  706. CHUNG GKK, Yeo W, Cheng A, Kwok C, et al
    Prognostic significance of abdominal obesity and its post-diagnosis change in a Chinese breast cancer cohort.
    Breast Cancer Res Treat. 2022 Apr 16. pii: 10.1007/s10549-022-06526.
    >> Share

  707. KWAN ML, Cheng RK, Iribarren C, Shen H, et al
    Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer.
    Breast Cancer Res Treat. 2022 Apr 16. pii: 10.1007/s10549-022-06586.
    >> Share

  708. HAGENAARS SC, Vangangelt KMH, Van Pelt GW, Karancsi Z, et al
    Standardization of the tumor-stroma ratio scoring method for breast cancer research.
    Breast Cancer Res Treat. 2022 Apr 16. pii: 10.1007/s10549-022-06587.
    >> Share

  709. LIAO YH, Lai JN, Hsu RJ, Wang TH, et al
    Breast-conserving surgery with whole breast radiation therapy has a subsequent lower mood disorder incidence rate than total mastectomy in early-stage breast cancer patients: a nationwide population-based longitudinal study.
    Breast Cancer Res Treat. 2022 Apr 16. pii: 10.1007/s10549-022-06579.
    >> Share

  710. KIM D, Bae SJ, Ahn SG, Jeong J, et al
    RT-induced dynamic changes in the lymphocyte-to-monocyte ratio in patients with breast cancer indicate poor prognosis.
    Breast Cancer Res Treat. 2022 Apr 15. pii: 10.1007/s10549-022-06601.
    >> Share

  711. DAVEY MG, Cleere EF, O'Donnell JP, Gaisor S, et al
    Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis.
    Breast Cancer Res Treat. 2022 Apr 15. pii: 10.1007/s10549-022-06580.
    >> Share

  712. FADELU TA, Erfani P, Lormil J, Damuse R, et al
    Gaps in completion and timeliness of breast surgery and adjuvant therapy: a retrospective cohort of Haitian patients with nonmetastatic breast cancer.
    Breast Cancer Res Treat. 2022 Apr 14. pii: 10.1007/s10549-022-06582.
    >> Share

  713. PERNAS S, Tolaney SM
    Clinical trial data and emerging strategies: HER2-positive breast cancer.
    Breast Cancer Res Treat. 2022 Apr 9. pii: 10.1007/s10549-022-06575.
    >> Share

  714. TO NH, Nguyen HQ, Thiolat A, Liu B, et al
    Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review.
    Breast Cancer Res Treat. 2022 Apr 9. pii: 10.1007/s10549-022-06533.
    >> Share

  715. DIRIX L, Buys A, Oeyen S, Peeters D, et al
    Circulating tumor cell detection: A prospective comparison between CellSearch(R) and RareCyte(R) platforms in patients with progressive metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Apr 9. pii: 10.1007/s10549-022-06585.
    >> Share

  716. YE L, Runger D, Angarita SA, Hadaya J, et al
    Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer.
    Breast Cancer Res Treat. 2022 Apr 7. pii: 10.1007/s10549-022-06581.
    >> Share

  717. KATUWAL S, Tapanainen J, Pukkala E
    Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer.
    Breast Cancer Res Treat. 2022 Apr 2. pii: 10.1007/s10549-022-06571.
    >> Share

  718. IYEVLEVA AG, Aleksakhina SN, Sokolenko AP, Baskina SV, et al
    Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.
    Breast Cancer Res Treat. 2022;192:283-291.
    >> Share

  719. WESTHOFF CL, Guo H, Wang Z, Hibshoosh H, et al
    The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.
    Breast Cancer Res Treat. 2022;192:321-329.
    >> Share

  720. POLLOCK NC, Ramroop JR, Hampel H, Troester MA, et al
    Differences in somatic TP53 mutation type in breast tumors by race and receptor status.
    Breast Cancer Res Treat. 2022;192:639-648.
    >> Share

  721. PALASSINI E, Mir O, Grignani G, Vincenzi B, et al
    Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses.
    Breast Cancer Res Treat. 2022;192:603-610.
    >> Share

  722. YANG J, He T, Wu Y, Fu Z, et al
    Nanoparticle-assisted axillary staging: an alternative approach after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers.
    Breast Cancer Res Treat. 2022;192:573-582.
    >> Share

  723. YAZGAN I, Chagpar A
    The effect of emotional disorders on adherence to mammography screening guidelines.
    Breast Cancer Res Treat. 2022;192:623-627.
    >> Share

  724. FRIDMAN I, Chan L, Thomas J, Fish LJ, et al
    A web-based personalized decision support tool for patients diagnosed with ductal carcinoma in situ: development, content evaluation, and usability testing.
    Breast Cancer Res Treat. 2022;192:517-527.
    >> Share

  725. MOORE GM, Powell SN, Higginson DS, Khan AJ, et al
    Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.
    Breast Cancer Res Treat. 2022;192:649-653.
    >> Share

  726. HA SM, Kim HK, Kim Y, Noh DY, et al
    Diagnostic performance improvement with combined use of proteomics biomarker assay and breast ultrasound.
    Breast Cancer Res Treat. 2022;192:541-552.
    >> Share

    March 2022
  727. FELIX GES, Guindalini RSC, Zheng Y, Walsh T, et al
    Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil.
    Breast Cancer Res Treat. 2022 Mar 30. pii: 10.1007/s10549-022-06560.
    >> Share

  728. JORDAHL KM, Malone KE, Baglia ML, Flanagan MR, et al
    Alcohol consumption, smoking, and invasive breast cancer risk after ductal carcinoma in situ.
    Breast Cancer Res Treat. 2022 Mar 27. pii: 10.1007/s10549-022-06573.
    >> Share

  729. LUO J, Carter SJ, Feliciano EMC, Hendryx M, et al
    Trajectories of objectively measured physical function among older breast cancer survivors in comparison with cancer-free controls.
    Breast Cancer Res Treat. 2022 Mar 26. pii: 10.1007/s10549-022-06568.
    >> Share

  730. MOUABBI JA, Hassan A, Lim B, Hortobagyi GN, et al
    Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.
    Breast Cancer Res Treat. 2022 Mar 26. pii: 10.1007/s10549-022-06572.
    >> Share

  731. ASSIDICKY R, Tokat UM, Tarman IO, Saatci O, et al
    Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 Mar 25. pii: 10.1007/s10549-022-06569.
    >> Share

  732. YANG YS, Ren YX, Liu CL, Hao S, et al
    The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target.
    Breast Cancer Res Treat. 2022 Mar 25. pii: 10.1007/s10549-022-06537.
    >> Share

  733. QI L, Sun B, Yang B, Lu S, et al
    PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 Mar 24. pii: 10.1007/s10549-021-06501.
    >> Share

  734. WANG S, Zhang X, Ning H, Dong S, et al
    B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis.
    Breast Cancer Res Treat. 2022 Mar 21. pii: 10.1007/s10549-022-06520.
    >> Share

  735. TAN Q, Qin Q, Huang Z, Lian B, et al
    Predictive and prognostic effect of HO-1 expression in breast cancer patients undergoing neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 Mar 18. pii: 10.1007/s10549-022-06565.
    >> Share

  736. WU Y, Han Y, Li Q, Zhang P, et al
    Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
    Breast Cancer Res Treat. 2022 Mar 16. pii: 10.1007/s10549-022-06559.
    >> Share

  737. SANTIA P, Jansana A, Del Cura I, Padilla-Ruiz M, et al
    Adherence of long-term breast cancer survivors to follow-up care guidelines: a study based on real-world data from the SURBCAN cohort.
    Breast Cancer Res Treat. 2022 Mar 15. pii: 10.1007/s10549-022-06563.
    >> Share

  738. ROBERSON ML, Nichols HB, Olshan AF, Wheeler SB, et al
    Trends in surgical treatment of early-stage breast cancer reveal decreasing mastectomy use between 2003 and 2016 by age, race, and rurality.
    Breast Cancer Res Treat. 2022 Mar 14. pii: 10.1007/s10549-022-06564.
    >> Share

  739. SCOTT OW, Tin Tin S, Elwood JM, Cavadino A, et al
    Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study.
    Breast Cancer Res Treat. 2022 Mar 14. pii: 10.1007/s10549-022-06528.
    >> Share

  740. ANKERSMID JW, Spronk PER, Zeillemaker AM, Siesling S, et al
    Health care professionals overestimate the risk for locoregional recurrences after breast cancer treatment depending on their specialty.
    Breast Cancer Res Treat. 2022 Mar 13. pii: 10.1007/s10549-022-06549.
    >> Share

  741. LIEBERMAN S, Chen-Shtoyerman R, Levi Z, Shkedi-Rafid S, et al
    Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews.
    Breast Cancer Res Treat. 2022 Mar 12. pii: 10.1007/s10549-022-06557.
    >> Share

  742. BOWLES EJA, Ramin C, Buist DSM, Feigelson HS, et al
    Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.
    Breast Cancer Res Treat. 2022 Mar 11. pii: 10.1007/s10549-022-06561.
    >> Share

  743. OMOFUMA OO, Steck SE, Olshan AF, Troester MA, et al
    The association between meat and fish intake by preparation methods and breast cancer in the Carolina Breast Cancer Study (CBCS).
    Breast Cancer Res Treat. 2022 Mar 11. pii: 10.1007/s10549-022-06555.
    >> Share

  744. QI TH, Hian OH, Kumaran AM, Tan TJ, et al
    Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer.
    Breast Cancer Res Treat. 2022 Mar 9. pii: 10.1007/s10549-022-06521.
    >> Share

  745. YOUL P, Philpot S, Moore J, Morris M, et al
    Trends in surgery and adjuvant treatment for early-stage breast cancer: a population-based study in Queensland, Australia.
    Breast Cancer Res Treat. 2022 Mar 7. pii: 10.1007/s10549-022-06551.
    >> Share

  746. ZHU Y, Tao Z, Chen Y, Lin S, et al
    Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT.
    Breast Cancer Res Treat. 2022 Mar 7. pii: 10.1007/s10549-022-06514.
    >> Share

  747. WU R, Patel A, Tokumaru Y, Asaoka M, et al
    High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer.
    Breast Cancer Res Treat. 2022 Mar 6. pii: 10.1007/s10549-022-06552.
    >> Share

  748. VAN LOEVEZIJN AA, van der Noordaa MEM, Stokkel MPM, van Werkhoven ED, et al
    Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.
    Breast Cancer Res Treat. 2022 Mar 3. pii: 10.1007/s10549-022-06545.
    >> Share

  749. RAGUSI MAA, van der Velden BHM, van Maaren MC, van der Wall E, et al
    Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA.
    Breast Cancer Res Treat. 2022 Mar 3. pii: 10.1007/s10549-022-06550.
    >> Share

  750. GEYER CE JR, Bandos H, Rastogi P, Jacobs SA, et al
    Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
    Breast Cancer Res Treat. 2022 Mar 1. pii: 10.1007/s10549-021-06417.
    >> Share

    February 2022
  751. SHANMUGALINGAM A, Hitos K, Hegde S, Al-Mashat A, et al
    Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers.
    Breast Cancer Res Treat. 2022 Feb 28. pii: 10.1007/s10549-022-06548.
    >> Share

  752. SMEDSLAND SK, Vandraas KF, Bohn SK, Dahl AA, et al
    Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey.
    Breast Cancer Res Treat. 2022 Feb 28. pii: 10.1007/s10549-022-06544.
    >> Share

  753. GANDHI S, Brackstone M, Hong NJL, Grenier D, et al
    A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.
    Breast Cancer Res Treat. 2022 Feb 28. pii: 10.1007/s10549-022-06522.
    >> Share

  754. CAMPONE M, De Laurentiis M, Zamagni C, Kudryavcev I, et al
    Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
    Breast Cancer Res Treat. 2022 Feb 25. pii: 10.1007/s10549-022-06543.
    >> Share

  755. MILLER RS, Mokiou S, Taylor A, Sun P, et al
    Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ(R) study.
    Breast Cancer Res Treat. 2022 Feb 22. pii: 10.1007/s10549-022-06541.
    >> Share

  756. NIE W, Ding H, Zou X
    Comment on "Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis".
    Breast Cancer Res Treat. 2022 Feb 17. pii: 10.1007/s10549-022-06542.
    >> Share

  757. BOGACH J, Cordeiro E, Reel E, Cil TD, et al
    Axillary surgery and complication rates after mastectomy and reconstruction for breast cancer: an analysis of the NSQIP database.
    Breast Cancer Res Treat. 2022 Feb 13. pii: 10.1007/s10549-022-06540.
    >> Share

  758. ALI A, Xie Z, Stanko L, De Leo E, et al
    Endocrine adherence in male versus female breast cancer: a seer-medicare review.
    Breast Cancer Res Treat. 2022 Feb 10. pii: 10.1007/s10549-022-06536.
    >> Share

  759. HICKISH T, Mehta A, Liu MC, Huang CS, et al
    Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.
    Breast Cancer Res Treat. 2022 Feb 9. pii: 10.1007/s10549-021-06449.
    >> Share

  760. JAGSI R, Mason G, Overmoyer BA, Woodward WA, et al
    Correction to: Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
    Breast Cancer Res Treat. 2022 Feb 8. pii: 10.1007/s10549-022-06534.
    >> Share

  761. DIRIX LY, Oeyen S, Buys A, Liegois V, et al
    Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer.
    Breast Cancer Res Treat. 2022 Feb 8. pii: 10.1007/s10549-021-06484.
    >> Share

  762. JACOBS CF, Soesan M, Sonke GS
    Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go???
    Breast Cancer Res Treat. 2022 Feb 7. pii: 10.1007/s10549-021-06505.
    >> Share

  763. KARIRI Y, Toss MS, Alsaleem M, Elsharawy KA, et al
    Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.
    Breast Cancer Res Treat. 2022 Feb 6. pii: 10.1007/s10549-022-06531.
    >> Share

  764. MORGANTI S, Marra A, Crimini E, D'Amico P, et al
    Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
    Breast Cancer Res Treat. 2022 Feb 6. pii: 10.1007/s10549-022-06535.
    >> Share

  765. OKINES A, Irfan T, Asare B, Mohammed K, et al
    Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.
    Breast Cancer Res Treat. 2022 Feb 4. pii: 10.1007/s10549-021-06432.
    >> Share

  766. LIN PH, Chen SC, Tseng LM, Chang KJ, et al
    Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients.
    Breast Cancer Res Treat. 2022 Feb 3. pii: 10.1007/s10549-021-06446.
    >> Share

  767. GANZ PA, Bandos H, Geyer CE Jr, Robidoux A, et al
    Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
    Breast Cancer Res Treat. 2022 Feb 3. pii: 10.1007/s10549-021-06475.
    >> Share

  768. BYUN HK, Kim JS, Chang JS, Cho Y, et al
    Validation of a nomogram for predicting the risk of lymphedema following contemporary treatment for breast cancer: a large multi-institutional study (KROG 20-05).
    Breast Cancer Res Treat. 2022 Feb 2. pii: 10.1007/s10549-021-06507.
    >> Share

  769. VO JB, Ramin C, Barac A, Berrington de Gonzalez A, et al
    Trends in heart disease mortality among breast cancer survivors in the US, 1975-2017.
    Breast Cancer Res Treat. 2022 Feb 2. pii: 10.1007/s10549-022-06515.
    >> Share

  770. BAEK SY, Kim J, Chung IY, Ko BS, et al
    Chemotherapy for ipsilateral breast tumor recurrence: a propensity score-matching study.
    Breast Cancer Res Treat. 2022;192:143-152.
    >> Share

  771. RODIN D, Sutradhar R, Nofech-Mozes S, Gu S, et al
    Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy.
    Breast Cancer Res Treat. 2022;192:223-233.
    >> Share

  772. RILEY D, Chrischilles EA, Lizarraga IM, Charlton M, et al
    Influence of rurality on lymph node assessment among women diagnosed with ductal carcinoma in situ and treated with mastectomy, SEER 2000-2015.
    Breast Cancer Res Treat. 2022;192:211-222.
    >> Share

  773. SEAH DS, Tayob N, Leone JP, Hu J, et al
    Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings.
    Breast Cancer Res Treat. 2022;192:201-210.
    >> Share

  774. KIM N, Kim H, Park W, Choi DH, et al
    Immediate breast reconstruction has no impact on the oncologic outcomes of patients treated with post-mastectomy radiation therapy: a comparative analysis based on propensity score matching.
    Breast Cancer Res Treat. 2022;192:101-112.
    >> Share

  775. GUMUSAY O, Callan J, Rugo HS
    Immunotherapy toxicity: identification and management.
    Breast Cancer Res Treat. 2022;192:1-17.
    >> Share

  776. LO GULLO R, Cloutier Lambert C, Lin O, Jochelson MS, et al
    Yield of flow cytometry in addition to cytology for lymph node sampling in patients with incidental axillary adenopathy without a concurrent diagnosis of primary breast malignancy.
    Breast Cancer Res Treat. 2022;191:677-683.
    >> Share

  777. GOHAR J, Do WL, Miller-Kleinhenz J, Conneely K, et al
    Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities.
    Breast Cancer Res Treat. 2022;191:653-663.
    >> Share

    January 2022
  778. VERHOEFF TJ, Holloway AF, Dickinson JL
    A novel long non-coding RNA regulates the integrin, ITGA2 in breast cancer.
    Breast Cancer Res Treat. 2022 Jan 31. pii: 10.1007/s10549-021-06496.
    >> Share

  779. NGUYEN TTA, Postlewait LM, Zhang C, Meisel JL, et al
    Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
    Breast Cancer Res Treat. 2022 Jan 27. pii: 10.1007/s10549-022-06530.
    >> Share

  780. LI C, Li R, Hu X, Zhou G, et al
    Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression.
    Breast Cancer Res Treat. 2022 Jan 27. pii: 10.1007/s10549-021-06433.
    >> Share

  781. ZHAO Y, Peng H, Liang L, Li Y, et al
    Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest.
    Breast Cancer Res Treat. 2022 Jan 26. pii: 10.1007/s10549-021-06490.
    >> Share

  782. REID S, Spalluto LB, Lang K, Weidner A, et al
    An overview of genetic services delivery for hereditary breast cancer.
    Breast Cancer Res Treat. 2022 Jan 26. pii: 10.1007/s10549-021-06478.
    >> Share

  783. FRANZOI MA, Lambertini M, Ceppi M, Bruzzone M, et al
    Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.
    Breast Cancer Res Treat. 2022 Jan 25. pii: 10.1007/s10549-022-06525.
    >> Share

  784. WILLIAMS AD, Buckley M, Ciocca RM, Sabol JL, et al
    Racial and socioeconomic disparities in breast cancer diagnosis and mortality in Pennsylvania.
    Breast Cancer Res Treat. 2022 Jan 22. pii: 10.1007/s10549-021-06492.
    >> Share

  785. CONDORELLI M, Sens M, Goldrat O, Delbaere A, et al
    A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients.
    Breast Cancer Res Treat. 2022 Jan 18. pii: 10.1007/s10549-021-06489.
    >> Share

  786. MARTINEZ JA, Wertheim BC, Roe DJ, Chalasani P, et al
    Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer.
    Breast Cancer Res Treat. 2022 Jan 18. pii: 10.1007/s10549-021-06485.
    >> Share

  787. SUELMANN BBM, Bakhuis CFJ, van Dooijeweert C, Verloop J, et al
    Prognosis of pregnancy-associated breast cancer: inferior outcome in patients diagnosed during second and third gestational trimesters and lactation.
    Breast Cancer Res Treat. 2022 Jan 18. pii: 10.1007/s10549-021-06471.
    >> Share

  788. LIANG Y, Besch-Williford C, Hyder SM
    The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth.
    Breast Cancer Res Treat. 2022 Jan 17. pii: 10.1007/s10549-021-06487.
    >> Share

  789. JONES GS, Hoadley KA, Benefield H, Olsson LT, et al
    Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression.
    Breast Cancer Res Treat. 2022 Jan 16. pii: 10.1007/s10549-021-06497.
    >> Share

  790. PAVANELLI AC, Mangone FR, Yoganathan P, Bessa SA, et al
    Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes.
    Breast Cancer Res Treat. 2022 Jan 15. pii: 10.1007/s10549-021-06452.
    >> Share

  791. CHOI SB, Park JM, Ahn JH, Go J, et al
    Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-022-06519.
    >> Share

  792. ALTERIO D, La Rocca E, Volpe S, Camarda AM, et al
    Hypofractionated proton therapy in breast cancer: where are we? A critical review of the literature.
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-022-06516.
    >> Share

  793. MEEGDES M, Ibragimova KIE, Lobbezoo DJA, Vriens IJH, et al
    The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-021-06472.
    >> Share

  794. FASANO GA, Bayard S, Chen Y, Varella L, et al
    Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-021-06481.
    >> Share

  795. ANGARITA FA, Oshi M, Yamada A, Yan L, et al
    Low RUFY3 expression level is associated with lymph node metastasis in older women with invasive breast cancer.
    Breast Cancer Res Treat. 2022 Jan 12. pii: 10.1007/s10549-021-06482.
    >> Share

  796. YOO TK, Kang J, Lee A, Chae BJ, et al
    A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
    Breast Cancer Res Treat. 2022 Jan 12. pii: 10.1007/s10549-021-06437.
    >> Share

  797. VERDONE CG, Bayron JA, Chang C, Wang CE, et al
    A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA.
    Breast Cancer Res Treat. 2022 Jan 11. pii: 10.1007/s10549-021-06460.
    >> Share

  798. PATEL R, Li Z, Zimmerman BS, Fink MY, et al
    Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Jan 10. pii: 10.1007/s10549-021-06504.
    >> Share

  799. DONZELLA SM, Lind KE, Skiba MB, Farland LV, et al
    The relationship between sleep and weight change among women diagnosed with breast cancer participating in the Women's Health Initiative.
    Breast Cancer Res Treat. 2022 Jan 10. pii: 10.1007/s10549-021-06486.
    >> Share

  800. VOHRA SN, Reeder-Hayes KE, Nichols HB, Emerson MA, et al
    Breast cancer treatment patterns by age and time since last pregnancy in the Carolina Breast Cancer Study Phase III.
    Breast Cancer Res Treat. 2022 Jan 10. pii: 10.1007/s10549-022-06511.
    >> Share

  801. SARMA M, Perimbeti S, Nasir S, Attwood K, et al
    Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study.
    Breast Cancer Res Treat. 2022 Jan 9. pii: 10.1007/s10549-021-06506.
    >> Share

  802. CHEUNG YM, Cromwell GE, Tolaney SM, Min L, et al
    Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer.
    Breast Cancer Res Treat. 2022 Jan 9. pii: 10.1007/s10549-021-06476.
    >> Share

  803. LEE J, Chang Y, Kim Y, Park B, et al
    Insulin resistance and the development of breast cancer in premenopausal women: the Kangbuk Samsung Health Study.
    Breast Cancer Res Treat. 2022 Jan 8. pii: 10.1007/s10549-022-06513.
    >> Share

  804. ANDERSON RA, Kelsey TW, Perdrix A, Olympios N, et al
    Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.
    Breast Cancer Res Treat. 2022 Jan 8. pii: 10.1007/s10549-021-06508.
    >> Share

  805. CONLEY CC, McIntyre M, Pensak NA, Lynce F, et al
    Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-022-06518.
    >> Share

  806. SAGHATCHIAN M, Abehsera M, Yamgnane A, Geyl C, et al
    Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-021-06445.
    >> Share

  807. KIRAC UTKU I, Safer U
    Comment on: sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer-results from the ABLE feasibility trial.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-021-06502.
    >> Share

  808. BLUMING AZ
    Safety of systemic hormone replacement therapy in breast cancer survivors.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-021-06479.
    >> Share

  809. ZHENG C, Chagpar AB
    Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis.
    Breast Cancer Res Treat. 2022 Jan 6. pii: 10.1007/s10549-022-06510.
    >> Share

  810. TANG A, Neeman E, Vuong B, Arasu VA, et al
    Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system.
    Breast Cancer Res Treat. 2022 Jan 6. pii: 10.1007/s10549-021-06468.
    >> Share

  811. BRINGUIER M, Carton M, Levy C, Patsouris A, et al
    Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort.
    Breast Cancer Res Treat. 2022 Jan 5. pii: 10.1007/s10549-021-06467.
    >> Share

  812. COOLBRANDT A, Vancoille K, Dejaeger E, Peeters H, et al
    Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer.
    Breast Cancer Res Treat. 2022 Jan 4. pii: 10.1007/s10549-021-06477.
    >> Share

  813. FALLOWFIELD LJ, Farewell D, Jones H, May S, et al
    IMPARTER, Phase 1 of an intervention to improve patients' understanding of gene expression profiling tests in breast cancer.
    Breast Cancer Res Treat. 2022 Jan 4. pii: 10.1007/s10549-021-06491.
    >> Share

  814. FAN Y, Xie G, Wang Z, Wang Y, et al
    PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy.
    Breast Cancer Res Treat. 2022 Jan 3. pii: 10.1007/s10549-021-06463.
    >> Share

  815. JAGSI R, Mason G, Overmoyer BA, Woodward WA, et al
    Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
    Breast Cancer Res Treat. 2022 Jan 1. pii: 10.1007/s10549-021-06434.
    >> Share

  816. HU Y, Burkard ME
    Classes of therapeutics to amplify the immune response.
    Breast Cancer Res Treat. 2022;191:277-289.
    >> Share

  817. PAWLOSKI KR, Gonen M, Wen HY, Tadros AB, et al
    Supervised machine learning model to predict oncotype DX risk category in patients over age 50.
    Breast Cancer Res Treat. 2022;191:423-430.
    >> Share

  818. KHAYEKA-WANDABWA C, Zhao J, Pathak JL, Wu H, et al
    Upregulation of estrogen receptor alpha (ERalpha) expression in transgenic mice expressing human CYP4Z1.
    Breast Cancer Res Treat. 2022;191:319-326.
    >> Share

  819. LEWIS PHILLIPS G, Guo J, Kiefer JR, Proctor W, et al
    Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics.
    Breast Cancer Res Treat. 2022;191:303-317.
    >> Share

  820. HUANG L, Wang R, Xie K, Zhang J, et al
    A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation.
    Breast Cancer Res Treat. 2022;191:51-61.
    >> Share

  821. BAKER JL, Haji F, Kusske AM, Fischer CP, et al
    SAVI SCOUT(R) localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
    Breast Cancer Res Treat. 2022;191:107-114.
    >> Share

  822. SIEGEL A, Bremer RC, Klein WMP, Savage SA, et al
    Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome.
    Breast Cancer Res Treat. 2022;191:159-167.
    >> Share

  823. POULSEN L, Kaur M, Jacobsen AL, Bjarnesen MP, et al
    Comparison of upper extremity lymphedema after sentinel lymph node biopsy and axillary lymph node dissection: patient-reported outcomes in 3044 patients.
    Breast Cancer Res Treat. 2022;191:87-96.
    >> Share

  824. SHIINO S, Ball G, Syed BM, Kurozumi S, et al
    Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis.
    Breast Cancer Res Treat. 2022;191:1-14.
    >> Share

  825. DOLEN UC, Law J, Tenenbaum MM, Myckatyn TM, et al
    Breast reconstruction is a viable option for older patients.
    Breast Cancer Res Treat. 2022;191:77-86.
    >> Share

    December 2021
  826. MORASSO C, Ricciardi A, Sproviero D, Truffi M, et al
    Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA).
    Breast Cancer Res Treat. 2021 Dec 21. pii: 10.1007/s10549-021-06474.
    >> Share

  827. YADAV K, Lim J, Choo J, Ow SGW, et al
    Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer.
    Breast Cancer Res Treat. 2021 Dec 20. pii: 10.1007/s10549-021-06470.
    >> Share

  828. SCHAEFGEN B, Funk A, Sinn HP, Bruckner T, et al
    Does conventional specimen radiography after neoadjuvant chemotherapy of breast cancer help to reduce the rate of second surgeries?
    Breast Cancer Res Treat. 2021 Dec 8. pii: 10.1007/s10549-021-06466.
    >> Share

  829. TURNER N, Dent RA, O'Shaughnessy J, Kim SB, et al
    Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
    Breast Cancer Res Treat. 2021 Dec 3. pii: 10.1007/s10549-021-06450.
    >> Share

  830. JAZIEH K, Baidoun F, Torrejon N, Merjaneh Z, et al
    Studying the association between breast cancer and renal cell carcinoma.
    Breast Cancer Res Treat. 2021 Dec 2. pii: 10.1007/s10549-021-06465.
    >> Share

  831. MORGAT C, Brouste V, Chastel A, Velasco V, et al
    Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors.
    Breast Cancer Res Treat. 2021;190:403-413.
    >> Share

  832. NEIRICH L, Yahiaoui-Doktor M, Lammert J, Basrai M, et al
    Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1.
    Breast Cancer Res Treat. 2021;190:463-475.
    >> Share

  833. MINK VAN DER MOLEN DR, Bargon CA, Batenburg MCT, van Stam LE, et al
    The impact of the COVID-19 pandemic on perceived access to health care and preferences for health care provision in individuals (being) treated for breast cancer.
    Breast Cancer Res Treat. 2021 Dec 1. pii: 10.1007/s10549-021-06458.
    >> Share

  834. DINH P, Graham JD, Elder EN, Kabir M, et al
    Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing.
    Breast Cancer Res Treat. 2021 Dec 1. pii: 10.1007/s10549-021-06456.
    >> Share

    November 2021
  835. METCALFE KA, Eisen A, Wright F, Poll A, et al
    Impact of rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis on psychosocial functioning.
    Breast Cancer Res Treat. 2021 Nov 30. pii: 10.1007/s10549-021-06457.
    >> Share

  836. DISIS ML, Cecil DL
    Breast cancer vaccines for treatment and prevention.
    Breast Cancer Res Treat. 2021 Nov 30. pii: 10.1007/s10549-021-06459.
    >> Share

  837. COE F, Misra V, McCabe Y, Adderley H, et al
    Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06438.
    >> Share

  838. DREHER N, Matthys M, Hadeler E, Shieh Y, et al
    A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06451.
    >> Share

  839. BRANDS-APPELDOORN ATPM, Thomma RCM, Janssen L, Maaskant-Braat AJG, et al
    Factors related to patient-reported cosmetic outcome after breast-conserving therapy for breast cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06461.
    >> Share

  840. LI Y, Zheng X, Tu D, Ingle JN, et al
    Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R.
    Breast Cancer Res Treat. 2021 Nov 26. pii: 10.1007/s10549-021-06448.
    >> Share

  841. HARBORG S, Ahern TP, Feldt M, Rosendahl AH, et al
    Circulating lipids and breast cancer prognosis in the Malmo diet and cancer study.
    Breast Cancer Res Treat. 2021 Nov 25. pii: 10.1007/s10549-021-06462.
    >> Share

  842. SMALL BJ, Lange M, Zhai W, Ahn J, et al
    Impact of taxane-based chemotherapy among older women with breast cancer on cognition and quality of life: a longitudinal pooled analysis.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06455.
    >> Share

  843. HONKANEN TJ, Luukkainen MEK, Tikkanen A, Karihtala P, et al
    Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06447.
    >> Share

  844. BARNI S, Cognetti F, Petrelli F
    Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06464.
    >> Share

  845. ROTHSCHILD HT, Abel MK, Patterson A, Goodman K, et al
    Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06453.
    >> Share

  846. SILVER J, Goldenberg A, Moore A
    Dietary supplement use and documentation in a breast cancer survivorship clinic.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06454.
    >> Share

  847. ZUO K, Yuan X, Liang X, Sun X, et al
    qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Nov 19. pii: 10.1007/s10549-021-06442.
    >> Share

  848. ROSIER L, Wang Y, Lee JH, Daily K, et al
    Does definitive local therapy have a role in select HER2+ de novo metastatic breast cancer patients treated with dual anti-HER2 blockade?
    Breast Cancer Res Treat. 2021 Nov 17. pii: 10.1007/s10549-021-06440.
    >> Share

  849. JANK P, Lindner JL, Lehmann A, Pfitzner BM, et al
    Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).
    Breast Cancer Res Treat. 2021 Nov 16. pii: 10.1007/s10549-021-06415.
    >> Share

  850. WU ZY, Han J, Kim HJ, Lee JW, et al
    Breast cancer outcomes following immediate breast reconstruction with implants versus autologous flaps: a propensity score-matched study.
    Breast Cancer Res Treat. 2021 Nov 10. pii: 10.1007/s10549-021-06350.
    >> Share

  851. BOSE M, Benada J, Thatte JV, Kinalis S, et al
    A catalog of curated breast cancer genes.
    Breast Cancer Res Treat. 2021 Nov 10. pii: 10.1007/s10549-021-06441.
    >> Share

  852. KLINGER M, Losurdo A, Lisa AVE, Morenghi E, et al
    Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: a multicenter Italian retrospective study.
    Breast Cancer Res Treat. 2021 Nov 9. pii: 10.1007/s10549-021-06444.
    >> Share

  853. REN M, Orozco A, Shao K, Albanez A, et al
    Correction to: Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
    Breast Cancer Res Treat. 2021 Nov 9. pii: 10.1007/s10549-021-06373.
    >> Share

  854. NYROP KA, Damone EM, Deal AM, Wheeler SB, et al
    Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2021 Nov 5. pii: 10.1007/s10549-021-06439.
    >> Share

  855. POGGIO F, Del Mastro L, Bruzzone M, Ceppi M, et al
    Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2021 Nov 3. pii: 10.1007/s10549-021-06436.
    >> Share

  856. WILSON BE, Gorrini C, Cescon DW
    Breast cancer immune microenvironment: from pre-clinical models to clinical therapies.
    Breast Cancer Res Treat. 2021 Nov 3. pii: 10.1007/s10549-021-06431.
    >> Share

  857. CHO Y, Chang Y, Jung HS, Kim CW, et al
    Fatty liver disease and changes in dense breasts in pre- and postmenopausal women: the Kangbuk Samsung Health Study.
    Breast Cancer Res Treat. 2021;190:343-353.
    >> Share

  858. AMITAI Y, Menes TS, Scaranelo A, Fleming R, et al
    The characteristics associated with upgrade on surgical pathology of conventional imaging occult DCIS diagnosed by MRI.
    Breast Cancer Res Treat. 2021;190:317-327.
    >> Share

  859. ARNONE AA, Cline JM, Soto-Pantoja DR, Cook KL, et al
    Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-alpha activity on breast metabolic signaling.
    Breast Cancer Res Treat. 2021;190:53-67.
    >> Share

  860. AL-KAWAZ A, Ali R, Toss MS, Miligy IM, et al
    The frequency and clinical significance of DNA polymerase beta (POLbeta) expression in breast ductal carcinoma in situ (DCIS).
    Breast Cancer Res Treat. 2021;190:39-51.
    >> Share

  861. TAPIA E, Villa-Guillen DE, Chalasani P, Centuori S, et al
    A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density.
    Breast Cancer Res Treat. 2021;190:69-78.
    >> Share

  862. LAZZARO C
    Lazzaro responds to Pouwels et al.
    Breast Cancer Res Treat. 2021;190:1.
    >> Share

    October 2021
  863. WU ZY, Kim HJ, Lee J, Chung IY, et al
    Oncologic outcomes of immediate breast reconstruction in young women with breast cancer receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Oct 31. pii: 10.1007/s10549-021-06428.
    >> Share

  864. WAN C, Caston NE, Ingram SA, Rocque GB, et al
    Exclusion criteria of breast cancer clinical trial protocols: a descriptive analysis.
    Breast Cancer Res Treat. 2021 Oct 31. pii: 10.1007/s10549-021-06422.
    >> Share

  865. TORRES ETR, Emens LA
    Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.
    Breast Cancer Res Treat. 2021 Oct 30. pii: 10.1007/s10549-021-06423.
    >> Share

  866. HUPPERT LA, Mariotti V, Chien AJ, Soliman HH, et al
    Emerging immunotherapeutic strategies for the treatment of breast cancer.
    Breast Cancer Res Treat. 2021 Oct 30. pii: 10.1007/s10549-021-06406.
    >> Share

  867. HO AY, Tabrizi S, Dunn SA, McArthur HL, et al
    Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 Oct 29. pii: 10.1007/s10549-021-06408.
    >> Share

  868. JENKINS JA, Marmor S, Hui JYC, Beckwith H, et al
    The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer.
    Breast Cancer Res Treat. 2021 Oct 29. pii: 10.1007/s10549-021-06429.
    >> Share

  869. SCHREIBER AR, Kagihara J, Eguchi M, Kabos P, et al
    Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
    Breast Cancer Res Treat. 2021 Oct 27. pii: 10.1007/s10549-021-06424.
    >> Share

  870. LUCANUS AJ, Thike AA, Tan XF, Lee KW, et al
    KIF21A regulates breast cancer aggressiveness and is prognostic of patient survival and tumor recurrence.
    Breast Cancer Res Treat. 2021 Oct 26. pii: 10.1007/s10549-021-06426.
    >> Share

  871. GOLD EB, Crawford SL, Leung K, Greendale G, et al
    Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN.
    Breast Cancer Res Treat. 2021 Oct 25. pii: 10.1007/s10549-021-06425.
    >> Share

  872. CRESCENZI R, Donahue PMC, Garza M, Lee CA, et al
    Elevated magnetic resonance imaging measures of adipose tissue deposition in women with breast cancer treatment-related lymphedema.
    Breast Cancer Res Treat. 2021 Oct 23. pii: 10.1007/s10549-021-06419.
    >> Share

  873. CORBAUX P, Lardy-Cleaud A, Alexandre M, Fontanilles M, et al
    Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Oct 23. pii: 10.1007/s10549-021-06382.
    >> Share

  874. ONEGA T, Zhu W, Kerlikowske K, Miglioretti DL, et al
    Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield.
    Breast Cancer Res Treat. 2021 Oct 22. pii: 10.1007/s10549-021-06418.
    >> Share

  875. CHIC N, Braso-Maristany F, Prat A
    Biomarkers of immunotherapy response in breast cancer beyond PD-L1.
    Breast Cancer Res Treat. 2021 Oct 21. pii: 10.1007/s10549-021-06421.
    >> Share

  876. MILLS MN, Potluri TK, Kawahara Y, Fahey M, et al
    The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs.
    Breast Cancer Res Treat. 2021 Oct 20. pii: 10.1007/s10549-021-06420.
    >> Share

  877. CAO L, Shenk R, Stabellini N, Miller ME, et al
    Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis.
    Breast Cancer Res Treat. 2021 Oct 16. pii: 10.1007/s10549-021-06411.
    >> Share

  878. LORONA NC, Malone KE, Li CI
    Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis.
    Breast Cancer Res Treat. 2021 Oct 15. pii: 10.1007/s10549-021-06311.
    >> Share

  879. ZHENG F, Du F, Wang W, Wang Y, et al
    Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
    Breast Cancer Res Treat. 2021 Oct 14. pii: 10.1007/s10549-021-06401.
    >> Share

  880. CHAMSEDDINE RS, Wang C, Yin K, Wang J, et al
    Penetrance of male breast cancer susceptibility genes: a systematic review.
    Breast Cancer Res Treat. 2021 Oct 13. pii: 10.1007/s10549-021-06413.
    >> Share

  881. MERZENICH H, Baaken D, Schmidt M, Bekes I, et al
    Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa).
    Breast Cancer Res Treat. 2021 Oct 9. pii: 10.1007/s10549-021-06412.
    >> Share

  882. HERNANDO-CALVO A, Cescon DW, Bedard PL
    Novel classes of immunotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 Oct 8. pii: 10.1007/s10549-021-06405.
    >> Share

  883. DE LAURENTIIS M, Borstnar S, Campone M, Warner E, et al
    Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
    Breast Cancer Res Treat. 2021 Oct 8. pii: 10.1007/s10549-021-06374.
    >> Share

  884. VARGAS A, Holub K, Biete A
    Omitting axillary dissection: could we offer a more tailored management to elderly patients with breast cancer?
    Breast Cancer Res Treat. 2021 Oct 5. pii: 10.1007/s10549-021-06404.
    >> Share

  885. BIANCO N, Milano M, Pagan E, Oriecuia C, et al
    Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis.
    Breast Cancer Res Treat. 2021 Oct 5. pii: 10.1007/s10549-021-06407.
    >> Share

  886. HASHIMOTO TAKIGAMI N, Kuniyoshi S, Miki Y, Tamaki K, et al
    Correction to: Breast cancer, diabetes mellitus and glucagonlike peptide1 receptor toward exploring their possible associations.
    Breast Cancer Res Treat. 2021 Oct 4. pii: 10.1007/s10549-021-06380.
    >> Share

  887. SAVAS P, Salgado R, Loi S
    Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers.
    Breast Cancer Res Treat. 2021;189:599-606.
    >> Share

  888. CHIPIDZA FE, Mushonga M, Kanda C, Chibonda S, et al
    Utilization and predictors of postmastectomy radiation receipt in an Oncology Center in Zimbabwe.
    Breast Cancer Res Treat. 2021;189:701-709.
    >> Share

  889. ESSERMAN L, Eklund M, Veer LV, Shieh Y, et al
    The WISDOM study: a new approach to screening can and should be tested.
    Breast Cancer Res Treat. 2021;189:593-598.
    >> Share

    September 2021
  890. SOLIMAN O, Lowery A, Kerin M
    Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06403.
    >> Share

  891. HAQUE R, Chlebowski RT, Chen L
    Sleep medication use and risk of fractures in breast cancer survivors.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06392.
    >> Share

  892. ROCQUE GB, Caston NE, Franks JA, Williams CP, et al
    Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06381.
    >> Share

  893. THOREN L, Eriksson M, Lindh JD, Czene K, et al
    Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.
    Breast Cancer Res Treat. 2021 Sep 27. pii: 10.1007/s10549-021-06386.
    >> Share

  894. TEINTURIER R, Abou Ziki R, Kassem L, Luo Y, et al
    Reduced menin expression leads to decreased ERalpha expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
    Breast Cancer Res Treat. 2021 Sep 24. pii: 10.1007/s10549-021-06339.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016